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Abstract 
Type 2 immune responses are generated to provide protection against parasitic 
helminth infections, however these responses also cause the pathologies associated with 
allergic inflammation. Studies of the cell types and signalling pathways that mediate 
Type 2 immune responses have been previously undertaken with the goals of efficient 
development of vaccines against helminths, and identification of pathways that can be 
inhibited to decrease the damage caused by allergic inflammation.  
The cytokines interleukin-4 (IL-4) and interleukin-13 (IL-13) mediate many of the 
downstream effector functions of the Type 2 immune response. To study the 
mechanisms that control expression of these two cytokines I have used a novel dual 
cytokine IL-4 and IL-13 transgenic reporter mouse. Utilising this tool along with other 
IL-4 reporter mice I have discovered that the amount of T cell receptor (TCR) 
signalling modulates the allelic expression of IL-4 by CD4+ T cells. The transgenic IL-4 
reporter mouse has for the first time allowed independent measurement of the effects of 
IL-4 deficiency on the expression of IL-4 in vivo. Using this system I have found that IL-
4 is not required for the in vivo generation or expansion of IL-4 producing CD4+ T cells. 
Th2 differentiated CD4+ T cells also expresses IL-13, however the dual reporter mice 
have demonstrated that IL-13 is expressed consistently later than IL-4 in vitro, and IL-13 
requires constant, or multiple exposures to TCR stimulus for expression to be induced. 
IL-13 expression is absent from lymph node CD4+ T cells during exposure to allergens 
or helminth infection. Sequestration of CD4+ T cells in the lymph node does not impact 
the number of IL-13 expressing CD4+ T cells in the lung during a helminth infection, 
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indicating that adaptive immune cell derived IL-13 may be entirely produced by lung 
resident cells not requiring transit through the lymph node. 
I have characterised a population of innate lymphoid cells (ILCs) within the skin and 
found that the proportion of these cells that constitutively express IL-13 decreases with 
age. These cells did not drastically change in numbers or IL-13 responses in a range of 
inflammatory conditions including a model of atopic dermatitis. Basophils were found 
to respond to the atopic dermatitis model by migrating specifically to the treated skin 
site and draining lymph node, and producing IL-4 in a thymic stromal lymphopoietin 
dependant manner.  
Treatment with exogenous cytokines induced IL-13 expression from group 2 ILCs 
(ILC2s) in the lung and these cells promoted protective immune responses against 
Nippostrongylus brasiliensis infection. The immune response generated during a primary 
infection by Nippostrongylus brasiliensis provides protection from re-infection. Long-term 
protection is dependent on CD4+ T cells but when sufficiently stimulated by cytokine, 
ILC2s can rescue the protection lost by the depletion of CD4+ T cells. 
This thesis has shown that CD4+ T cells and populations of innate immune cells 
differentially regulate the expression of the closely related Type 2 cytokines IL-4 and IL-
13. These discoveries will help direct future research aiming to boost the effectiveness of 
anti-helminth vaccines, or decrease the pathology caused by allergic diseases by 
targeting specific cytokine expression. 
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1 Introduction 
1.1 The Type 2 immune Response 
The immune system is a network of cells found in all tissues of the body. These cells 
communicate by the production of molecules that they either express on their cell 
surface or release into their environment, these molecules interact with receptors on 
other cells, allowing coordination of actions and targeted responses against potential 
threats. By communicating and working together the cells of the immune system keep 
the body free from invading pathogens, control the commensal microbes that live on 
the body and maintain homeostasis of many body systems. To be effective the immune 
system must be able to mount different responses against different threats, an immune 
response against one type of pathogen such as a virus may not work against a 
multicellular parasite, so the immune system must have the ability to modify its 
approach on a case-by-case basis. Despite this flexibility there are common types of 
immune responses initiated against related groups of pathogens. The cells and signalling 
proteins that contribute to clearance of a bacterial infection are similar to the cells and 
signals that the immune system employs to clear intracellular prokaryote pathogens1. 
Type 1 responses are associated with the clearance of viruses and intracellular 
pathogens. Type 2 responses are related to the expulsion of multicellular parasites such 
as helminths, responses to ectoparasites such as ticks, and wound healing following 
infection. However, when activated against innocuous substances Type 2 responses can 
be pathogenic, causing diseases including allergies and asthma2.  
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CD4+ T cells expressing the α and β T cell receptor chains, and differentiated towards 
a specific activation phenotype, named T helper 2 (Th2), are critical for orchestrating 
Type 2 immunity3. Through the production of specific signalling molecules called 
cytokines, Th2 CD4+ T cells mediate the recruitment, expansion and activation of a 
number of myeloid derived cells4, 5. Th2 cells also mediate B cell activation and direct 
activated B cells to produce the IgE antibody isotype; increased serum IgE is strongly 
correlated with Type 2 immune responses6. The granulocytes, mast cells, basophils and 
eosinophils are also associated with Type 2 immune responses. These cells carry 
granules packed with enzymes, toxic products, histamine and cytokines that they release 
upon activation7, 8. Cross-linking of surface bound IgE molecules by an antigen is a 
signal that drives activation and degranulation of basophils and mast cells9. 
Granulocytes can also actively produce large amounts of Type 2 associated cytokines10.  
Macrophages respond to Type 2 cytokines by exhibiting an alternate activation 
phenotype. These macrophages are implicated in both protection against parasites and 
wound healing11. Type 2 immune responses can also affect non-immune cells, with 
cytokines produced by Th2 cells directly activating fibroblasts and increasing 
extracellular matrix deposition12. This can assist wound healing, but in cases of 
excessive Type 2 responses, may lead to fibrosis and loss of function in tissues including 
the lung and liver13. Increased smooth muscle function is also seen with Type 2 
signalling, which can assist the expulsion of intestinal parasites14. A recently discovered 
subset of lymphoid cells, devoid of antigen specific receptors but able to produce Type 2 
cytokines in responses to epithelial derived signals, have been labelled the group 2 
innate lymphoid cells (ILCs)15. While these cells have been implicated in models of 
parasite expulsion and asthma, further investigation is required to assess their roles in 
other models associated with Type 2 inflammatory responses. 
In this thesis I will characterise the expression of two cytokines produced by several 
cellular subsets that contribute to Type 2 immune responses, assessing the signals that 
induce and regulate the expression of these cell-signalling molecules in a range of in vitro 
and in vivo models. I will investigate the mechanisms via which CD4+ T cells control 
their production of the Type 2 cytokines interleukin-4 (IL-4) and interleukin-13 (IL-13) 
by utilising both newly generated and existing cytokine reporter mice. Using the same 
reporter systems the contributions of ILCs and basophils to inflammatory responses in 
the skin will be evaluated. Finally, I will examine how both CD4+ T cells and ILCs 
mediate protective responses in the lung against hookworm infection. Integrating the 
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knowledge gained from this body of work will allow greater understanding of how 
individual cells regulate their cytokine responses, and how these cells work in the greater 
network that is the Type 2 immune response. 
1.2 The activation, differentiation and physiological 
functions of CD4+ T cells 
CD4 expressing T cells, known as T helper cells (Th cells) are important for mediating 
both innate and adaptive immune responses. These cells have roles in helping the 
production and isotype selection of antibodies by B cells, supporting and expanding 
CD8+ T cell responses and recruitment of cells from the innate arms of the immune 
system. CD4+ T cells are also very important in regulation and resolution of immune 
processes16. Due to their varied roles, CD4+ T cells are often likened to the generals of 
the immune cell army17. What allows CD4+ T cells to be so multifunctional is their 
ability to differentiate after activation into distinct subsets capable of producing specific 
signalling cytokines and driving specific immune responses18. This section will discuss 
the signals that drive activation and differentiation of the currently recognised CD4+ T 
cell subsets and the proposed roles of these cells. 
1.2.1 Ontogeny of CD4+ T cells 
T helper cells express the T cell receptor (TCR) α and β chains, which along with the 
co-receptor molecule CD4, recognise peptides of 15-20 amino acids loaded in the cleft 
of the major histocompatibility complex class II (MHC II) molecule. All T cells derive 
from common lymphoid progenitors (CLPs), which migrate from the bone marrow to 
the cortex of the thymus19. While CLPs are double negative in respect to their CD4 and 
CD8 expression, they develop the expression of their TCR β chain through germ line 
recombination. This is followed by the expression of CD8 and CD4, and finally by the 
generation and expression of the TCR α chain. Double positive (CD4+ CD8+) cells with 
complete TCRs then begin the first of two rounds of selection. Positive selection 
requires appropriate interactions with MHC molecules, interactions that are neither too 
weak nor too strong lead to the cells receiving pro-survival signals. Cells that have 
sustained interactions with MHC class II molecules will down regulate expression of 
CD8 becoming CD4+ T cells. The CD4+ T cells then migrate to the thymic medulla 
and undergo negative selection, ensuring that auto-reactive cells are either forced into 
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an apoptotic directive, or in some situations becoming the immune modulating natural 
CD4+ regulatory T cells (nTregs).20 The relatively few CD4+ T cells that successfully 
navigate these processes may then depart the thymus and begin circulating through the 
peripheral secondary lymphoid tissues sampling MHC II molecules, seeking the cognate 
peptide their TCR is specific for.  
Unlike the nearly ubiquitous expression of MHC class I molecules, MHC II expression 
is restricted, with highest constitutive levels found upon professional antigen presenting 
cells (APCs)19. Professional APCs include dendritic cells (DCs), macrophages and B cells. 
During the synthesis of MHC II, the invariant chain blocks the occupation of the 
peptide-binding cleft by endogenous peptides. The MHC II molecules are assembled 
and trafficked from the endoplasmic reticulum, to the golgi body and eventually into 
vesicles where they are bound to the internal membranes. APCs, particularly DCs and 
macrophages, are adept at sampling environmental proteins, phagocytosing them 
through receptor mediated or random endocytosis, and packaging the proteins into 
endosomes. These endosomes, containing partially digested peptides, bind to vesicles 
where the invariant chains are sequentially removed from the MHC II binding cleft, 
allowing insertion of environmental peptides into the cleft. The endosomes with peptide 
carrying MHC II molecules are then transported to the cell surface where they merge 
with the cells external membrane. This results in surface presentation of the MHC II 
molecules and allows interactions with CD4+ T cells.21 
1.2.2 Activation of naïve CD4+ T cells 
Once the naïve CD4+ T cells enter lymphatic circulation they begin interrogating 
MHC II expressing on APCs until they encounter a bound peptide that their TCR can 
bind with high enough affinity to induce signalling. The TCR chains cannot be 
expressed on the cell surface without associating with the CD3 complex22. The CD3ε, 
CD3δ, CD3γ and CD3ζ chains carry immunoreceptor tyrosine-based activation motifs 
(ITAMs), which are critical for downstream signalling of the TCR19. Once a TCR binds 
to a peptide-MHC II complex with sufficient affinity CD4 brings its associated 
intracellular tyrosine kinase Lck into close connection with the intracellular domains of 
the CD3 chains, allowing Lck to phosphorylate the CD3 chain ITAMs. This process is 
also assisted by another tyrosine kinase Fyn. Once phosphorylated the CD3ζ chains can 
be bound by another tyrosine kinase Zap70 (ζ chain associated protein 70), which then 
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phosphorylates the two scaffold proteins SLP-76 and linker of T cells (LAT) allowing 
binding with GRB2-related adaptor downstream of Shc (GADS) and phospholipase C-γ 
(PLC-γ). Itk, itself having been activated by Lck, activates this complex after receiving a 
final phosphorylation. The activated PLC-γ complex can cleave the membrane bound 
phosphatidylinositol 3,4-bisphosphate (PIP2) and, along with phosphatidylinositol-3 (PI3) 
kinase, generates inositol 1,4,5 triphosphate (IP3) and diacylglycerol (DAG). These two 
molecules are instigators of three main transcriptional pathways downstream of the 
TCR, causing nuclear translocation of the transcription factors nuclear factor κ B 
(NFκB), nuclear factor of activated T cells (NFAT) and activator protein 1 (AP-1).19, 23, 
24 
IP3 release causes increased intracellular Ca2+ concentrations initially by opening 
calcium channels in the membrane of the endoplasmic reticulum (ER). The depletion of 
ER Ca2+ causes the opening of plasma membrane calcium channels leading to a 
massive flux of calcium into the cytosol. NFAT resides in the cytosol of cells, with its 
nuclear translocation blocked by phosphorylation. Calmodulin, activated in the 
presence of increased cytosolic Ca2+concentrations, binds calcineurin and together these 
enzymes dephosphorylate NFAT. Dephosphorylated NFAT is then released from the 
cytosol and able to carry out its transcription factor functions.24 
The mitogen-activated protein kinase (MAPK) pathway is an internal signalling cascade 
pathway common to many different receptors. In TCR activation DAG binds RAS 
guanine nucleotide releasing protein (RasGRP), which activates Ras. Ras is a small G-
protein that activates the first of the triad of MAP kinases, Raf that activates Mek, 
which subsequently activates Erk to phosphorylate the transcription factor Elk-1 leading 
to the transcription of the fos gene. In the nucleus c-FOS and phosphorylated c-Jun 
form the heterodimeric transcription factor AP-1.25 
DAG and increased intracellular Ca2+ concentrations together lead to the activation of 
protein kinase C-θ (PKC-θ), which recruits several proteins into a membrane-bound 
complex that binds and activates inhibitor of κB kinase (IKK) complex. Once active 
IKK can, via ubiquitination and degradation, remove the inhibitor of κB (IκB) from the 
NFκB molecule allowing it to enter the nucleus. The activation and translocation of 
these three transcription factors leads to the transcription of many genes, including Il2 
the importance of which will be discussed later in this section. 25 
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Antigen recognition by the TCR is only the first of three signals required to fully 
activate CD4+ T cells; without adequate co-stimulation TCR activated cells will become 
anergic and unresponsive to activation. Binding of the T cell expressed CD28 to CD80 
and CD86 (also known as B7.1 and B7.2 respectively) on the APC is the primary and 
most important co-stimulatory signal required for sustained T cell activation. Binding of 
CD28 to the B7 complex leads to several signalling pathways that support and 
complement TCR activation. Binding of tyrosine kinases Lck and Itk to CD28 removes 
inhibition and boosts their kinase activity. CD28 can also recruit adaptor proteins that 
can activate the MAPK pathway, and it activates PI3 kinase that recruits Akt and has 
roles in inhibiting cell death, such as increasing BCL-XL protein and inhibiting FAS 
signalling, thus increasing survival of the activated cell. CD28 signalling also increases 
activation of IKK, further removing inhibition of NFκB nuclear function.26 
CD28 signalling contributes to the boosting of IL-2 secretion via several diverse 
mechanisms. The IL-2 promoter has binding sites for NFAT, NFκB, AP-1 and Oct1, 
these binding sites are also regulatory elements inhibiting transcription until bound by 
transcription factors. Oct1 is constitutively expressed in lymphocytes but the CD28 
signalling induction of the other transcription factors assists the TCR driven 
deregulation of Il2 transcription. CD28 ligation also supports IL-2 expression via post-
transcriptional mechanisms. Cells have various mechanisms of degrading mRNA, one 
of which is production of proteins targeting AU-rich elements within the 3’ untranslated 
regions, which are common in cytokine mRNA. TCR activation leads to the production 
of one of these proteins tristetraprolin (TTP), the absence of which causes augmented 
IL-2 production, and CD28 signalling has been shown to inhibit TTP driven 
degradation of IL-2 mRNA through as yet unresolved mechanisms. Through both pre- 
and post-transcriptional mechanisms CD28 co-stimulation leads to a 50-100 fold 
increase in IL-2 production by activated T cells.19, 26 
Cytokine signalling provides the third signal that promotes T cell activation. IL-2 in an 
important cytokine for driving optimal CD4+ T cell activation. Along with IL-2 
production, expression of IL-2 receptor α (CD25) is also initiated by TCR ligation. 
CD25 is a high affinity receptor and has been found to first bind IL-2 then bind IL2Rβ 
(CD122) and the common gamma chain (γc), which brings in the intracellular signalling 
motifs. CD122 and γc can bind IL-2 and cause signalling alone, but CD25 increases the 
receptor affinity significantly and stabilises the complex. The TCR driven expression of 
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IL-2 and CD25 leads to autocrine and paracrine signalling through the IL-2R inducing 
MAPK and PI3K pathways to boost cell survival and proliferation, and STAT5, which 
mediates expression of cytokines such as IL-4 and also causes a second, and greater 
increase of CD25 expression. Optimal activation of CD4+ T cells requires the three 
signals of TCR binding, co-stimulation and cytokine signalling, however the quality and 
quantity of the all three signals can dictate the activation phenotype a CD4+ T cell 
acquires. 27 
1.2.3 Differentiation of activated CD4+ T cells 
The seminal paper in 1986 by Mosmann and Coffman first documented that clones of 
activated CD4+ T cells could be segregated into two populations based upon their 
cytokine secretion profiles. These subsets were defined as Th1 identified by the 
production of interferon-γ (IFN-γ), and the IL-4 producing Th2 cells28. It was found that 
IL-12, produced by APCs and other innate immune cells responding to 
proinflammatory signals, drives newly activated CD4+ T cells to a Th1 phenotype29. 
For in vitro differentiation IL-4 is critical for Th2 cell generation30, though it appears to 
not be required in vivo as Th2 cells can be identified in IL-4 deficient mice31. Two 
differentially expressed transcription factors, T-bet and GATA3 were found to be 
required for stable differentiation into Th1 and Th2 respectively32, 33.  
In the past two decades it has been recognised that CD4+ T cells can occupy more than 
just two activation states34. Suppressive regulatory T cells were identified as a unique 
phenotype of CD4+ T cells35. Th17 cells, predominantly expressing IL-17 were 
subsequently discovered36 followed by IL-9 producing Th9s37 and IL-22 (but not IL-17) 
producing Th2238. CD4+ T cells that support antibody production reside either within 
the lymph node (LN) T and B cell zone borders or in the reactive germinal centre and 
were named T follicular helper (Tfh) cells and germinal centre Tfh (GC-Tfh) 
respectively39. Recently a putative granulocyte-macrophage colony stimulating factor 
(GM-CSF) producing population has been discovered but the in vivo relevance of these 
cells needs to be confirmed40. Briefly described below are the characterised CD4+ T cell 
activation phenotypes and their proposed roles in infection and disease. 
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Figure 1.1 – The differentiation phenotypes of activated CD4+ T cells.  
Activated CD4+ T cells have been shown to differentiate into seven activation phenotypes that 
can be identified by their expression of specific transcription factors and cytokine profiles. The 
presence of some cytokines preferentially drive differentiation of certain phenotypes. These 
cytokines have been listed as differentiating cytokines, but there are varied requirements for 
these cytokines in vivo. Adapted from O’Shea and Paul, 201034. 
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1.2.3.1 Th1 
The drivers of the Th1 phenotype and what roles these cells play in immune responses 
have been well researched41. Initially it was shown that IL-12 was required for Listeria 
monocytogenes driven Th1 activation29, and later it was shown that IFN-γ also played an 
important role in sustaining the Th1 phenotype42. The transcription factor T-bet is the 
master regulator of the Th1 phenotype, controlling the expression of IFN-γ, while also 
suppressing many of the genes associated with Th2 and the other Th phenotypes32. Th1 
cells are characterised by their production of high levels of IFN-γ, as well as tumour 
necrosis factor-α (TNF-α) and IL-243. Functionally, Th1 cell have been associated with 
the control of intracellular bacterial infections, such as mycobacterial species44. Their 
production of IFN-γ activates macrophages, the major reservoir of these infections, 
increasing their bactericidal abilities45, while TNF-α can induce macrophage death 
depriving the bacilli of intracellular refuge46. Th1 cells also support B cell activation and 
isotype switching, driving the production of IgG2a, which can be important in 
controlling extracellular bacterial infections47. 
1.2.3.2 Regulatory T cells 
Regulatory T cells (Tregs) represent another potential phenotype of CD4+ T cells that 
demonstrate particular proficiency in inhibiting autoimmune inflammation48. The 
expression of CD25 on CD4+ T cells from naïve animals has been found to mark a 
population of Tregs known as natural Tregs (nTregs) that develop from cells with 
moderately high self-recognition during negative selection in the thymus49. Forkhead 
box P3 (FoxP3) is the master transcription factor maintaining Treg function; it represses 
the transcription of IL-2, IL-4, IFN-γ and promotes CD25 and cytotoxic T-lymphocyte-
associated protein 4 (CTLA-4) expression50.  
Peripheral naïve CD4+ T cells can be stimulated in certain conditions to become one of 
several populations of Tregs; these populations are gathered under the generic title of 
inducible Tregs (iTregs)51. In vitro activation of naïve CD4+ T cells in the presence of 
TGF-β induces FoxP3 expression; the addition of IL-2 further solidifies the Treg 
phenotype52. Tregs can express IL-10 and TGF-β, though the ability to suppress 
inflammatory responses depends on different factors in different models53. CTLA-4 
expression by Tregs can signal back to APCs via CD80 and CD8654, causing down-
regulation of co-stimulatory ligands and production of indoleamine 2,3-diogenase (IDO) 
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by the APCs, which cause death of T cells in the vicinity by converting tryptophan to 
the T cell toxic kynurenine55. The production of IL-10 by Tregs has been shown to be 
critical for inhibiting the development of colitis56. Through their expression of the high 
affinity IL-2Rα subunit CD25 it is also proposed that Tregs can act as IL-2-sinks, taking 
up available IL-2 limiting the support that newly activated effector cells would usually 
receive via autocrine or paracrine IL-2 signalling57. Tregs represent an important CD4+ 
T cell phenotype; these cells are critical for inhibiting self-reactive T cell responses, 
inducing tolerance to foreign proteins and limiting and resolving immune reactions. 
1.2.3.3 Th17 
The discovery of the IL-12 related cytokine IL-23 lead to the recognition of a separate 
phenotype of effector CD4+ T cells, the Th17 cell58. These cells can be identified by the 
expression of IL-17 and the master transcription factor, a splice variant of retinoic acid 
receptor related orphan receptor γ (RORγ), RORγt59. Similar to Tregs, Th17 cells 
respond to TGF-β for in vitro differentiation but also require a second signal. This was 
originally found to be IL-6, though this can be replaced by IL-21, and IL-1 signalling 
can replace TGF-β, indicative of redundancy in their activation. It was also found that 
IL-23 actually reinforces the Th17 phenotype of already activated cells.60 Th17 cells are 
critical in promoting antifungal immunity61, but inappropriate Th17 activation has 
been implicated in autoimmune responses in multiple sclerosis6261. Along with IL-17, 
Th17 cells also produce IL-22, IL-6, IL-21 and TGF-β63. RORγt and FoxP3 negatively 
regulate the CD4+ T cell differentiation programmes of Tregs or Th17 respectively64.  
1.2.3.4 Th22 
The production of the cytokine IL-22, part of the IL-10 family of cytokines, was 
originally attributed to Th17 cells. However, identification of cells producing IL-22 
independently of IL-17 lead to the discovery of Th22 cells65. These cells rely upon the 
aryl hydrocarbon receptor as a master transcription factor66. Epithelial cells, 
keratinocytes and some fibroblasts, are the only cells which express IL-22R; signalling 
by IL-22 on these cells drives the production of antimicrobial products67. IL-22 
production from Th22 cells is associated with controlling microbial colonisation of 
mucosal surfaces. Limiting the ability of potentially pathogenic microbes to colonise 
intestinal surfaces has been shown to be vital for controlling inflammatory colitis68 and 
mediating wound repair69. 
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1.2.3.5 Th9 
IL-4 and TGF-β are required for optimal differentiation of a CD4+ T cell phenotype 
known as Th9 cells 37. While IL-9 production was originally attributed to Th2 cells, 
identification of IL-9 expressing, IL-4 negative, and GATA3 low cells defined Th9 as a 
separate activation lineage70. Pu.1 is the transcription factor that maintains the Th9 
phenotype71}. These cells have pathogenic roles in airway inflammation72, but have 
been shown to contribute to anti-helminth responses73 and the maintenance of innate 
cells in several inflammatory models74. The discovery that IL-1 family cytokines, along 
with TGF-β could induce Th9 cells independently of IL-4 reinforces the independent 
status of Th9 cells75. 
1.2.3.6 T follicular helpers 
T follicular helpers (Tfh) are a distinct subset of CD4+ T cells residing within the 
germinal centres of lymphoid organs and supporting B cell antibody production. Tfh 
express CXCR5, a chemokine allowing migration into the B cell follicle, programmed 
cell death protein 1 (PD-1), inducible T cell co-stimulator (ICOS) and IL-2176. With the 
discovery of the master transcription factor Bcl6, a transcriptional repressor that inhibits 
the expression of many genes through both epigenetic modifications and DNA binding, 
Tfh was resolved into a CD4+ T cell effector subset separate from Th1 or Th277. IL-21 
and IL-6, both signalling via STAT3, can induce differentiation in vitro of CD4+ T cells 
with a Tfh phenotype78. Recently the Tfh subset has been divided in two with a 
population of cells expressing very high levels of CXCR5, PD-1 and ICOS being 
separated from the intermediate expressing cells. These high expressers have been 
labelled germinal centre Tfh (GC Tfh) as opposed to the intermediate expressing Tfh 
that appear to be located closer to the T-B cell border79, 80. Whether these are distinct 
differentiation states, or rather representative of a spectrum of phenotypes that cells can 
display depending upon activation state and signals, is yet to be delineated. Along with 
IL-21 Tfh cells can make moderate levels of cytokines usually associated with Th1, Th2 
and Th17 cells39. Furthermore rather than Th2 cells, Tfh make up the majority of IL-4 
producing cells in the LN during parasitic infections81. Tfh promote B cell responses, 
survival and isotype switching by mediating formation of the GC, producing supportive 
and isotype driving cytokines and expressing cell surface molecules such as CD40L and 
PD-1, which provide proliferative and pro-survival signals to the B cell82. Their 
importance in antibody production and their ability to co-express cytokines of the other 
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Th phenotypes make these cells a confounding factor when assessing the roles of 
activated CD4+ T cell phenotypes in immune responses. 
1.2.3.7 Th2 
IL-4 is a strong promoter of Th2 differentiation but experiments demonstrating Th2 
generation in IL-4 deficient mice indicate that it is not a required factor which mean the 
signals which drive Th2 differentiation in vivo remain unknown31, 83. GATA3 is the 
master transcription factor of Th2 cells and instigates their production of the cytokines 
IL-4, IL-5 and IL-13, though IL-4 can be expressed independently of GATA3 in 
already differentiated Th2 cells84. These cells will become one of the major focuses of 
this thesis so more detail regarding differentiation, regulation and effector functions are 
covered in subsequent sections. 
1.2.4 Mechanisms influencing CD4+ T cell differentiation 
Activating CD4+ T cells in vitro in the presence of certain combinations of cytokines 
drives the generation of specific Th effector subsets. These data strongly influenced the 
view that it was the in vivo cytokine environment within which a cell was activated that 
would direct differentiation18. This theory was confounded by the fact that the cytokines 
required in vitro to generate certain Th phenotypes, were predominantly produced in vivo 
by the fully differentiated effector Th cells themselves, leading to a causality dilemma. 
Studies demonstrating that Th subsets could be generated in the absence of the in vitro 
driving cytokine lead to investigation into other potential signals that could initiate 
differentiation31, 85. In light of these data, evidence is mounting that rather than being 
the deterministic switches, signalling by some cytokines support selective outgrowth, and 
increase expression of genes that reinforce a particular Th phenotype. 
1.2.5 The contribution of dendritic cells to differentiation 
Antigen presenting DCs have been proposed to provide the deterministic signals that 
drive CD4+ T cell differentiation in vivo. Some studies show that specific subsets of DCs 
are predetermined to preferentially drive a particular activation state86, 87. Other work 
however indicates that the signals DCs received prior to interacting with CD4+ T cells 
can change the DC to promote a certain Th effector phenotype88, 89. In either case the 
route via which DCs dictate Th phenotype is either through the production of cytokines 
like IL-12, or through altered surface ligand expression changing the signalling through 
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co-stimulatory receptors on the CD4+ T cell. CD28 is critical for optimal T cell 
activation but there are several families of co-stimulation receptors, which when 
signalled through, boost T cell activation and can modulate CD4+ T cell differentiation. 
CD70 expression is induced on stimulated DCs and can drive Th1 differentiation by 
signalling through the receptor CD27, the constitutive expression of which is increased 
on activated CD4+ T cells90, 91. Significantly, CD27 signalling inhibited IL-17 
production and Th17 differentiation via transcriptional and epigenetic regulatory 
pathways92. CD28 and CD27 signalling inhibit the generation of iTregs, and the 
absence of CD80, and CD40 on DCs enhances iTreg differentiation91.  
OX40:OX40L interactions have long been proposed as a Th2 skewing pathway, with 
OX40L over-expressing mice being biased towards a Th2 phenotype, potentially by 
directly increasing IL-4 expression93, 94. Recently OX40 signalling along with IL-4 and 
TGF-β has been shown to be a potent initiator of IL-9 production and the Th9 
phenotype95. ICOS signalling was first associated with Th2 generation96 but further 
work has demonstrated that the induction of c-Maf leads to increased IL-4 and IL-21, 
which in turn induces Bcl-6 and CXCR5 on the activated CD4+ T cell and a Tfh 
phenotype97. One predominant theory states the signals the newly activated cells receive 
at the T and B cell zone border divides the closely related Tfh and Th2 phenotypes. 
CXCR5 and ICOS are induced by CD28, CD40 and OX40. If they bind to their 
ligands CXCR13 and ICOSL respectively, which are enriched in the B cell follicle, this 
may seal Tfh destiny and induce migration into the B cell zone98. Extended interaction 
with OX40L or IL-33-expressing border DC could promote Th2 differentiation and 
migration out of the LN instead99. With an increasing amount of literature indicating 
sub-populations, or particular activation states of DCs are critical for the generation of 
certain Th phenotypes, it is becoming clearer that the signals, both cytokine and cell-cell 
receptor mediated, coming from the DC are likely to be very important in determining 
activated CD4+ T cell phenotypes. 
1.2.6 The quantity and quality of T cell receptor stimulation 
influences differentiation 
High affinity antigen-TCR interactions can lead to stronger initial signalling through 
the TCR, stronger binding and increased interaction time with the APC allowing 
paracrine cytokine signalling and contacts with co-stimulatory receptor ligands100. The 
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same DCs presenting slightly different peptides can induce very different CD4+ T cell 
responses79.  
Differing levels of infection in vivo, or antigen dose in vitro differentially can drive Th1 
and Th2 responses. Infection with very low numbers of Leishmania major induced 
protective Th1 responses in usually susceptible Balb/c mice, where as increasing the 
dose lead to Th2 induction101. In vitro studies utilising TCR transgenic cells cultured 
with ranged concentrations of peptide showed that very high levels of peptide lead to 
preferential Th2 differentiation. An intermediate peptide concentration strongly 
favoured Th1 while the balance would move towards Th2 differentiation again at very 
low peptide concentrations102, 103. Antigen dose has also been implicated in the switch 
between Th1, Tfh and GC-Tfh, with an increasing dose of attenuated Listeria 
monocytogenes leading to a decrease in Th1 and Tfh cells and subsequent increase in GC-
Tfh104. The expansion of GC-Tfh with high dose may just represent the increased 
availability of antigen to GC-B cells, which drives GC-Tfh activation by presenting 
peptide within the B cell follicle, though there are intracellular signalling pathways that 
may also explain this pattern. Increased TCR signalling induces interferon regulatory 
factor 4 (IRF4), which allows the expression of Blimp-1, a critical transcription factor for 
Th1, however, expression of IL-12Rβ2 is inhibited at very high levels of TCR 
signalling79. This may explain the preferential differentiation towards Th2 and GC-Tfh, 
and away from Th1, seen with high antigen dose in in vitro and in vivo models 
respectively. 
The sheer number of TCRs that are engaged with peptide-MHC II complexes is not 
enough to fully explain what drives CD4+ T cell differentiation, with many experiments 
indicating that the quality of the interactions must also have a role. The affinity a given 
TCR has for a peptide loaded MHC II molecule can significantly change the APC-T 
cell interaction, increasing the time the cells interact (dwell time) and thus increasing the 
signals a T cell receives105. One group of studies looked at a population of 50 CD4+ T 
cells clones that were all responders to lysteriolysin O peptide from Listeria monocytogenes. 
When exposed in vivo to the peptide together, the polyclonal population produced 
activated CD4+ T cells with the ratio of 2:1:1 of Th1, Tfh and CG Tfh respectively. 
When the clones were analysed individually, they expressed very different 
differentiation patterns with some becoming all Th1 or Tfh, and others with mixed 
phenotypes, however when the phenotypes were averaged they matched the original 
mixed population’s ratios of 2:1:1 Th1, Tfh and CG Tfh104. This indicated that while 
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CD4+ T cells might be able to respond to the same peptide presented by APCs in the 
same conditions, the differences in their TCRs can change the phenotypic outcome of 
the effector cells. 
Differentiation driven by affinity between TCR and peptide-MHC II complexes has 
been demonstrated by measuring the responses of identical transgenic TCR clones to 
slightly altered peptides. P25 TCR transgenic mice have CD4+ T cells that are specific 
for a peptide from antigen 85B (Ag85B), part of a complex of proteins that are the 
major secretion products from Mycobacterium tuberculosis106. Infected mice and humans 
have Ag85B reactive CD4+ T cells that are strongly polarised towards a Th1 
phenotype107. Immunisation with the 15-mer P25 peptide induces strong I-Ab restricted 
Th1 differentiation and expansion of Vβ11 expressing CD4+ T cells, which were able to 
protect against subsequent challenge with M. tuberculosis108. TCR transgenic mice were 
generated from P25 reactive CD4+ T cell clones, and cells from these mice stimulated 
by P25 peptide-loaded APCs display Th1 differentiation in the absence of IL-12, IFN-γ 
or any other polarising conditions109. It was found that decreasing the peptide 
concentration that the DCs were pulsed with did swing the P25 TCR transgenic cell 
responses to a more Th2 phenotype, as had been reported in other models109. Tamura 
et al wished to understand the role of the peptide in driving CD4+ T cell differentiation 
so they created an altered peptide (altered peptide ligand, APL) to compare to P25. The 
binding of the P25 peptide into the I-Ab cleft and the interaction with the transgenic 
TCR had been characterised, allowing targeted single amino acid modification from 
glutamic acid to alanine, ensuring the altered peptide maintained its MHC II binding 
characteristics but decreased the affinity of the TCR. Then they compared the in vitro 
differentiation of P25 TCR transgenic cells stimulated with DCs pulsed with the same 
concentration of each of the peptides and found that, unlike the P25 driven Th1, the 
APL induced Th2 polarisation.106 The phenotype of DCs pulsed with either of the 
ligands were not reported to be significantly different so it was inferred that the 
alteration in TCR affinity was the sole driver of the differential polarisation by the two 
peptides. 
1.2.7 Multiple signals drive differentiation 
The understanding of what drives differentiation of CD4+ T cells into the range of 
effector subsets recognised today has significantly evolved over the last two decades. 
From initial studies which demonstrated that the cytokine milieu determined effector 
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function, to demonstrations that different DC subsets, or the expression of co-
stimulatory molecules by APCs, were critical, and work comparing the contribution of 
TCR affinity, it appears likely that no single factor is the switch that decides a CD4+ T 
cell fate. It is highly probable a complex matrix of factors, with certain combinations of 
signals preferentially driving differentiation towards one of the Th phenotypes.  
A recent study by Van Panhuys et al. has attempted to compare the relative 
contribution by several different factors in determining the difference between Th1 and 
Th2 differentiation. This study assessed in vivo responses by TCR transgenic CD4+ T 
cells specific for pigeon cytochrome C peptide (pPPC) to pPPC loaded DCs exposed to 
Th1 skewing adjuvants lipopolysaccharide (LPS) and CpG oligodeoxynucleotides (CpG) 
or Th2 skewing papain or Schistosomal egg antigen (SEA) prior to adoptive transfer. 
The CD4+ T cells spent a longer time interacting with Th1 skewed DCs than Th2, and 
the expected cytokine profiles (IFN-γ from Th1 and IL-4 from Th2) were induced by 
each of the adjuvant treated DCs. It was found that Th1 stimulated DCs expressed 
higher levels of CD80, and blocking antibodies against this co-stimulatory ligand led to 
Th1 skewed DCs inducing increased CD4+ T cell IL-4, decreased IFN-γ and having 
decreased interaction times with the CD4+ T cells.89 
The antigen dose the DCs were loaded with can drastically change the CD4+ T cell 
phenotype irrespective of the adjuvant DCs are treated with. Transgenic CD4+ T cells 
exposed to Th1 or Th2 skewed DCs pulsed with low peptide concentrations showed a 
significant expression of IL-4, while increasing the dose of peptide lead to a proportional 
increase in IFN-γ expression and decreased IL-4. The effect of peptide dose was 
considerable with low peptide concentrations inducing equal IL-4 and IFN-γ even from 
Th1 skewed DCs, and high peptide Th2 skewed DCs inducing much more IFN-γ than 
IL-4. The increase of peptide dose also had a significant effect on the expression of IL-
12Rβ only 24 hours after stimulation. This increase was even more exaggerated with 
the Th1 skewed DCs, though it was still present in the Th2 group.89 This pathway could 
be a mechanism through which Th1 differentiation is perpetuated in high antigen 
exposed CD4+ T cells. This study found that antigen dose was a strong mediator of 
CD4+ T cell differentiation, although in situations of equal TCR stimulation, adjuvants 
could drive differential co-stimulation ligand expression by DCs, which also 
preferentially induced different Th phenotypes. Finally, increased TCR stimulation lead 
to cells being more sensitive to their cytokine milieu, potentially allowing reinforcement 
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of a certain phenotype if the right environmental signals are present.89 Although far 
from complete, this research effectively compares different signals in a very controlled 
system, and further studies will need to consider the full context of T cell stimulation 
while assessing the contributions of certain signals to differentiation.  
 
1.3 T helper 2 cells; orchestrators of Type 2 immunity 
The identification of Th2 as a specialised phenotype of activated CD4+ T cells lead to 
the association of these cells with immune responses against particular infections110, 111, 
but also in diseases caused by overactive immune responses112. Th2 cells are 
distinguishable by their expression of IL-4, IL-5, and IL-13 and the master transcription 
factor GATA3, however other genes are also closely related to Th2 function113. IL-3 has 
long been associated with Type 2 immune responses114 and mediates basophilia and the 
development of mast cells and eosinophils115. IL-9, which is also important for inducing 
mastocytosis was once attributed to Th2 cells but identification of the closely related 
Th9 cells and ILCs means most IL-9 production is now considered Th2 independent116. 
The dual roles of Th2 cells in protection and pathology have been widely studied, and 
while many of their specific functions have been characterised in a variety of models it is 
still not known what differentiates a pathogenic from a protective Type 2 immune 
response. 
1.3.1 Protective roles for Th2 cells 
Initial experiments using Leishmania major and Trichinella spiralis infection models found 
that strains of mice that displayed resistance to infection tended to induce a Th1 
phenotype, while production of Th2 cytokines was associated with susceptibility to 
infection117, 118. However for many of the parasitic worms known as helminths, Type 2 
immune responses were critically important for the protection observed in mice 
receiving a second infection challenge. Type 2 immune responses were shown to be able 
to disrupt the life cycles, and pathology associated with infection of model nematodes, 
trematodes and cestodes, though the mechanisms controlling these infections varied 
with the specific parasites119.  
The production of the IgE antibody requires both CD4+ T cells and IL-4, and the 
driving of class switching B cells to IgE production was long attributed to Th2 cells, 
however the recent discovery of Tfh as the major IL-4 producer in LNs has changed 
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this interpretation120. Despite its roles in increasing survival and activation of basophils 
and mast cells through FcεRI ligation121, the role for IgE in the expulsion of, or 
protection against intestinal helminths remains controversial122, 123.  
The lumen of the intestines are a desirable place for a parasite to reside, with ample 
access to nutrients, relative shielding from direct attack by host immune responses and 
an easy way to disseminate eggs; many helminth species spend at least part of their life 
cycle within the gut. Th2 responses play a critical role in expulsion of these gut residing 
helminths. Nippostrongylus brasiliensis is a nematode that follows an infectious route 
common to many human and rodent hookworms. Larvae penetrate the skin then travel 
through currently undetermined routes to the lung parenchyma where the larvae 
undergo a moult and travel via the mucociliary ladder up the trachea then down into 
the small intestines, where the adult worms mate and produce eggs.124 In a primary 
infection Th2 derived signals are required for expulsion of these worms from the gut; 
the absence of CD4+ T cells, either in Rag1-/- or antibody depleted mice, allows worms 
to remain in the gut for a significantly longer time14, 125, 126. The loss of expulsion with 
CD4+ depletion can be largely rescued by the addition of Th2 cytokines IL-4 and IL-
1314, 126. However, a recent discovery found that T cell specific IL-4-/- and IL-13-/- mice 
have normal expulsion of worms, while global IL-4-/- and IL-13-/- mice have a 
significant number of the worms surviving in the intestine at day 9 post-infection127. So 
while CD4+ T cells may be important for N. brasiliensis expulsion, they may be recruiting 
another population of Type 2 cytokine producing inflammatory cells. 
The immune response initiated against Trichuris muris depends on the strain of mouse 
infected; the preferential differentiation of Th1 or Th2 CD4+ T cells dictates whether a 
given strain will be susceptible or resistant to long term infection128. Mice ingest Trichuris 
muris eggs, which hatch in the ileum and larvae migrate to the proximal colon and 
caecum, there they burrow into the gut wall, constructing tunnel-like structures 
consisting of dead epithelial cells and actin129. Strains of mice that are resistant to the T. 
muris infection induce strong Th2 responses that mediate expulsion of the worms130. 
The direct mechanisms that drive T. muris infection are unknown but as it burrows into 
the gut tissue, similar to Heligmosomoides polygyrus, there are likely to be shared pathways 
that dictate protective responses. 
Heligmosomoides polygyrus larvae have a free-living stage after hatching, however instead of 
infecting via skin penetration H. polygyrus requires ingestion to initiate infection. Once in 
the small intestine H. polygyrus larvae rapidly invade the wall of the intestines where they 
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undergo two moults, emerging approximately 8 days later into the lumen of the 
intestine as adults. Primary infection establishes a chronic infection, with the length of 
infection mouse strain dependent, ranging from 4 to 20 weeks.124 T and B cell deficient 
mice display prolonged infections, CD4 depletion leads to increased fecundity (a read 
out of worm health), whereas adoptive transfer of CD4+ T cells to naïve mice can 
decrease the length of infection114. Whilst Type 2 immune responses play a role in 
resolution of the primary infection, it is in a secondary reaction that the Th2 cell is truly 
important. Mice that have had their primary infection cleared after two weeks by 
treatment with anti-helminthics, will efficiently clear a secondary infection within two 
weeks of reinfection110. The clearance of the secondary infection requires responses by 
memory Th2 cells and macrophages in the granulomas that form around the larvae 
once they bury into the gut wall of an immune individual. Th2 cells maintain the 
macrophages in an alternately activated phenotype that is critical for causing the worm 
stress and decreasing worm survival.131 
N. brasiliensis primary infection is transient in immune-competent mice and the strong 
Th2 driven immune responses generated are able to provide protection against 
secondary challenge, with up to 90% of worms being killed before they can migrate to 
the intestines and become adults132. The mechanism of killing and the location where 
this protection occurs is still uncertain, though strong evidence indicates the lung 
immune environment may play a significant role in protection. Protection against 
secondary infection is diminished in CD4+ T cell deficient MHC II-/- mice and in mice 
deficient for the intracellular signalling molecule downstream of the IL-4 and IL-13 
receptors, signal transducer and activator of transcription 6 (STAT6)132. Using TCR 
transgenic animals with varying proportions of their CD4+ T cell repertoire consisting 
of N. brasiliensis non-responding cells it was demonstrated that bystander activation was 
uncommon, with none of the CD4+ T cells with specific transgenic TCRs for either 
ovalbumin (OVA) or lymphocytic choriomeningitis virus (LCMV) peptides becoming 
Th2 differentiated, despite measurable responses from CD4+ T cells not expressing the 
restricted TCR within the same tissues. These experiments also found that protection 
was inversely proportional to the fraction of CD4+ T cells that had restricted TCRs; the 
more unrestricted TCR carrying CD4+ T cells the greater the protective response. In 
mice where their entire CD4+ T cell population consisted of cells carrying a restricted 
TCR there was a total loss of protection.133 
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Harvie et al. targeted the lung as the principal site for Th2 priming in eloquent 
experiments where mice were initially infected subcutaneously (for skin and lung 
priming), intranasally (i.n.) (lung priming) or by oral gavage (gut priming) with 
developmentally appropriate larvae for each site. The skin and/or lung primed mice 
were treated with anti-helmenthics to kill the worms before they could effectively 
migrate to the gut. These primed mice were then challenged subcutaneously and the 
numbers of worms in the lung on day 2, or the gut on day 6-post infection enumerated 
to assess the ability of mice primed at different locales to protect against the worms. 
These experiments demonstrated that only mice that were primed by infection passing 
through the lung had effective protection and the ability to kill worms early in the 
infection. Mice with both skin and lung priming had the same level of protective 
responses as those that were just primed via the lung, indicating the skin is not a strong 
site of protective responses. Mice that had only received gut priming had the same 
number of intestinal larvae as the other primed mice indicating that they could expel 
intestinal worms efficiently, but they had high worm counts at day 2 in the lung 
indicating gut priming did not provide systemic protection.132 This study was followed 
by a publication that demonstrated that adoptive transfer of CD4+ T cells from the lung 
of a primed mouse could provide protection to naïve mice, and signalling through IL-
4Rα was required to induce protection134. While earlier papers had demonstrated the T 
cell specific IL-4Rα expression was required for optimal N. brasiliensis induced cytokine 
responses135, it was then demonstrated using FTY720, a sphingosine 1 phosphate 
receptor agonist which blocks LN egress of naïve lymphocytes, that a population of IL-
4Rα dependent lung resident CD4+ T cells responded to N. brasiliensis infection and 
were sufficient for providing protection134. These data demonstrate that lung Th2 
responses are essential for protecting against N. brasiliensis infection, though how the 
worms are arrested and killed remains to be demonstrated. 
1.3.2 Pathogenic roles for Th2 cells 
Th2 activation, when targeted towards killing or expulsion of parasites has obvious 
benefits for the host, however, Th2 cell responses also mediate the development of 
allergic diseases and the associated detrimental pathologies. Allergic diseases arise when 
the immune system responds to an innocuous antigen. The overt immunological 
response can cause significant damage to tissues often impairing function and 
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occasionally leading to potentially lethal systemic anaphylactic reactions19. These 
immune responses are predominantly of a Type 2 phenotype, sharing many features of 
an anti-parasite response including Th2 differentiation, IgE production, accumulation 
of mast cells, basophils and eosinophils, and mucus production136, 137. For experimental 
models of allergic disease two phases are required; a sensitisation phase, which initiates 
the Type 2 response often at a systemic level138. This is followed by a challenge, which 
accumulates the necessary mediators in the particular tissue and initiates the 
pathology137. While it is unknown if this is how allergies are generated in humans, these 
sensitisation/challenge models produce pathologies that mirror many of the salient 
features of the human diseases. 
Asthma is a term used to cover a number lung diseases with a range of causes and 
phenotypes, however allergic asthma is a form of the disease associated with Type 2 
immune responses towards a single, or group of trigger antigens139. Allergic asthma’s 
most significant characteristic is eosinophilia in the lungs particularly in the bronchial-
alveolar lavage fluid (BALF)140. In murine models of allergic asthma mice are 
commonly sensitised against an allergen then challenged with the same antigen either 
intranasally or with inhaled aerosolised antigen141. The lungs undergo significant 
pathological changes after challenge, with infiltrations of a range of leukocytes, 
particularly eosinophils and mucus production that can cause obstruction of airways in 
severely asthmatic individuals142. An objective read out of asthma severity is airways 
hyperreactivity (AHR), this can be assessed by administration of a non-specific 
bronchoconstrictive stimulant such as acetylcholine or methacholine. Subsequently, 
lung function changes can be measured by using whole-body plethysmography, or 
measuring pulmonary resistance and dynamic compliance in tracheotomised mice.141 
Mice with AHR will have far greater bronchoconstriction compared to baseline or 
naïve mice. This is due to increased responsiveness of smooth muscle cells to the 
bronchoconstrictive stimulant141, 142. The direct mechanisms priming the smooth muscle 
cells are unknown, but both nervous and cytokine signalling appear to play a role143, 144. 
Eosinophilia in the lung can be decreased by antibody neutralisation of the Th2 
cytokine IL-5, or by simultaneous disruption of IL-4 and IL-13 signalling145. AHR and 
mucus production require the priming and presence of Th2 cells, as does antigen 
specific IgE production146.  
Food allergy demonstrates many of the same the features and requirements as allergic 
asthma. Th2 dependent IgE production induced by sensitisation is required for the 
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development of disease147. Mast cells infiltrate the gut and are primed to release 
anaphylaxis-inducing factors including histamines and mast cell proteases upon antigen 
binding and cross-linking of FcεRI bound IgE148. Th2 (and Th9) associated cytokines 
IL-3 and IL-9 are proposed to be important for mucosal mastocytosis149. IgE loaded 
mast cells and basophils in the skin are also proposed to be important for wheal and 
flare reactions during localised exposure to an allergen150. Allergic skin diseases such as 
atopic dermatitis and eczema can also have Th2 dependent eosinophilia, which often 
correlates with severe pathology. Th2 cells in atopic dermatitis models have been shown 
to produce the cytokine IL-31 that potentially increases the itch response leading to 
increased damage to the skin and further inflammation.151 
Atopic diseases including allergic asthma, rhinitis, food allergies and atopic dermatitis 
are caused by dysregulated tolerance leading to differentiation of Th2 cells that 
choreograph the pathogenic responses in the effected tissues. While the exact reason 
these immune responses are initiated is still unknown significant research has been 
focussed on blocking the downstream pathogenic Type 2 responses that mediate 
pathology.  
1.3.3 Immunopathologies as side effects of protective Type 2 
responses against helminths 
The Type 2 immune response is associated with wound healing and the resolution of 
damage. While in some situations Type 2 responses induce appropriate healing 
responses, in others the overactive immune system causes more damage than what 
would have occurred in the absence of a response. Th2 cell responses in the lung are 
critical for mediating protection against a secondary infection, they are also important 
for limiting and resolving the damage caused by the invading parasites119. As reported 
by Chen et al. when N. brasiliensis enter the lung they cause a large amount of damage 
resulting in haemorrhaging into the airways. IL-17 driven responses can recruit 
neutrophils that increase the number of red blood cells (RBCs) in the BALF. Both Th2 
cytokines IL-4 and IL-13, signalling through IL-4 receptor α (IL-4Rα), redundantly 
opposed the Th17 induction, limiting neutrophilia and decreasing haemorrhaging. 
Macrophages activated by Th2 signals were critical to both clearance of RBCs from the 
airways and limiting inflammation, their depletion or functional inhibition leading to 
significantly greater inflammation in the alveolar spaces.152 
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After a primary N. brasiliensis infection has passed through the lungs a long-term 
response is initiated which leads to major remodelling of the lung architecture, resulting 
in AHR and an emphysema-like phenotype. Marsland et al. have shown that the 
remodelling appears permanent, having been measured out to 300 days following 
infection153. The excreted products of the N. brasiliensis larvae were sufficient to induce 
AHR but not emphysema, signifying potentially divergent mechanisms, with an 
inflammatory cause for the AHR, while infection related damage may cause the 
emphysema development. IL-13-/- animals were slightly protected from developing 
AHR, while IFN-/- mice displayed more severe AHR after infection, hinting that the 
Th2 cytokines may play a role. This correlates with data demonstrating high levels of 
Th2 cytokines in the lungs over 36 days post-infection. However, IL-13-/- and IL-4Rα-/-
mice both developed the emphysema phenotype concluding that neither IL-4 nor IL-13 
was the driving cytokine for the lung remodelling.153 It has been suggested that the 
remodelling events may be part of the protective mechanism, making it more difficult 
for subsequent infections to transit the lung, though this remains to be evaluated. So 
while Th2 responses are initially protective in limiting haemorrhage, they can then 
contribute to the development of post-infection AHR, giving them a mixed role in the 
lung during primary infection. 
Schistosoma mansoni is a trematode, or blood fluke, that infects both mice and humans. 
The adult worms live in the blood and immune responses generated against them are 
initially Th1 polarised, but once a mating pair of adults begin releasing eggs a very 
strong Th2 shift occurs. The released eggs pass through the liver on their way to the 
intestines or bladder, they can become lodged in the sinusoids of the liver where a 
strong Th2 driven immune response generates a granuloma to wall off the egg.154 In the 
absence of IL-4 signalling a pathogenic, largely Th1 mediated, inflammation develops 
in both the liver and the intestine, which could lead to lethal septic shock. In the 
presence of sufficient regulatory pathways largely controlled by IL-10 and macrophages, 
the granulomatous response is kept under control.155 In the absence of regulation IL-13 
driven fibrosis can significantly compromise liver function156. This represents another 
situation where Th2 responses are the balance between regulation and pathology; while 
Th2 cytokines control Th1 driven inflammation, which may be lethal for the Schistosoma 
mansoni infected host, IL-13 also drives the development of fibrosis leading to long-term 
liver damage.  
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1.4 Functions and expression of IL-4 and IL-13 
IL-4 and IL-13 mediate many of the down stream effector functions of the Type 2 
immune response; although these two cytokines share many common features they have 
been found to have very divergent roles in vivo. IL-4 and IL-13 are closely related 
cytokines, their genes are adjacent to each other on mouse chromosome 11 (human 
chromosome 5)157. Both proteins have a structure largely consisting of α-helices and use 
the IL-4Rα chain as part of their receptor complexes158. They have many overlapping 
functions in Type 2 immune responses. IL-4 was originally identified as a B cell 
stimulating factor, shown to promote proliferation of activated B cells159 and class 
switching to the IgG1 isotype160. It was soon shown that T cells could produce IL-4 and 
upon the realisation that Th1 and Th2 clones could be identified by IFN-γ and IL-4 
respectively, IL-4 became the signature cytokine of Th2 activation28. IL-13 was 
identified as a very closely related cytokine sharing approximately 30% sequence 
homology with IL-4161. IL-13 was subsequently shown to be able to induce many of the 
same immune responses as IL-4, including driving the class switching of human B cells 
to IgG4 and IgE production162, although the generation of genetic knock-out and 
neutralising antibody reagents for IL-13 delineated non-redundant functions in a range 
of models. 
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Figure 1.2 – CD4+ T cells and IL-4/IL-13 signalling are central to Type 2 immune 
responses.  
Damaged epithelial cells release cytokines including IL-25, IL-33 and TSLP that drive 
migration and activation of DCs to the LN where they present antigen and drive differentiation 
of Th2 cells. Epithelial derived cytokines also activate ILC2s within the tissues. IL-4 and IL-13 
from ILC2s, mast cells, basophils and Th2 differentiated CD4+ T cells signal through the type I 
and type II receptors. IL-4 drives IgE isotype switching by B cells through the type I receptor 
(IL-4Rα and γc). IL-13 has higher affinity for the type II receptor complex (IL-4Rα and IL-
13Rα1) than IL-4; signals through this receptor promote eosinophilia, goblet cell mucus 
production and smooth muscle contractility. Macrophages responding to IL-4 and IL-13 
through both receptor complexes express an alternate activation phenotype associated with 
wound healing and protective responses against helminths. 
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1.4.1 IL-4 and IL-13 receptor complexes 
The receptor for IL-4 is widely expressed on both haematopoietic and non-
haematopoietic cells163. The receptor consists of a heterodimer of IL-4Rα and the γc, 
which is shared by a large number of cytokine receptors including IL-2, IL-7, IL-9, IL-
15 and IL-21164. Ligation of IL-4 to the receptor triggers two intracellular signalling 
pathways, one via STAT6 and another that phosphorylates insulin receptor substrate 2 
(IRS2) and can cause activation of the PI3 and MAPK pathways. IRS2 triggering may 
be important for myeloid responses to IL-4, though lymphoid cells appear to rely 
completely on the STAT6 pathway.165 Naïve lymphocytes express about 300 IL-4Rα 
molecules and upon activation this number increases between 5-10 fold, increasing their 
sensitivity to IL-4, which can reinforce Th2 phenotype differentiation of CD4+ T cells 
or class switching by B cells166. T cell expression of IL-4Rα1 is tightly regulated, IL-2 
signalling induces upregulation but once the TCR is engaged and begins signalling, 
expression of IL-4Rα1 is negatively regulated, leaving only a small window just before 
and during early antigen recognition that CD4+ T cells can respond to initial IL-4 
signalling. Once STAT6 is phosphorylated transcription of IL-4Rα1 and IL-4 is stably 
increased.165  
IL-13 also utilises the IL-4Rα subunit for its receptor, but replaces the γc with a specific 
IL-13Rα1 subunit. IL-4 can also bind this receptor complex167. The sharing of 
receptors and the relative abundance of the subunits on different cell populations has 
exposed some interesting biology about these two cytokines. The γc is expressed 
preferentially on haematopoietic cells, so non-haematopoietic cells respond to both 
cytokines via the type II receptor (IL-4Rα/IL-13Rα1)168. The affinity of IL-13 for the 
IL-13Rα1 chain is far lower than IL-4 for the IL-4Rα (K= 3 x 107 M-1 and 1010M-1 
respectively), but the IL-4/IL-4Rα complex has about 25 times lower affinity for the IL-
13Rα1 chain that the IL-13/IL-13Rα1 complex does for IL-4Rα chain158, 169. Greater 
amounts of IL-13 are required to saturate initial receptor binding, but once bound there 
is a higher level of signalling induced by IL-13 than IL-4. So, while IL-4 reaches peak 
signalling at lower concentration, provided there is enough IL-13 available it can induce 
a higher maximum signal via the type II receptor. 
IL-13 can bind to the separate IL-13Rα2 chain170, which adds complexity when 
attempting to correlate the amount of IL-13, produced and potential downstream 
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functions. This IL-13Rα2 chain has a four-fold higher affinity for IL-13 than the IL-
13Rα1 and with no obvious intracellular signalling motifs identified it has been 
proposed to act as decoy receptor, regulating the functions of IL-13171. Soluble IL-
13Rα2 has also been detected, this soluble receptor is a potent inhibitor of in vivo IL-13 
function172. The production of IL-13Rα2 can be driven by IFN-γ, IL-17 and TNF-α, 
indicating a potential regulatory pathway via which Th17 cells could attenuate Th2 
effector function173, 174. Knock-out mice deficient for the IL-13Rα2 chain had increased 
levels of tissue IL-13 and decreased serum levels, indicating that the IL-13Rα2 may 
have a role in trafficking IL-13 to the serum or stabilising it there. Macrophages also 
had diminished NO responses to LPS in the absence of the receptor.171 While there is 
still relatively little known about the role of IL-13Rα2, it is an important factor to 
consider when assessing the role of IL-13 function. 
1.4.2 Lymphocyte responses to IL-4 and IL-13 
The generation of an IL-4 neutralizing antibody and an IL-4 knock-out mouse allowed 
assessment of the role for IL-4 in vivo. The near complete inhibition of IgE production 
and diminished IgG1 levels in these models demonstrated the importance of IL-4 for B 
cell function175, 176. Other than the requirement for STAT6 signalling, little is known 
about what signals mediate B cell switch to IgE, or the potential life cycle and location 
of IgE switched cells120. IgE binds to the high affinity receptor FcεRI, and the low 
affinity FcεRII (CD23) receptor. FcεRI is highly expressed on mast cells and basophils, 
and these cells collect serum IgE, which stabilises them and increases their survival. 
When the bound IgE comes in contact with cross-linking antigen, signalling through 
FcεRI causes cellular activation, cytokine production and degranulation.121 FcεRII is 
expressed on B cell surface and can regulate the production of IgE120. Populations of 
macrophages and DCs can express both Fcε receptors, which mediate uptake and 
processing of bound IgE-antigen complexes177. Despite the robust production in 
response to parasitic infection, there is mixed evidence of a role for IgE in most 
experimental helminth infection models122, 123. Production of IgE against an innocuous 
antigen can have dire consequences, as seen in allergies, where the production of 
allergen specific IgE is required for the development of both localised and systemic 
anaphylaxis178.  
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IL-13 was originally shown to drive isotype switching of human B cells, however murine 
B cells do not express the IL-13Rα1 chain so are directly unresponsive to IL-13179. 
Despite this IL-13 is important for mouse B cell effector function in vivo. The 
development of IL-13 over-expressing transgenic mice, and exposure of wild-type (WT) 
mice to recombinant IL-13, increases serum levels of IgE180. IL-13Rα2 knock-out mice, 
with their higher levels of tissue IL-13 also exhibit increased serum levels of IgE, IgA, 
IgG2a and IgG2b antibody isotypes171. Mature T cells in both mice and humans do not 
express the IL-13Rα1 chain, so are also unable to respond to IL-13, however CD4+ T 
cells from IL-13 knock-out mice demonstrated diminished Th2 responses (as measured 
by production of IL-4 and IL-5 expression) both in vivo and with in vitro stimulation. This 
also correlated with diminished antigen specific IgE production in response to 
sensitisation with OVA.181 The fact that IL-13 addition to cultures could not rescue Th2 
responses of CD4+ T cells from IL-13 deficient animals indicates that IL-13 may not be 
directly acting on lymphocytes but may be modulating the function of another cell 
population that is important in lymphocyte development or responsiveness.. This was 
supported by apparent changes in thymic development observed in IL-13 over-
expressing transgenic mice180. However, it was also discovered that the deletion of the 
Il13 gene in mice also disrupted the expression of the adjacent Il4 gene, potentially 
explaining their generally decreased Type 2 responses182. So while IL-13 dependent 
changes in IgE production may be explained by decreased CD4+ T cell availability and 
function or defective IL-4 expression in IL-13-/- mice, how mouse T cells and B cells are 
responding to application of recombinant IL-13 remains to be explained.  
1.4.3 Alternate activation of macrophages 
Macrophages respond to IL-4 and IL-13, which both drive the development of an 
alternate activation phenotype, designated M2a, which is markedly different to IFN-γ or 
toll-like receptor (TLR) stimulated, classically activated M1 macrophages5. 
Macrophages express the IL-13Rα1, which means they can respond to both IL-4 and 
IL-13183. Juntrila et al. demonstrated that macrophages unlike non-haematopoietic cells, 
which rely on the type II receptor, macrophages also express the γc, which modifies 
their relative sensitivities to the two cytokines. Any cell with high abundance of γc and 
IL-4Rα will respond more strongly to IL-4 than equal concentrations of IL-13, 
regardless of IL-13Rα1 expression. If either γc or IL-13Rα1 expression is limited, IL-4 
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driven signalling is significantly diminished. The limiting factor on IL-13 driven 
signalling is the initial binding. Once present in sufficient concentrations to bind, IL-13 
efficiently induces strong recruitment of receptor chains and signalling.168 So while IL-4 
signalling is dependent upon levels of receptor chain availability, IL-13 more heavily 
relies on reaching a critical concentration. 
 M2a phenotypes decrease the production of nitric oxide and express a particular array 
of chitinases. Arginase-1 (Arg1) expression is a defining feature of M2a macrophages, 
and it is an enzyme that directly opposes a crucial pathway utilised by M1 
macrophages5. Inducible nitric oxide synthase (iNOS) is an M1 associated enzyme that 
converts L-arginine to nitric oxide (NO) and L-citrulline, Arg1 depletes the L-arginine 
availability, converting it instead to L-ornithine, which can have roles in mediating the 
metabolic functions of the M2a macrophages184, and potentially in killing helminths122. 
Consumption of L-arginine can have a negative effect on local T cell proliferation and 
may also be a mechanism of suppressing T cell responses184.  
M2a macrophages express the mannose receptor (MR, CD206), which potentially 
mediates the binding of M2a macrophages to carbohydrate rich targets185. While MR 
expression has been inferred to allow macrophages to endocytose glycoproteins for 
processing and presentation, the decreased phagocytosis measured in M2a 
macrophages could diminish the importance of this MR role. Chitinase expression, 
particularly Ym-1 and Ym-2, are significantly increased by macrophages in response to 
IL-4 and IL-13 signalling. Chitin is found in insects and fungi, however the Type 2 
associated upregulation of Ym-1 and Ym-2 lead to theories about the roles these 
enzymes might have in controlling helminths, which both produce chitin and induce 
strong IL-4 and IL-13 expression during infection186. Resistin-like molecule α (Relmα) 
is another protein characteristically expressed by M2a macrophages, Relmα can 
mediate extracellular matrix deposition but also appears to have roles in supressing 
CD4+ T cell effector functions187. M2a macrophages occupy a conflicting position 
within Type 2 immunity, while they are strongly induced by Type 2 cytokines and 
secrete products that may directly effect invading parasites, they also display regulatory 
roles and may be part of a negative feedback loop keeping the inflammatory response in 
check. Identifying macrophages expressing the M2a activation phenotype has proven 
difficult, early studies found that the MR can act as a surrogate for identification but 
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more recent studies have required the expression of multiple identifying molecules 
including Arg-1, Relmα and phosphorylated STAT6 (pSTAT6)5.  
1.4.4 Responses by non-haematopoietic cells to IL-4 and IL-13 
Both IL-4 and IL-13 are expressed by Th2 cells in non-lymphoid tissue during Type 2 
inflammation, however many of the responses seen by non-haematopoietic cells are 
attributed to IL-13 rather than IL-4 signalling. This may be due to differences in the 
relative abundance of the two cytokines but this has yet to be conclusively shown. 
Through the use of cytokine, receptor and STAT6 knock-out mice IL-4 and/or IL-13 
have been shown to be important for leukocyte chemotaxis, mucus secretion, smooth 
muscle hyper contractibility, fibrosis, and tissue remodelling188. 
Through the IL-4Rα/IL-13Rα1 type II receptor both IL-4 and IL-13 are able to 
induce the expression of vascular cell adhesion molecule-1 (VCAM-1) on endothelial 
cells, encouraging the diapedesis of activated leukocytes from circulation into the 
parenchymal tissue189. Comparison of WT mice to those with a genetic deletion of the 
IL-13Rα1 chain demonstrated several significant roles these receptors play in 
inflammatory models. Loss of the IL-13Rα1 chain means IL-13 cannot signal at all and 
IL-4 will no longer be able to signal on cells not expressing the γc, regardless of the 
presence of the IL-4Rα. The liver pathology of Schistosoma mansoni infection has been 
associated with Type 2 immune responses154. In IL-13Rα1-/- mice granuloma 
expression of the eosinophil recruiting chemokine eotaxin (CCL11) was very much 
diminished, though there were normal levels of eosinophils in the granuloma. This may 
be accounted for by increased systemic IL-5 leading to greater expansion of eosinophils. 
IL-13Rα1-/- mice had slightly diminished eosinophil responses in a Schistosoma egg 
antigen (SEA) model of AHR.190  
Two papers published in 1998 demonstrated IL-13 is critically important to the 
pathology associated with allergic airways models. The neutralisation of IL-13 activity 
by a fusion protein combining portions of IgG-Fc and the soluble IL13Rα2 chain, lead 
to diminished acylcholine induced AHR in antigen sensitised and challenged mice191. 
Treatment of mice with IL-13 was also able to increase AHR, serum IgE levels and 
cause transient eosinophilia. This verified IL-13 was both necessary and sufficient for 
inducing AHR192. Further work comparing IL-4-/- and IL-4Rα-/- animals demonstrated 
that AHR could be induced independently of IL-4191, 193. Adoptive transfer of antigen 
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specific IL-13 sufficient CD4+ T cells but not IL-13-/- CD4+ T cells could induce AHR, 
despite detection of high levels of other Th2 associated outcomes, including IL-4 and 
IgE production, driven by the IL-13 deficient cells194.  
IL-13 is critical for the production of mucus in a range of Type II inflammatory models. 
In the lung non-ciliated cells of the airway epithelium, called Clara cells, have been 
shown to respond through the type II receptor causing them to become mucus secreting 
goblet cells in a process known as mucus metaplasia. Specific inhibition of IL-4Rα on 
Clara cells alone lead to significant diminishment of mucus production in an allergic 
airways model, with decreases in the mucins Muc5ac, and Muc5b, and also the 
chitinase AmCase. Although there was no effect on AHR or other Type 2 associated 
inflammatory responses.195 Mucus production is another function that has been 
specifically attributed to IL-13, with the inhibition of IL-13 totally abrogating goblet cell 
hyperplasia and mucus production in the lung.192. 
Mucus production is rare in the lung of healthy individuals, however goblet cells in the 
intestines are constitutively present and producing mucus. Increased intestinal mucus 
and the number of goblet cells is measured during infection with enteric parasites and 
these increases can be attributed at least in part to T cells196. Gastrointestinal parasites 
have been widely utilised to elucidate the roles of signalling through the IL-4Rα chain 
in the intestines. Clearing lumen residing parasites usually involves a mechanism that 
increases expulsion; the mechanism that causes this is known as ‘weep and sweep’188. 
For expulsion IL-4Rα signalling is required on non-haematopoietic cells but not on 
haematopoietic cells, indicating that the mediators of the STAT6 dependent expulsive 
mechanism are intestinal stromal cells197. Clearance of intestinal infection is reliant on 
IL-13198. Intestinal mucus is proposed to trap the parasites in the lumen, inhibiting their 
attachment to the gut wall and potentially affecting their feeding, this is what is referred 
to in the ‘weep’ of the weep and sweep mechanism188. The sweep refers to the increased 
rate of peristalsis observed in parasite resistant intestines, this occurs via increased 
smooth muscle contractility. Both IL-4 and IL-13 cause hyper-contractility of smooth 
muscle cells but IL-13 has a much greater effect199, 200. Treatment with IL-13 but not 
IL-4 caused a STAT6 dependent modification of smooth muscle response to the 
neurotransmitters acetylcholine and substance P. These IL-13 driven changes were 
shown to involve nerve signalling, as addition of the neurotoxin tetradotoxin diminished 
the hyper-contractility displayed by IL-13 treated smooth muscle.200 Therefore, the 
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‘weep and sweep’ mechanism incorporates the production of parasite trapping mucus, 
increased luminal fluid and increased peristalsis to expel intestinal helminths in a 
STAT6 and mostly IL-13 dependent way. 
Physiological changes in tissues are often observed where there are concentrated Type 2 
immune responses ongoing, this is seen in the asthmatic lung142, helminth infected 
lung153, intestinal wall and liver during infection17, and in the skin during allergic 
dermatitis151. Hyper-proliferation of fibroblasts leading to increased collagen production 
and extracellular matrix (ECM) deposition is known as fibrosis. Excessive fibrosis 
disrupts organ architecture and eventually decreases function, significantly affecting an 
individual’s quality of life.201 Both IL-4 and IL-13 can induce increased ECM 
production by fibroblasts in vitro202, but treatment with IL-13 neutralising antibodies has 
a greater effect on limiting pulmonary fibrosis than blocking IL-4 in fungal203 and FITC 
induced asthma models204. A similar pattern was observed when comparing the liver 
fibrosis induced by Schistosoma mansoni infection156. Fallon et al. demonstrated that Type 
2 immune responses are required to control Schistosoma mansoni infection, as evidenced 
by the increased mortality observed in IL-4-/-IL-13-/- double knock-out mice. 
Intriguingly IL-13Rα1-/- mice not only had increased survival over WT mice, they also 
had decreased fibrosis, liver damage and obstructed biliary ducts. This data indicates 
that IL-4 is able to drive protective Type 2 immune responses. In contrast IL-13 is 
dispensable for controlling the infection and is also is one of the main causes of the 
fibrotic pathology associated with Schistosoma mansoni infection.156 Skin specific over 
expression of IL-13 also causes significant fibrosis and atopic dermatitis205. Furthermore, 
intradermal injections of IL-33 causes cutaneous fibrosis in an IL-13 dependent manner, 
indicating IL-13 signalling may be important in skin changes particularly in atopic 
dermatological diseases206. While it appears that IL-13 can modulate fibroblast function 
directly there is evidence it may be working by increasing the release of TGF-β which 
effects stromal cell functions and proliferation207.  
Both IL-4 and IL-13 are able to signal through the type II receptor but genetic knock-
out and antibody neutralisation experiments have shown that IL-13 is more important 
than IL-4 for driving many of the non-haematopoietic cell responses. This may be due 
to differential expression of receptor subunits, with very high expression of IL-13Rα1, 
or very low expression of IL-13Rα2 potentially increasing a cells ability to respond to 
IL-13. It is also possible that haematopoietic cells expressing the γc can bind and 
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respond to IL-4 with increased efficiency, essentially lowering the available IL-4 
concentration. In either situation IL-13 is extremely important for modulating tissue 
responses during Type 2 inflammation, while IL-4 appears to have a greater effect upon 
immune cell activation and effector function. 
1.4.5 Intracellular controls on the expression of IL-4 and IL-13 
It remains uncertain which extracellular signals drive Th2 differentiation in vivo, 
however the intracellular events that mediate the switch of a newly activated CD4+ T 
cell into a fully functional Th2 cell have been extensively studied. The Il4 promoter has 
many binding sites for mediators downstream of TCR and CD28 signalling, including 
NFAT, AP-1 and c-Maf, which promote IL-4 expression208. However some pathways 
initiated by TCR signalling are distinctly inhibitory, such as those involving the MAPK 
family member Erk and Src family kinases50. While IL-4 expression is one of the 
characterising features of Th2 cells there are several Th2 specific pathways that must be 
initiated for it to be expressed. 
GATA3 is the master transcription factor for Th2 cells, and is critical for their effector 
functions. Enforced expression of GATA3 will drive Th2 differentiation even in Th1 
polarising conditions209, 210, while deletion of the GATA3 gene inhibits the induction of 
Th2 cytokines IL-4, IL-5 or IL-13 in newly activated cells211. IL-4 signalling through 
STAT6 induces large increases in the expression of GATA3 in CD4+ T cells212, 
although IL-4 independent expression can be induced by exposure to low 
concentrations of antigen213. Once expressed GATA3 has multiple roles in inducing 
Th2 cytokine expression and inhibiting signals that could promote an alternate 
phenotype, especially Th1. The DNA segment that contains the Il4, Il13 and Il5 genes 
is known as the Th2 locus. It contains multiple regulatory sites many of which are 
affected by GATA3214. The Il4 gene has several binding sites for GATA3, many 
associated with DNase I hypersensitive (HS) sites113. The Il4 gene’s HSII site is located 
within intron 2, and binds GATA3. This site is critical for the optimal expression of IL-
4, however disruption of this site has no effect on IL-13 or IL-5 expression. Furthermore 
there is strong GATA3 dependent H3K4 trimethylation at the HSII site only in Th2 
cells (not Th1), indicating that GATA3 may play a role in mediating epigenetic changes 
of the Th2 locus to stabilise Th2 differentiation.215 Binding of GATA3, along with 
NFAT1, to the HSVa site, located downstream from the Il4 gene, is also critical for 
normal expression of IL-4216, 217. The conserved GATA response element (CGRE) is 
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located upstream of the Il13 promoter and contains four sites that GATA3 can bind218, 
disruption of this region leads to diminished IL-13 expression while IL-4 and IL-5 
remained unaffected219. The Th2 locus has a locus control region (LCR) positioned 
within the Rad50 gene, upstream of both Il13 and Il4214. GATA3 has multiple binding 
sites within the LCR and disruption of these sites causes decreases in either IL-4 
expression alone, or expression of all three Th2 cytokines, depending on which binding 
site is deleted220. Finally, it has been reported that GATA3 may bind directly to the Il13 
and Il5 promoter regions, which may explain why conditional knock-out of GATA3 in 
established Th2 cells results in loss of IL-13 and IL-5 expression, but IL-4 remains 
unaffected84.  
Phosphorylated STAT5 binds several regulatory elements within the Th2 locus, of note 
the HSII and HSIII regions of the Il4 gene. It has been shown that expression of an 
activated form of STAT5a leads to IL-4 expression even without increasing GATA3 
levels, although GATA3 is still required for this expression. Similarly even in high levels 
of GATA3 IL-4 cannot be expressed without STAT5 signalling.221 STAT5 is part of the 
intracellular signalling pathways of several cytokines, but for Th2 cells, IL-2 receptor 
signalling is essential for optimal Th2 differentiation222. It is proposed that STAT5 is 
important in maintaining the accessibility to the Il4 gene, particularly during early 
differentiation before epigenetic modifications can occur to more permanently stabilise 
the locus. STAT5 can also promote GATA3 transcription223. As with GATA3 
expression STAT5 signalling via the IL-2R is optimal in cells exposed to low antigen 
doses. Cells responding to high doses not only failed to express GATA3 but also had 
decreased responses to IL-2, inhibition of the MAPK pathway could release the 
inhibition on GATA3 and STAT5 signalling223. 
1.4.6 Probabilistic regulation of IL-4 expression 
Between 0.5% and 15% of mammalian genes display random mono-allelic regulation 
where expression of the gene by different cells is randomly limited to one of the parental 
alleles. There are several mechanisms that mediate the regulation of allelic expression. 
Mammalian female cells inactivate one whole X chromosome, packaging them into 
Barr bodies, to ensure normal levels of transcription of X linked genes, and the 
chromosome a cell will express is set during early embryogenesis. Epigenetic imprinting 
in gametes can silence a gene from one parent while ensuring the gene from the other 
parent is the exclusively expressed allele. Lymphocytes also undergo a process called 
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allelic exclusion to ensure they only produce a single form of antigen specific receptor. 
Expression of several cytokines by activated CD4+ T cells has been shown to be limited 
to a single allele, however which allele a cell expresses is not consistent across the 
population, and while some cells express mono-allelically others can express from both 
alleles (bi-allelically).224  
The expression of both IL-4 and IL-13 is under allelic regulation in Th2 cells225, 
however the mechanisms controlling this are not fully understood. One explanation is 
that limited transcriptional machinery results in stochastic periods of expression from 
each of the alleles, so examination of a population at a given time point will find cells 
that are expressing mono-allelically and small population in a transition state expressing 
from both alleles. Another theory relies upon chromosomal alterations allowing 
stochastic availability of one allele or the other, and in a rare population of cells both 
alleles simultaneously. Positive feedback such as autocrine signalling and expression of 
transcription factors, GATA3 in the case of IL-4 and IL-13, can stabilise the remodelled 
chromatin allowing stable expression from the available allele(s)212, at least until cell 
division when chromatin is repackaged. If the theory of chromatin remodelling is true it 
may be expected that stabilisation of one section of chromatin would ensure the 
expression of both IL-4 and IL-13 from the same chromosome, however it has been 
observed that IL-4 and IL-13 are regulated separately226. Cells expressing IL-4 mono-
allelically do not show a preference for expression of the IL-13 allele on the same 
chromosome. The possibility that chromatin remodelling occurs independently for each 
of the adjacent genes cannot yet be dismissed, so allelic availability mediated by 
chromatin changes remains a viable potential model for allelic regulation.  
The mechanisms controlling mono-allelic and bi-allelically expressing cells have been 
postulated to play an important role in limiting the amount of cytokine produced by the 
total population169. Only a relatively minor population of polarised Th2 cells can be 
detected expressing IL-4 or IL-13 at any one time, despite all activated cells expressing 
equal levels of GATA3227. It is proposed that mechanisms controlling allelic expression 
may actually be in place to regulate the number of cytokine producing cells, a more 
effective way of controlling cytokine levels then controlling the amount each individual 
cell releases169.  
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1.5 Group 2 innate lymphoid cells 
1.5.1 The populations of innate lymphoid cells 
Recently several distinct innate cell populations have been characterised that are able to 
carry out some of the functions usually attributed to the adaptive lymphoid cells, despite 
the absence of antigen specific receptors. ILCs, residing in non-lymphoid tissues around 
the body respond to tissue-derived signals and contribute to inflammation by producing 
cytokines15. ILCs are hematopoietic cells that express CD45 and Thy1 (CD90) but 
distinctly lack expression of cell surface molecules that are associated with other 
immune cell lineages. Lineage markers that are commonly used to isolate ILCs include 
cell surface molecules found on; T cells CD3, CD4, CD8, B cells CD19, B220, 
granulocytes, Gr-1, CD11b, FcεRI and the DCs CD11c228. However, the specific 
cocktail of lineage specific antibodies used varies from laboratory to laboratory, and this 
has caused some confusion especially in early publications as to what exactly defined an 
ILC15. All ILCs depend upon the transcription factor inhibitor of DNA binding 2 (Id2) 
for their development229. The ILC populations can be classified by both their expression 
of cell surface molecules and also expression of the master transcription factors often 
associated with the T helper subsets Th1, Th2, Th17 and Th22; T-bet, GATA3, Ror-γt 
and aryl hydrocarbon receptor respectively229. Since 2010 there have been increasing 
numbers of publications implicating the different ILC populations in a range of 
inflammatory situations. 
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Figure 1.3 – Ontogeny of the innate lymphoid cell populations.  
Common lymphoid progenitor (CLP) cells differentiate into an Id2 expressing population of 
common helper-like ILC progenitor (CHILP) through a proposed common ILC (CILP) 
precursor. Natural killer (NK) precursor (NKP) derives from the CILP cells before becoming 
conventional NK (cNK) cells. IL-15 dependent immature ILC1 express T-bet in the bone 
marrow before becoming mature ILC1s in the periphery. GATA3 expressing ILC2 precursors 
depend on IL-7 and mature in the periphery. All three populations of ILC3s require IL-7 
signalling, including the lymphoid tissue inducer (Lti) cells. Modified from Klose and 
Diefenbach, 2014230. 
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In early 2013, after 2 years of publications identifying and attributing roles to different 
populations of ILCs a naming and grouping system was proposed that would cover the 
lineages and functions of the identified ILC populations and standardise their 
nomenclature15. The different populations were gathered into three broad categories 
named group 1, group 2 and group3. Group 1 contained both NK cells, and the 
putative ILC1s, these populations were largely grouped based on their expression of 
IFN-γ. It was initially unclear if ILC1s represented a unique population due to their 
similarities with NK cells, however recent papers have identified them as distinct 
lineages231. NK cells require Eomes for their development while ILC1s do not, ILC1s 
however are dependent on both T-bet expression for normal generation and the 
depletion of T-bet only marginally inhibits NK cell. Promyelocytic leukaemia zinc 
finger (PLZF) is a transcription factor that has been shown to preferentially drive ILC, 
rather than NK cell development from the common lymphoid progenitor stage232. As 
with NK cells, ILC1s rely upon IL-15 for their development and survival in tissues. 
A relatively diverse range of different ILC populations are encompassed within the 
group 3 ILCs (ILC3s), their reliance upon the transcription factor Ror-γt is the common 
element which unites the populations233. Lymphoid tissue inducer (LTi) cells, as with 
NK cells, have been well studied before the discovery of other ILC populations, but 
retrospective comparisons have meant they have been amalgamated within the ILC3 
group15. LTi cells are required for the development of secondary lymphoid tissues and 
upon stimulation produce both IL-17 and IL-22234. Two other Ror-γt dependent ILC3 
populations have been defined that are divergent from LTi cells, in mice they can be 
distinguished by their lack of CD4233. One population only expressed IL-22 not IL-17, 
and these cells express the NK cell associated natural cytotoxicity triggering receptor 
(NCR) NKp46, thus they have been named the NCR+ ILC3s and express T-bet at low 
levels alongside Ror-γt and the aryl hydrocarbon receptor235. The third ILC3 
population, the NCR- ILC3s, do not express T-bet and can produce both IL-17 and IL-
22236. These three populations are similar in many ways and there may be much 
plasticity between them. This is highlighted by the fact that T-bet deficient mice lack 
NCR+ ILC3s, so it may simply be the relative expression of the mutually repressive 
Ror-γt and T-bet that differentiate the NCR+ and NCR- ILC3 populations237.  
The group 2 ILCs consist of only a single population, the ILC2s. These cells are 
critically dependent on GATA3238 for their function and produce IL-5, IL-13239, 
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amphiregulin240 and IL-9116 in response to tissue derived cytokines such as IL-33, IL-
25239 and thymic stromal lymphopoietin (TSLP)241. As with the ILC1s and all ILC3 
populations, ILC2s rely upon IL-7 for their development and express the IL-7R 
(CD127), however ILC2s also constitutively express the IL-2Rα chain (CD25), ICOS 
and the IL-33R (T1-ST2)15. All of the ILC populations (excluding NK cells) require 
GATA3 for their development however only the ILC2s maintain the expression of 
GATA3 once mature242. 
Functionally, and by expression of certain transcription factors, the different ILC 
populations share many characteristics with T cells effector phenotypes. Group 1 ILCs 
rely upon T-bet and produce IFN-γ, like Th1 cells ILC1s have been shown to respond 
to IL-12 and IL-18 and contribute to immune responses against intracellular 
pathogens243, 244. Both in terms of function and the reliance on Eomes, parallels have 
also been drawn between NK cells and memory CD8+ T cells245. The group 3 ILCs 
mirror Th17 cells and have been shown to play roles in controlling pathogenic intestinal 
bacteria246, 247, 248, 249. All group 3 ILCs respond to IL-1β and IL-23, which are largely 
produced by innate immune cells250. The barrier derived cytokines IL-25, IL-33 and 
TSLP have been demonstrated to induce cytokine responses from Th2 cells, and have 
similar effects on ILC2s. Both Th2 and ILC2s rely on GATA3 for their maintenance 
and function. Largely through their production of IL-5 and IL-13, ILC2s have been 
implicated in many models of Type 2 inflammation; from helminth infections to asthma 
and allergic inflammation of the skin ILC2s appear to be able to recapitulate many of 
the functions of peripheral tissue Th2 cells.251 
1.5.2 Identification and functions of group 2 ILCs 
ILC2s were not identified as a unique population until 2010, however earlier work had 
indicated Th2 associated cytokines could be elicited from a non T cell population by 
stimulation with IL-25. IL-25 was found to increase the expression of IL-5 and IL-13 
from a population of non-B non-T cells, and this was enough to induce expedited 
expulsion of N. brasiliensis from the gut252. In 2010 four papers were published 
independently identifying populations of what appeared to be closely related cell types 
in fat associated lymphoid clusters253, intestines254, 255 and many other tissues256. These 
cells could all respond to IL-25 and/or IL-33 and produce Type 2 cytokines. 
Retrospective review found that while three papers had been focused on phenotypically 
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similar ILCs, the paper by Saenz et al had identified another population of cells that did 
not express Thy1 (CD90), IL-7R or T1.ST2 but did display abilities of multipotent 
progenitors (MPPs). Stimulation of these cells generated monocytes/macrophages, 
basophils and mast cells. This progenitor ability is not shared by any of the ILCs, 
showing that MPPs and ILCs are distinct populations of cells.239  
c-Kit was originally used as an identifying molecule for ILC2s, however IL-13 reporter 
mice demonstrated that only a proportion of non-B non-T cells reporting IL-13 were c-
Kit+257. ILC2 populations in multiple tissue sites consistently express CD25, T1.ST2, 
CD69, CD44 and ICOS, further cementing their similarities with activated Th2 cells. 
Low levels of MHC II expression can be detected on ILC2s as well, indicating the 
potential for ILC2 - CD4+ T cell interactions.251 
All ILC populations derive from CLPs arising from the bone marrow, expression of the 
transcription factor Id2 drives ILC, as opposed to T cell, NK cell or B cell, 
development258. The transcriptional regulators GATA3, retinoic acid receptor α 
(Rorα)259, T cell factor 1 (TCF-1)260 and growth factor independent 1 (Gfi1)261 are all 
critical mediators at various steps of ILC2 development. GATA3 is lowly expressed by 
cells that maintain the potential to become all three ILC populations, and it’s expression 
level increases as cells become ILC2 precursors (ILC2Ps) and eventually mature 
ILC2s242. ILC2Ps are found in the bone marrow and in some tissues. They have 
diminished cytokine producing abilities compared with mature ILC2s, and can be 
distinguished by their decreased expression of killer cell lectin-like receptor subfamily G 
member 1 (KLRG1)238. GATA3 may play a role in the stabilization of Gfi expression262, 
while Gfi1 and TCF-1 both promote GATA3 potentially indicating a reinforcement 
pathway for ILC2 development251. Gfi1 increases expression of both IL25R and 
T1.ST2261, while TCF-1 promotes IL-7R and CD25263, some of the key receptors 
required for ILC2 maintenance and activation. Rorα deficient mice lack mature ILC2s, 
and the few ILC2P that can be found are negative for T1.ST2. Notch signalling and 
cytokine dependent stimulation of CLPs from the thymus can generate ILC2s, however 
athymic mice have peripheral ILC2s indicating that the thymus is not critical to ILC2 
development259. 
GATA3 stabilizes the Th2 locus in an open position promoting cytokine expression264. 
The high level of GATA3 expression in ILC2s is likely required for their ubiquitous IL-
13 and IL-5 production as demonstrated using reporter mice265, 266. GATA3 also opens 
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the IL-4 locus, which explains why IL-4 expression by mRNA and fluorescent reporter 
can be detected from ILCs but only with stimulation that induces calcium flux such as 
ionomycin and phorbol 12-myristate 13-acetate (PMA) stimulation251. This mirrors 
what has been seen with differentiated Th2 cells, where NFκB signalling pathways (such 
as those induced by IL-33 signalling) promote IL-5 and IL-13 expression267 while IL-4 
expression requires calcium signalling and NFAT, which in Th2 cells is provided by the 
TCR268, 269.  
Through their production of IL-13 ILC2s play an important role in the gut for the 
expulsion of intestinal helminths. Administration of IL-33 or IL-25 induces strong Type 
2 cytokine responses even in T cell deficient Rag2-/- mice, and the responding cells were 
found to be ILC2s254, 256. Adoptive transfer of WT ILC2s into IL-25R-/- mice was able 
to rescue exogenous IL-25 driven expulsion of N. brasiliensis, however, this expulsion is 
depended upon IL-13 expression254. Transfer of ILC2s, along with IL-25 can similarly 
rescue normal N. brasiliensis expulsive responses in γc-/-Rag2-/- mice256. While Rag2-/- 
mice have increased numbers of ILC2s, likely due to the decreased competition from T 
and B cells for survival factors including IL-7, γc-/-Rag2-/- mice are deficient for ILC2s, 
as the γc is required for IL-7 signalling251. IL-5 production by ILC2s supports IgA 
production and survival of B1 cells within the fat associated lymphoid clusters of the 
mesenteries253. An interesting model of micronutrient deficiency demonstrated that in 
the absence of vitamin A ILC2s expanded at the cost of ILC3 populations within the 
intestine. Expanded ILC2s lead to increased expulsion of helminths, potentially linking 
nutrient deficiency to protective responses against parasites, however the decreased 
ILC3 populations also left the mice susceptible to bacterial invasion.270 
In the lung ILC2s have been demonstrated to play roles in both Type 1 and Type 2 
associated immune responses240. While in the intestines both ILC2 and ILC3 
populations can be identified, the lung has been characterised as being dominated by 
group 2 innate lymphoid cells270. IL-33271 and IL-25257 can both induce lung ILC2 
expansion, cytokine expression and AHR, but IL-33 induces more resilient responses 
than IL-25272. Again, adoptive transfer of cytokine stimulated WT ILC2s was sufficient 
to induce AHR in IL-13-/- mice in an IL-13 dependent manner257. ILC2s are major 
producers of Type 2 cytokines in AHR models induced by the administration of 
OVA257, HDM273, papain protease274 or Alternaria alternata allergen271. IL-33 was critical 
to AHR and ILC2 responses in OVA and ragweed induced airways inflammation271, 
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while HDM induced AHR demonstrated a greater reliance on IL-25273. ILC2s were 
shown to be major producers of IL-9 in the lung in responses to papain. This IL-9 
signalled in an autocrine fashion increasing IL-5 and IL-13 production, and was found 
to increase the survival of pulmonary ILC2s during infection by N. brasiliensis74. ILC2s 
also play an important role in lung repair, mice depleted of ILC2s had decreased 
survival after infection with Type 1 immune response inducing influenza. Amphiregulin, 
a member of the epidermal growth factor family, is produced by ILC2s and mediates 
repair of the lung epithelia damaged by influenza infection. Depletion of ILC2s 
decreased these repair responses and increased the chance of death from the 
infection.240 
Increasing evidence indicates that ILC2s play critical roles in maintaining fat and 
metabolic homeostasis. IL-5-/- mice are more susceptible to obesity when on a high fat 
diet while transgenic IL-5 overexpressing mice are leaner and have increased glucose 
tolerance275, 276. This along with the fact that IL-4 administration protects from insulin 
resistance on a high fat diet277, 278 indicates that Type 2 immune response may not be 
evolutionarily conserved simply for protection against multicellular parasites. ILC2s 
maintain alternately activated macrophages and eosinophils within visceral adipose 
tissues275. Eosinophil numbers in visceral adipose tissues fluctuate in a circadian rhythm 
that is dependent upon IL-5 production by ILCs responding to neuropeptides released 
upon feeding279. Alternately activated macrophages sequester iron and inhibit its 
accumulation in adipocytes, which can induce the production of lipid aldehydes and 
effect adipocyte function280. Through the production of IL-13 and the recruitment of 
IL-4 producing eosinophils, ILC2s control alternately activated macrophages in 
subcutaneous fat which are responsible for the conversion of white adipose cells to 
thermogenic beige adipose cells in response to cold stress. IL-4 and IL-13 also expand a 
population of adipocyte precursor cells that are predisposed to becoming beige 
adipocytes.281 ILC2s not only have roles in expelling helminths from the gut and 
causing asthmatic responses in the lung, they also maintain health through epithelial 
repair mechanisms and controlling of obesity by maintaining homeostatic conditions 
within fat tissues. 
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1.5.3 Reporter mice for identification of cytokine producing 
cells; the benefits and caveats 
Genetically modified mice have become an invaluable tool for studying the biology of 
the immune system, both at homeostasis and in disease settings. Early genetic 
engineering techniques developed by Gordon, Plotkin, Barbosa and Ruddle in 1980 
simply involved microinjection of genetic material into the embryos of mice, these DNA 
segments would randomly insert into the genome. As long as the embryo was freshly 
fertilized and hadn’t undergone cell division when the DNA was injected, all the cells of 
the mature mouse would carry the genetic material. This technique created the first 
transgenic mice.282 While this technology was effective for introducing genetic material 
into a mouse strain, it was imprecise; parental genes could not be targeted and 
implantation could disrupt expression of unintended genes.  
The development of targeted mutagenesis allowed disruption of desired genes and 
insertion of genetic material that can be controlled by the promoter of a gene of 
interest.283 This technique relies upon homologous recombination, whereby similar 
double stranded DNA can be swapped via one of several mechanisms. Eukaryote cells 
use this to repair double stranded breaks and for the swapping of genetic material 
between homologous chromosomes during the generation of gametes. Addition of a 
section of DNA to a cell with 5’ and 3’ sequences that match germ line DNA sequences 
can lead to integration of the novel DNA section into the germ line via homologous 
recombination.284 These recombination events are rare so selection strategies are 
required to identify cells that have successfully incorporated the foreign DNA. The most 
common technique is the insertion of a gene that allows antibiotic resistance, allowing 
selection by culturing of cells in antibiotic spiked media, thus only cells that have 
incorporated and are expressing the DNA construct containing the resistance gene will 
survive. To generate genetically modified mice using this technique embryonic stem 
(ES) cells are microinjected with a DNA construct that includes the sequence of an 
antibiotic resistant gene and 3’ and 5’ sequences that are homologous for sections of a 
target gene. Successful incorporation of the construct can be selected for by identifying 
surviving ES cells cultured in antibiotic media. These modified ES cells are transferred 
into a mouse blastocyst and this is implanted into a pseudo-pregnant female to 
eventually give rise to chimeric offspring that have a proportion of cells heterozygous for 
the targeted gene. These mice can be bred and their offspring tested by PCR for the 
presence of the modified gene. Finally, the antibiotic resistance sequence can be spliced 
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by utilising Cre-Lox technology, crossing these mice to a strain that constitutively 
expresses the Cre recombinase enzyme can lead to the splicing out of the antibiotic 
resistant gene if it was originally designed with Lox-P sites on either side of the 
sequence.285 
If the 3’ and 5’ sequences of the inserted DNA construct are spaced across exons of a 
targeted gene, these exons are excised during the recombination event, disrupting the 
sequence of the gene and leaving the cell unable to express protein from that allele. 
Crossing of these mice can generate offspring homozygous for the disrupted allele 
(assuming that the targeted gene is not essential for development or survival of the 
mouse). This allowed the generation of knock-out mice, mice that could not express 
RNA or protein from a gene of interest.284 Using knock-out mice allowed study of the 
roles particular genes play in modulating immune responses, for instance IL-4 knock-
out mice have been used to demonstrate that IL-4 expression increased susceptibility to 
Leishmania major infection.176 
Addition of sequences that produce functional proteins into an inserted DNA construct, 
other than those that conveyed antibiotic resistance, increased the scope of homologous 
recombination based targeted gene modification. The insertion of genes that produce 
fluorescent proteins allows identification of cells that are actively transcribing the 
modified gene and this is how knock-in fluorescent reporter mice were created. 
Reporter mice are valuable for characterising the cells that are producing soluble 
proteins, such as cytokines. Their identification would generally require restimulation in 
the presence of poisons that inhibit golgi body function followed by fixation and 
intracellular antibody staining or western blotting. Knock-in reporter constructs can 
allow identification of cells that are transcribing the protein of interest in real time and 
directly ex-vivo without any further manipulation.286 
Several different variations of IL-4 reporter mice have been generated each with 
different systems for marking IL-4 producing cells. Two types of IL-4 green fluorescent 
protein (GFP) reporter mice have been produced, one known as the G4 mouse that is a 
simple knock-in reporter with the GFP gene replacing the first exon and 178 nucleotides 
of the first intron of the IL-4 gene227. The second GFP reporter designated IL-4/ GFP-
enhanced transcript, or 4get mice employed an internal ribosome entry site (IRES) 
sequence in an attempt to avoid disruption to the parental IL-4 genes. The IRES-GFP 
sequences were targeted just downstream of the translational stop codon of the IL-4 
gene, allowing the full transcription of the IL-4, IRES and GFP mRNA. This permitted 
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normal translation of the IL-4 mRNA which would cease at the endogenous stop codon, 
however the IRES sequence allowed transcription of GFP despite it’s sequence 
beginning part way through the mRNA strand. The 4get mice should therefore be able 
to produce normal IL-4 levels, but also report by GFP expression any cell that is 
transcribing IL-4 mRNA.287 
A third type of IL-4 reporter mouse was generated twice by two different groups on 
separate occasions, and is also a knock-in mouse with the modified sequence for the 
human CD2 (huCD2) molecule replacing just the first exon of the IL-4 gene. When the 
IL-4 promoter was engaged huCD2 would be expressed, and these molecules would be 
translocated to the cell surface. The normal intracellular signalling sequences had been 
modified so the huCD2 would be unable to signal within the mouse cells even if it was 
bound to a ligand. By staining with fluorescently bound antibodies specific for human 
CD2, cells that are producing IL-4 can be identified.288 The huCD2 and G4 GFP 
reporters are constructed similarly and appear to work in similar ways; only T cells that 
are actively expressing the IL-4 allele that carries the reporter are positive. The 4get 
mice are referred to as mRNA reporter mice, they mark a cell that is competent for IL-
4 expression but not necessarily a cell expressing IL-4 protein. For example, a Th2 cell 
that has been differentiated will remain reporter positive even after the cell ceases IL-4 
protein production.289 
In an attempt to retain protein sufficiency, but restrict reporting only to protein 
producing cells, recent reporters have been created using variants on older transgenic 
technology. To create transgenic reporters a bacterial artificial chromosome (BAC) 
carrying a section of mouse chromosome with the gene of interest is created or screened 
for from a library. Employing the same homologous recombination technology as used 
to create knock-in reporters; the reporter sequences are inserted after the promoters of 
the gene of interest within the BACs. The BAC vectors are then isolated, linearized and 
microinjected into embryonic stem cell for transfer into a blastocyst. These transgenic 
reporters have a third allele of the gene of interest that has been disrupted by the 
reporter construct inserted randomly into their genome. While these mice are able to 
produce normal protein from their parental alleles, the reporters being randomly 
inserted in the genome may be missing regulatory elements that enhance or control 
gene expression of the parental alleles, meaning their reporting may not consistently 
reflect parental gene expression.290 
 46 
Reporter mice can allow temporal and spatial identification of protein producing 
populations of cells in a range of models however each method of reporter generation 
comes with caveats that need to be considered when interpreting data produced using 
these systems.  
1.6 Thesis Aims 
In this thesis I aim to investigate how cells regulate their cytokine production in a 
number of models of Type 2 inflammation. To do this I will validate and use a novel 
IL-4 and IL-13 reporter mouse. I will investigate how CD4+ T cells mediate their allelic 
regulation of IL-4 expression and compare how these cells and innate immune cells 
control IL-4 and IL-13 expression. The principle aim of this work is to understand if 
Type 2 cytokines are regulated in the same way or if there are refined mechanisms that 
differentially regulate the expression of these cytokines. The specific aims are: 
• To assess how CD4+ T cells regulate allelic expression of IL-4 in vitro and how 
IL-4 contributes to the generation of Th2 cells in an in vivo model of Type 2 
inflammation. 
• To compare of CD4+ T cell expression of IL-4 and IL-13 and how Th2 cells 
regulate the production of IL-13 both in vitro and in vivo. 
• To identify and characterise a dermal ILC population and determine how these 
cells, and basophils in the skin, produce cytokines in response to models of skin 
inflammation. 
• To compare cytokine production by lung CD4+ T cells and ILC2s in response 
to infection by N. brasiliensis and how these cells interact to maintain protective 
immune responses. 
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2 Materials and Methods 
2.1 Materials 
2.1.1 Labware  
Supplier/ 
Manufacturer 
Product 
Alphatech Systems 
Ltd & Co, Auckland, 
NZ. 
• Acrodisc® Serum Filter. Glass Fiber prefilter, 0.2um 
Supor membrane, Sterile, 37mm 
Axygen Scientific 
Inc., Union City, CA, 
USA. 
• 0.5-20ul, 200ul, 1000ul Tips, Racked & Pre-Sterilized 
•  0.6ml, 1.7ml, 2.0ml MAXYMum Recovery™ 
Microtubes 
 
Becton Dickinson Pty 
Ltd, Mountain View, 
CA, USA. 
• BD Ultra-Fine™ & Ultra-Fine™ II Insulin Syringes - 
Bulk Packaged - Box/100 15ml, 50ml high-clarity 
polypropylene conical centrifuge tube 
• 5ml, 10ml, 25ml polystyrene serological pipet. 
• 12x75 mm, 5 ml polystyrene round bottom test tube. 
No cap. Non-sterile. 
• BD Falcon™ 175 cm2 Cell Culture Flask, 750 ml, 
tissue culture treated, straight neck, black lined 
phenolic screw cap. 
• BD Falcon™ CELLine™ CL - 1000 System Flask 
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• BD Falcon™ 60 mm BD Falcon™ Cell Culture Dish, 
tissue culture treated polystyrene. 
• BD Falcon™ 6-well Multiwell Plate. Tissue culture 
treated polystyrene, flat bottom, with low-evaporation 
lid. 
• BD Falcon™ 12-well Multiwell Plate. Tissue culture 
treated polystyrene, flat bottom, with low-evaporation 
lid. 
• BD Falcon™ 24-well Multiwell Plate. Tissue culture 
treated polystyrene, flat bottom, with low-evaporation 
lid. 
• BD Falcon™ Clear 96-well Microtest™ Plate. Tissue 
culture treated polystyrene, flat bottom, with low- 
evaporation lid. 
• BD Falcon™ Clear 96-well Microtest™ Plate. Tissue-
culture treated polystyrene, U-bottom, with low- 
evaporation lid.   
• BD Plastipak™ Syringes 30 mL, Luer- Lok™ 
• BD Syringe 1ml, 2ml, 3ml, 5ml, 
• 10ml Luer-Slip Tuberculin  
• Cell strainer with 70 µm nylon mesh, white frame 
color. Sterile. 
GE Healthcare, 
Auckland, New 
Zealand 
• HI Trap protein G columns 
Hawksley Medical 
Laboratory Products, 
Lancing UK.  
Improved Neubauer Haemocytometer 
Miltenyi Biotec, 
Bergisch, Germany. 
AutoMACS Pro Separator Instrument 
Molecular Devices, 
Sunnyvale, CA, USA. 
VersaMax ELISA Microplate reader  
Olympus CX21 Compound Microscope 
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Corporation, 
Shinjuku, Japan. 
CX40 Inverted Microscope 
SZX10 Stereo Microscope 
Sefar Filter Specialist, 
Nelson, New Zealand. 
70µm nylon gauze 
80µm stainless steel mesh 
Thermo Fisher 
Scientific, Waltham, 
MA, USA. 
• Nunc CryoTube 1.0mL 1.8mL PP sterile 
• Nunc-Immuno™ Plates Polystyrene, without lids. 96 
wells per plate. MaxiSorp®. 
• Transfer pipette graduated 1ml large bulb 
• SecureSeal™ Thermal Adhesive Sealing Film for 
PCR application 
• Slide-A-Lyzer Dialysis Cassettes, 10000 MWCO 
• Glass Pasteur pipette 150mm (p/1,000) 
• Sartorius Stedim Vivaspin 20 ml tubes 10000 MWCO 
• Nanodrop 1000 Spectrophotometer  
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2.1.2 Reagents and buffers 
2.1.2.1 Culture media reagents 
2-mercaptoethanol 
2 ME was from Invitrogen (Auckland, NZ, 21985-023) and stored in aliquots at 4ºC. 
 
Penicillin-Streptomycin 
Penicillin-Streptomycin was purchased in liquid form from Invitrogen (Gibco, Auckland, 
NZ, 15140-122) and stored as single use aliquots at 4ºC until used. 
 
Foetal bovine serum (FBS) 
FBS was purchased from Invitrogen (GIBCO, Auckland, NZ, 12203C) and stored in 25 
ml aliquots at -20ºC. 
 
Complete Iscove’s modified Dulbecco’s medium (cIMDM) 
IMDM was purchased from Invitrogen (Auckland, NZ, 31980-097) and supplemented 
with 100 U/ml Penicillin-Streptomycin from Invitrogen (Gibco, Auckland, NZ, 15140-
122), 55 μM 2 ME and 5% FBS. Media was filter sterilised and stored at 4ºC for a 
maximum of 14 days. 
2.1.2.2 Enzymes and tissue processing reagents 
Dulbecco's phosphate buffered saline (dPBS) 
dPBS powder containing no calcium or magnesium was purchased from Invitrogen 
(Gibco, Auckland, NZ, 21600-069) and dissolved in dH2O. 
 
Collagenase I  
Collagenase I was purchased from Invitrogen (Auckland, NZ, 17100-017). The 
lyophilised powder was reconstituted in cIMDM to a concentration of 2.4 mg/ml and 
stored in aliquots at -20ºC. 
 
Collagenase IV (Collagenase from histolyticum)  
Collagenase IV was purchased from Sigma-Aldrich New Zealand Ltd (Auckland, NZ, 
C5138). The lyophilised powder was reconstituted in dPBS to a concentration of 50 
mg/ml and stored in aliquots at -20ºC. 
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Red blood cell lysis buffer  
RBC Lysing Buffer was purchased from Sigma-Aldrich New Zealand Ltd (Auckland, 
NZ, R7757) and stored at room temperature. 
 
DNase I  
DNase I was purchased as a lyophilised powder from Roche Diagnostics New Zealand 
Ltd (Auckland, NZ, 10104159001) dissolved in cIMDM to a concentration of 10 
mg/ml and stored at -20ºC. 
 
Ethylenediaminetetraacetic acid (EDTA) 
Diluted EDTA (0.5M) was purchased from Invitrogen (Auckland, NZ, 15575-020) and 
stored at room temperature until used. 
 
Liberase TL 
Lyophilized enzyme was purchased from Roche Diagnostics New Zealand Ltd, 
(Auckland, NZ, 5401020001) stored at – 20 °C for long term storage. Enzymes were 
resuspended in IMDM and agitated to reconstitute to a concentration of 1 mg/mL. 
Reconstituted enzymes were used immediately or stored at -20°C for up to three 
months.  
 
Sodium Hydroxide (NaOH) 
NaOH was purchased from BDH Laboratory Supplies (Poole, UK). Stored at 5M at 
room temperature. 
 
Hydrochloric acid (HCl) 
HCl was bought from Merck KGaA (Darmstadt, Germany) and stored at 11.65M at 
room temperature. 
 
Tris 
UltraPure™ Tris was diluted in ddH2O to a 1M concentration. 
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Lung digestion buffer 
Collagenase type I at a final concentration of 2.4 mg/ml from stock at 24 mg/ml and 
DNAse1 at 120 μg/ml from a stock of 10 mg/ml were made up in cIMDM to the 
required volume. 
 
Skin digestion buffer 
Collagenase type IV at a final concentration of 5 mg/ml from stock at 50 mg/ml and 
DNAse1 at 120 μg/ml from a stock of 10 mg/ml were made up in cIMDM to the 
required volume. 
 
Spleen digestion buffer 
Liberase at a final concentration of 0.125 mg/ml from stock at 1 mg/ml and DNAse1 
at 100 μg/ml from a stock of 10 mg/ml were made up in cIMDM to the required 
volume. 
 
Alsever’s Solution 
20.5 g Dextrose (BDH Laboratory Supplies, Poole, England), 8 g sodium citrate (BDH 
Laboratory Supplies, Poole, England) and 4.2 g NaCl (Sigma, Auckland, NZ) were 
dissolved in distilled 1000 ml MQ H2O (MilliQ) and the pH was adjusted to 6.1 with 1 
M citric acid (BDH Laboratory Supplies, Poole, England). Alsever's solution was stored 
at room temperature. 
 
1.8% NaCl solution 
1.8g NaCl from Sigma-Aldrich New Zealand, Ltd (Auckland, NZ) was diluted in 
100mL ddH2O. 
 
Tail lysis buffer for genomic DNA  
NaOH and EDTA were diluted to 25mM and 0.2mM respectively in ddH2O and pH 
was set to 12. 
 
Tail lysis neutralisation buffer 
Tris-HCl was diluted in ddH2O to a concentration of 40nM and pH was set with HCl 
to a pH of 5. 
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Isolation buffer 
2 mM EDTA, 0.5% FBS and 0.012% DNase I were made up in dPBS, filter sterilised 
and stored at 4ºC. 
 
CD4 Dynabeads isolation kits 
Dynabead CD4 isolation kits were purchased from Invitrogen (Auckland, NZ, 11145D). 
Kits were stored at -4ºC. 
 
CD11c Microbead isolation kits 
CD11c Microbead isolation kits were purchased from Miltenyi Biotec (Bergisch 
Gladbach, Germany, 130-052-001). Kits were stored at -4ºC. 
 
Trypan Blue 
Trypan Blue was purchased from Invitrogen (Auckland, NZ, 15250-061) and stored at 
room temperature. 
 
2.1.2.3 Cytokines 
Recombinant human interleukin-2 
Recombinant rhIL-2 (Proleukin) from Novartis Vaccines & Diagnostics was stored 
lyophilised at 4ºC. It was made up in IMDM at a concentration of 105 U/mL, aliquots 
stored at -20ºC. 
 
Interleukin-4 
Supernatant of IL-4 producing Chinese hamster ovary cells was collected. IL-4 activity 
was compared via ELISA to standards originally calibrated using CT.4S cell line as 
described30. 1 unit is approximately 0.5pg of IL-4. 
 
Interleukin-33 
Interleukin-33 purchased from R&D Systems (Minneapolis, Minnesota, USA, 3626-
ML-010) and was resuspended in dPBS to a concentration of 10µg/mL. Aliquots were 
stored frozen at -20ºC. 
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Thymic Stromal Lymphopoietin (TSLP) 
TSLP was purchased from R&D Systems (Minneapolis, Minnesota, USA, 555-TS-010), 
lyophilised TSLP was stored at -20ºC. TSLP was reconstituted in dPBS to a 
concentration of 10µg/mL and aliquots are stored at -20ºC. 
 
Complexed IL-2 (IL-2c) 
Recombinant murine IL-2 was purchased from Peprotech (Rocky Hill, NJ, USA, 212-
12) stored lyophilised at -20ºC and reconstituted to 1 mg/ml in dPBS. αIL-2 (clone 
JESS6-1 from WEHI, Melbourne, Victoria, AUS) was stored at shipping concentration 
at -70ºC and diluted to 1mg/mL in dPBS. IL-2 and αIL-2 antibody was mixed at a 
molar ratio of 1:5 and incubated for 30 minutes at 37ºC. Aliquots of this mixture were 
stored at -70ªC. Prior to use these aliquots were diluted 1:16.67 in dPBS. 
 
2.1.2.4 Purified antibodies 
Rat anti-mouse CD3 (Clone 2C11) 
Anti-mouse CD3 was affinity-purified in house from hybridoma culture supernatants 
using Hi Trap protein G-Sepharose columns. 
 
Hamster anti-mouse CD28 (Clone 37.51) 
Anti-mouse CD28 was grown in house from hybridoma culture supernatants were 
tested against previous supernatants in T cell cultures. 
 
Rat anti-mouse IL-4 (Clone 11B11) 
Anti-mouse IL-4 was affinity-purified in house from hybridoma culture supernatants 
using Hi Trap protein G-Sepharose columns. 
 
Rat anti-mouse IFN-γ (Clone AN-18) 
Anti-mouse IFN-γ was affinity-purified in house from hybridoma culture supernatants 
using Hi Trap protein G-Sepharose columns. 
 
Rat anti-mouse MHC II (Clone M5/114.15.2) 
Anti-mouse MHC II was affinity-purified in house from hybridoma culture 
supernatants using Hi Trap protein G-Sepharose columns. 
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Rat anti-mouse IL-2 (Clone JES6-1A12) 
Anti-mouse IL-2 was purchased from WEHI Antibody Services (Melbourne, Victoria, 
AUS). It was stored at shipping concentration at -70ºC. 
 
Rat anti-mouse CD4 (Clone GK1.5) 
Anti-mouse CD4 was purchased from Bio X cell (West Lebanon, New Hampshire, 
USA). It was stored at shipping concentration at -70ºC. 
 
Rat anti-mouse CD90 (Clone 30H12) 
Anti-mouse CD90 was purchased from Bio X cell (West Lebanon, New Hampshire, 
USA). It was stored at shipping concentration at -70ºC. 
 
Rat anti-mouse CD16 (FcεRIII)/CD32 (FcεRII) (Clone 2.4G2) 
Anti-mouse CD16 (FcεRIII)/CD32 (FcεRII) was affinity-purified in house from 
hybridoma culture supernatants using Hi Trap protein G-Sepharose columns. 
 
Rat anti-mouse IL-13 
Anti-mouse IL-13 antibody was kindly provided by Abbvie. It was stored at -70ºC at 
shipping concentration.  
2.1.2.5 Allergens and peptides 
ISQ peptide from ovalbumin  
Ova peptide ISQAVHAAHAEINEAGR (OVA323-339) was purchased from 
Mimotopes Pty Ltd (Clayton, VA, AUS) and referred to as ISQ peptide. Lyophilized 
protein was reconstituted in dPBS to 1 mM and stored at -80oC. 
 
House dust mite 
House dust mite (HDM) purchased from Greer laboratories (Lenoir, NC, USA) was 
resuspended in sterile dPBS to 100 μg/ 30 μl and stored at -80ºC. 
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2.1.2.6 Drugs 
Anaesthetic 
10x stock solution was diluted in sterile dPBS to 8.6 mg/ ml ketamine and 0.26 mg/ ml 
xylazine working solution. 
 
Calcipotriol (MC903) 
Calcipotriol was purchased from Cayman Chemicals (Ann Arbor, Michigan, USA). 
Calcipotriol was diluted in absolute ethanol from Pure Science (Porirua, New Zealand) 
to a concentration of 1.6mM and stored at -20°C. Diluting stock solution 1:10 in 
absolute ethanol made a working stock solution. 
 
FTY720 
Lyophilised FTY720 (Novartis Biopharma) was dissolved into sterile milliQ water and 
frozen in 10mg/mL aliquots at -80°C. FTY720 was further diluted for use to 50 μg/mL. 
FTY720 was administered by daily gavage at a dose of 10 mg/mouse unless. 
 
2.1.2.7 Flow cytometry reagents 
Sodium azide 
NaN3 was purchased in powder form from Sigma-Aldrich New Zealand, Ltd (Auckland, 
NZ, S8032) and dissolved in dPBS to give a stock concentration of 5%. The solution 
was stored at room temperature. 
 
Fluorescent activated cytometry (flow) buffer 
0.01% NaN3 and 2% FBS were made up in dPBS and stored at 4ºC. 
 
Fluorescent activated cell-sorting (FACS) buffer 
0.002% DNase I and 2% FBS were made up in dPBS, filter sterilised and stored at 4ºC. 
 
4’, 6-diamidino-2-phenylindole dihydrochloride (DAPI) 
DAPI was purchased from Invitrogen (Auckland, NZ D1306) and resuspended in dH2O 
to a stock concentration of 5 mg/mL and stored in aliquots at -80ºC. Stock was diluted 
in flow buffer to a concentration of 200mg/mL and stored protected from light at 4øC. 
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LIVE/DEAD® Fixable blue dead cell Stain kit  
LIVE/DEAD® Fixable blue was purchased from Invitrogen (Auckland, NZ L-23105) 
and stored protected from light at -20ºC. Each vial was resuspended with room 
temperature 50 µL anhydrous DMSO (component B of the kits) to forma working 
solution. 
 
Anti-Mouse Ig, κ/Negative control compensation particle 
Mouse antibody binding compensation beads were purchased from Becton Dickinson 
Pty Ltd (Auckland, NZ, 552843) and stored at 4ºC. 
 
Anti-Rat/Hamster Ig, κ/Negative control compensation particle 
Mouse antibody binding compensation beads were purchased from Becton Dickinson 
Pty Ltd (Auckland, NZ, 552845) and stored at 4ºC. 
 
Carboxyfluorescein succinimidyl ester (CFSE) 
CFSE was purchased from Molecular Probes (Eugene, OR, USA) and resuspended in 
was stored at -20°C, as a 10 mM solution in DMSO Sigma-Aldrich New Zealand Ltd 
(Auckland, NZ). 
 
FoxP3 Transcription Factor Staining Set 
The FoxP3 transcription factor staining set (Affymetirx, eBioscience San Diego, CA, 
USA) was stored at 4 °C. 4x Fixation/Permeabilization Concentrate was diluted 1:4 in 
Fixation/Permeabilization Diluent immediately prior to use. 10x Permeabilization 
Buffer was diluted 10 fold in ddH20 immediately prior to use, or diluted and stored at 4 
°C. 
 
IL-4 extracellular capture reagent 
Mouse IL-4 secretion assay detection kit was purchased from Miltenyi Biotec (Bergisch, 
Germany, 130-090-479) and stored at 4°C. 
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2.1.2.8 Fluorescently conjugated antibodies 
Specificity Fluorophore Clone Company 
B220 Biotin RA3-6B2 In house 
 Horizon V450 RA3-6B2 BD Biosciences 
 PE-Texas Red RA3-6B2 BD Biosciences 
 PE-CF594 RA3-6B2 BD Biosciences 
CD2 Biotin RM2-5 Biolegend 
CD3 Biotin 2C11 eBiosciences 
 BV786 145-2C11 BD Horizon 
 PE 145-2C11 eBiosciences 
 PerCP-Cy5.5 145-2C11 BD Pharmingen 
 PE-Cy7 2C11 eBiosciences 
CD4 Biotin GK1.5 In house 
 FITC RM4-4 BD Pharmingen 
 BV605 RM4-5 BD Horizon 
 APC RM4-5 BD Pharmingen 
 APC-H7 GK1.5 BD Pharmingen 
 Qdot605 RM4-5 Invitrogen 
CD8 Biotin 2.43 In house 
 AF700 53-6.7 Biolegend 
 PE 53-6.7 BD Pharmingen 
 PE-Cy7 53-6.7 BD Pharmingen 
CD11a PE-Cy7 2D7 BD Pharmingen 
CD11b FITC M1/70 BD Pharmingen 
 PE M1/70 BD Pharmingen 
 PerCP-Cy5.5 M1/70.15 BD Pharmingen 
CD11c PE HL3 BD Pharmingen 
 PE-Cy7 HL3 BD Pharmingen 
CD16/CD32 APC 2.4G2 BD Pharmingen 
CD19 APC-H7 ID3 BD Pharmingen 
CD25 FITC 7D4 BD Pharmingen 
 APC PC61 BD Pharmingen 
CD34 BV421 MEC14.7 Biolegend 
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CD40 PE 3/23 BD Pharmingen 
CD44 PE IM7 BD Pharmingen 
 APC IM7 BD Pharmingen 
 AF700 IM7 BD Pharmingen 
CD45 Pacific Blue 30-F11 Biolegend 
 APC-Cy7 30-F11 BD Pharmingen 
CD45.2 APC 104 Biolegend 
CD49b PE-Cy7 DX5 eBiosciences 
CD62L Biotin MEL-14 BD Pharmingen 
 FITC MEL-14 BD Pharmingen 
 PE-Cy7 MEL-14 eBiosciences 
CD69 PE H1.2F3 BD Pharmingen 
 PE-Cy7 H1.2F3 BD Pharmingen 
CD80 APC 16-10A1 Biolegend 
CD86 PE GL1 BD Pharmingen 
CD90.2 BV605 53-2.1 Biolegend 
 APC 53-2.1 BD Pharmingen 
CD95 PE-CF594 Jo2 BD Horizon 
CD103 APC 2E7 eBiosciences 
CD117 APC 2B8 BD Pharmingen 
CD121b PE 4E2 BD Pharmingen 
CD122 PE TMb1 BD Pharmingen 
CD127 PE SB199 BD Pharmingen 
 PE-Cy7 A7R34 Biolegend 
CD152 PE UC10-4F10-11 BD Pharmingen 
CD154 PE MR1 BD Pharmingen 
CD200R3 APC Ba13 Biolegend 
CD278 PE C398.4A Biolegend 
CD279 PerCP-ef710 RMPI-30 eBiosciences 
CXCR5 APC 2G8 BD Pharmingen 
FcεRI Biotin MAR-1 Biolegend 
 PE MAR-1 eBiosciences 
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GATA-3 AF647 L50-823 BD Pharmingen 
huCD2 APC RPA2.10 BD Pharmingen 
 PE S5.2 BD Pharmingen 
IA/IE(MHC II) PE M5/114.15.2 BD Pharmingen 
 PE-Cy7 M5/114.15.2 BD Pharmingen 
IgE Biotin R35-118 BD Pharmingen 
IL-4 AF647 11B11 BD Pharmingen 
IL-13 AF647 eBio13A eBiosciences 
KLRG1 APC 2F1 BD Horizon 
Ly6A/E PE D7 Biolegend 
Ly6C/Ly6G (GR1) Biotin RB6-8C5 In house 
 APC RB6-8C5 BD Pharmingen 
NK1.1 PE PK136 BD Pharmingen 
 PerCP-Cy5.5 PK136 BD Pharmingen 
Siglec F PE E50-2440 BD Pharmingen 
T1 ST2 FITC DJ8 MD Bioproducts 
Vα2 APC B20.1 Invitrogen 
Vβ5.1/5.2 Biotin MR9-4 BD Pharmingen 
Fluorophore bound Streptavidin  Company 
SA-APC BD Pharmingen 
SA-PE-Texas Red BD Pharmingen 
SA-PE-Cy7 BD Pharmingen 
SA-QDot565 Invitrogen 
Table 2-1 – List of fluorescently labelled antibodies used in this thesis for flow 
cytometry.  
Listed are the antibody specificities, fluorophore, clone and supplier. 
2.1.2.9 Polymerase chain reaction reagents 
4C13R primers 
Gene target: DS-Red 
5’-GCTCCAAGGTGTACGTGAAG-3’ 
5’-GCTTGGAGTCCACGTAGTAG-3’ 
Produced an approximately 450 base pair product. Primers bought from Sigma-Aldrich 
New Zealand Ltd (Auckland, NZ). 
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Diethylpyrocarbonate (DEPC) treated water 
UltraPure DEPC-Treated water from Invitrogen (Auckland, NZ, 10813-012) was stored 
at room temperature. 
 
DNA polymerase kit 
i-Taq DNA polymerase kit from iNtRON Biotechnology (Korea, 25022) was stored at -
20ºC.  
 
Agarose 
Agarose from BDH Laboratory Supplies (Poole, UK) was stored in powder form at 
room temperature. 
 
Gel loading dye 
10x concentration BlueJuice gel loading buffer from Invitrogen (Auckland, NZ, 10816-
015) was stored at 4ºC. 
 
SYBR safe DNA gel stain 
SYBR safe DNA gel stain from Invitrogen (Auckland, NZ, S33102) was stored at room 
temperature. 
 
DNA ladder 
TrackIt 1 Kb plus DNA ladder from Invitrogen (Auckland, NZ, 10488-085) was stored 
at 4ºC. 
 
2.1.3 Mice 
2.1.3.1 Maintenance and ethics approvals 
Mice were bred and maintained in specific pathogen free conditions within the 
Biomedical Research Unit of the Malaghan Institute of Medical Research. For most 
experiments six week or older mice were age and sex matched as much as possible. For 
age experiments mice younger than 6 weeks were culled for tissues without 
manipulation. Experimental procedures were approved by the Victoria University 
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Animal Ethics Committee and carried out in accordance with the guidelines of Victoria 
University of Wellington, New Zealand. This work was performed under the following 
protocols: 
2009R7M - Immunopathogenesis of food allergy 
2009R14M - The role of cytokines and immune cells in protective immunity to 
parasites and inflammatory diseases 
2011R10M - Novel vaccine approaches for protecting against parasitic helminths 
2011R22M - Basic biology of the Th2 response in the context of allergic disease 
2014R15M - Immunomodulation and Immune protection by helminth parasites and 
their products 
2014R17M - Activation and role of novel Th2 subtypes in allergic disease 
 
2.1.3.2 Mouse strains 
Balb/c mouse strain 
Obtained from Jackson Laboratory (Bar Harbour, Maine, USA) and maintained as an 
inbred strain. 
 
C57Bl/6 mouse strain 
Obtained from Jackson Laboratory (Bar Harbour, Maine, USA) and maintained as an 
inbred strain. 
 
G4/G4 (GFP/GFP) mouse strain 
Obtained from W. E. Paul at the Laboratory of Immunology, National Institute of 
Allergy and Infectious Diseases, National Institute of Health, Bethesda MD 20892-1892, 
USA227. Mice were originally on a C57Bl/6 background but were crossed to a Balb/c 
background. Both strains were maintained as inbred strains. 
 
G4/IL-4 (GFP/IL-4) mouse strain 
This strain is also available on both C57Bl/6 and Balb/c backgrounds. These mice 
were generated as the F1 offspring from crosses between the GFP/GFP mice and the 
appropriate WT strain, either Balb/c or C57Bl/6.  
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KN2/KN2 (huCD2/huCD2) mouse strain 
Obtained from R. M. Locksley from the Howard Hughes Medical Institute, University 
of California, San Francisco, CA 94143-0795, USA289. Mice are on a Balb/c 
background and maintained as an inbred strain.   
 
KN2/IL-4 (huCD2/IL-4) mouse strain 
This strain was generated as F1 offspring between the KN2/KN2 mice and Balb/c 
mice. 
 
KN2/G4 (huCD2/GFP) mouse strain 
This strain was generated as F1 offspring between the KN2/KN2 mice and G4/G4 
mice. 
 
4C13R mouse strain 
Obtained from W. E. Paul at the Laboratory of Immunology, National Institute of 
Allergy and Infectious Diseases, National Institute of Health, Bethesda MD 20892-1892, 
USA. Mice were generated as follows; BAC-clone (RP23.97H11) containing the Th2 
locus control region (lcr), Il13, Il4, and Kif3 genes was obtained from the Children’s 
Hospital of Oakland Research Institute. A galk cassette containing 5’ and 3’ homology 
arms from the Il4 gene inserted via homologous recombination targeted to the starting 
ATG codon of the Il4 gene. The resultant “Il4 galk” was then targeted with an 
AmCyan construct, which replaced galk. Using the same principle, the starting ATG 
codon of the Il13 gene of the “Il4 AmCyan” BAC was targeted and replaced with a galk 
cassette. A DsRed-DR construct replaced the galk sequence. The BAC was linearized 
by digestion with Asc1 and the fragment containing Th2 LCR, Il13-DsRed-DR, Il4-
AmCyan, and KIF3 was microinjected into C57Bl/6 oocytes. These oocytes were 
subsequently transferred into pseudo-pregnant foster mothers of C57Bl/6 background. 
Offspring carrying the 4C13R reporter construct were selected for by polymerase chain 
reaction (PCR)265. The strain was maintained by crossing to C57Bl/6 mice, offspring 
were tested by PCR and non-transgenic offspring kept for controls. 
 
4C13RxG4/IL-4 (4C13RxGFP/IL-4) mouse strain 
This strain was generated as F1 offspring between the 4C13R mice and G4/G4 mice. 
Offspring were tested by PCR for presence of the 4C13R construct. 
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4C13RxG4/G4 (4C13RxGFP/GFP) mouse strain 
This strain was generated as F1 offspring between the 4C13RxG4/IL-4 mice and 
G4/G4 mice. Offspring were tested by PCR for presence of the 4C13R construct and 
by flow cytometry, assessing basophil GFP fluorescence to determine hetero- or 
homozygosity for the IL-4-GFP allele. 
 
4C13RxKN2/G4 (4C13Rx huCD2/GFP) mouse strain 
This strain was generated as F1 offspring between the 4C13RxG4/IL-4 mice and 
KN2/KN2 mice. Offspring were tested by PCR for presence of the 4C13R construct 
and by flow cytometry, assessing basophil GFP fluorescence to assess the presence of the 
IL-4-GFP allele. 
 
4C13RxOTII mouse strain 
This strain was generated as F1 offspring between the 4C13R mice and OTII mice 
(Provided by S. Hook, School of Pharmacy, Otago University, Dunedin, New Zealand 
with permission from F. Carbone, Melbourne, Victoria, AUS)291. Offspring were tested 
by PCR for presence of the 4C13R construct. 
 
Rag1-/- mouse strain 
Obtained from Jackson Laboratory (Bar Harbour, Maine, USA)292. These mice were on 
a C57Bl/6 background and maintained as an inbred strain. 
 
TSLPR-/- x G4/G4 mouse strain 
TSLPR-/-xG4/G4 mice were obtained from Prof. William Paul (NIAID, NIH, 
Bethesda, USA), with permission from Prof. Warren Leonard (National heart, lung, and 
blood institute, NIH, Bethesda, USA)293. TSLPR-deficient mice were crossed with 
G4/G4 mice and the offspring crossed to generate TSLPR deficient mice that were 
homozygous for the GFP IL-4 reporter. These mice were on a C57Bl/6 background 
and maintained as an inbred strain. 
 
eGFP mouse strain 
Transgenic mice with the sequence for enhanced GFP under control for the beta actin 
promoter for widespread eGFP expression were obtained from Hercus Taieri Research 
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Unit, (Dunedin, NZ)294. These mice were on a C57Bl/6 background and maintained as 
an inbred strain. 
 
DS-Red mouse strain 
Transgenic mice with the sequence for DS-Red under the control of the chicken beta 
actin promoter coupled with the cytomegalovirus (CMV) immediate early enhancer for 
widespread DS-Red expression were obtained from Jackson Laboratory (Bar Harbour, 
Maine, USA)295 these mice were on a C57Bl/6 background and maintained as an 
inbred strain. 
 
2.1.4 Nippostrongylus brasiliensis 
Nippostrongylus brasiliensis from L. A. Dent (Adelaide, South Australia, AUS) in 1995 has 
maintained by passage through Lewis rats as described124. 
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2.2 Methods 
2.2.1 Trypan blue exclusion assay 
Cell suspensions were mixed 1:1 with Trypan blue dye. 10ul of the mixture was 
transferred to a haemocytometer and cell numbers counted on a compound microscope. 
 
2.2.2 Hybridoma culture 
Hybridoma cells cultured in cIMDM with optimised concentrations of FBS (either 10% 
or 20%) were seeded at 2x106 cells/mL into the cell compartments of the CELLine 
flasks. The nutrient compartments were filled with 5% cIMDM. After one week 
supernatant from the cell compartment was collected, filtered through Serum filters and 
antibodies isolated from the supernatant by fast pressure liquid chromatography using 
Hitrap protein G affinity columns. Antibodies were dialysed in dPBS using 1000 
molecular weight cut-off (MWCO) cassettes. Concentration of antibody was measured 
using Nanodrop absorption readings at 280 nm. Antibody was concentrated using 
10000 MWCO Vivaspin tubes. 
 
2.2.3 Genotyping 
2.2.3.1 4C13R strains 
PCR genotyping was performed on DNA extracted from tail tips. Tails were hydrolysed 
in tail lysis buffer at 95ºC for 2 hours to extract DNA, hydrolysis was quenched with 
neutralisation buffer. PCR was performed with the appropriate primers using the i-Taq 
DNA Polymerase kit. PCR products were run on 1.8% Agarose gel, loaded with 10X 
BlueJuice Gel Loading Buffer and visualised with SYBR Safe DNA Gel Stain. TrackIt 1 
Kb Plus DNA Ladder was used to determine PCR product size. 
 
2.2.3.2 G4 (GFP) strains 
Blood was collected and processed as in 2.2.7.8. After red blood cell lysis, cells were 
stained with antibodies against FcεRI, CD49b and CD45 to identify basophils and 
analysed via flow cytometry. Basophils were identified by the expression of 
CD45midCD49b+FcεRI+ and GFP median fluorescent intensity of basophils was 
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compared to control samples from G4/IL-4 and G4/G4 mice to allow classification of 
mice as GFP/IL-4 and GFP/GFP. 
 
2.2.4 Preparation of infectious larvae 
Infective L3 were harvested from faecal cultures, larvae were washed in sterile dPBS, 
allowed to settle and the dPBS taken off. This was repeated three times then the larvae 
were counted and the sample was diluted to 11000 larvae/mL (550/50 µL)124. 
 
2.2.5 Mouse manipulations 
2.2.5.1 Serum Collection 
Blood was collected by lateral tail vein into a 1.7 mL Microtubes and left to clot 
overnight at 4ºC. Blood was spun for 3 minutes at 4 degrees at 1523 x g and serum was 
removed and frozen at -20ºC until analysed. 
 
2.2.5.2 Nippostrongylus brasiliensis infection 
All infections were via the intravenous route unless otherwise stated. Washed larvae 
from 2.2.4 were injected subcutaneously in the scruff of the neck or intravenously into 
the tail vein. For intravenous injection mice were heated under a heat lamp for a short 
time (2-4 minutes) until tail veins were readily visible. For secondary infections primary 
infected mice were left for 30 days to clear the adult worms from the intestine. On day 
30 post-primary the mice were re-infected either subcutaneously or intravenously.124 
 
2.2.5.3 Primary Th2 immune response assay (pTh2 assay) 
IL-4 reporter mice were anesthetised with 200µL of working concentration anaesthetic. 
Mice received 30µL house dust mite (100µg) intradermally into the pinna of each ear. 
At harvest the auricular draining lymph nodes were excised and collected into plates 
with flow buffer on ice.296 
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2.2.5.4 MC903 
Mice were anesthetised with 200µL of working concentration anaesthetic. 10µL of 
working concentration MC903 was applied to each side of the mice ears (20µL/ear).297 
 
2.2.5.5 Tape striping 
Mice were anesthetised with 200µL of working concentration anaesthetic. Masking tape 
from Office Max (Wellington, New Zealand) was applied to the dorsal side of each ear 
and pulled off in a quick motion; this was repeated 20 times/ear with a new piece of 
tape for each strip.298 
 
2.2.5.6 Antibody administration  
CD4 depletion 
Stock GK1.5 antibody was diluted with sterile dPBS to 2.5mg/mL 0.5mg antibody was 
administered intraperitoneally125. Mice received GK1.5 either 24 hours before primary 
infection or 24 hours before secondary infection (Day -1) or 7 days and 3 days before 
secondary infection (Day -7). 
 
CD90 depletion 
Stock 30H12 antibody was diluted with sterile dPBS to 2.5mg/mL 0.5mg antibody was 
administered intraperitoneally299. For ILC2 depletion in Rag1-/- mice, mice were 
treated daily for 5 days prior to primary infection and once again 24 hours post 
infection. 
 
IL-13R blocking 
Stock was diluted to 5mg/mL with sterile dPBS was administered intraperitoneally. 
 
2.2.5.7 Cytokine administration 
Intranasal IL-33 
Mice were anesthetised with 200µL of working concentration anaesthetic and were laid 
on their back. 50µL of IL-33 (0.5µg) was carefully pipetted into the nostrils of each 
mouse300. For the cytokine protection models mice were treated 2 days prior to infection. 
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IL-2 complex (IL-2c) 
Stock IL-2c was thawed and diluted 1:16.67 (30:500 µL) in sterile dPBS. Mice received 
100µL intraperitoneally301. For the cytokine protection models mice were treated 2 days 
prior to infection. For rescuing protection by ILC2 stimulation in CD4+ T cell depleted 
mice, mice were treated three times every second day beginning 6 days prior to 
secondary infection. 
 
2.2.6 Tissue processing for larval counts 
Mice were sacrificed by cervical dislocation and lungs excised. Lungs are collected in 
plates with no liquid. Lungs were then mechanically dissociated, placed in cheesecloth 
and suspended in a 50mL Falcon tube of dPBS and placed in a 37ºC water bath 
overnight. Viable larvae migrate out of the tissue and collect at the base of the tube, 
these can be enumerated using a stereo microscope124. 
 
2.2.7 Tissue processing for single cell suspension 
2.2.7.1 Spleen for flow cytometry and Th polarising cultures 
Mice were sacrificed by CO2 asphyxiation and spleen excised and placed in plates with 
IMDM on ice. Under sterile conditions spleens were dissociated by crushing with the 
plunger from 2mL syringe through a 70µm cell strainer and washed through with 
IMDM. Cells were pelleted at 419 x g for 4 minutes. Pellet was resuspended in 4 mL 
Red Blood Cell Lysis buffer for 4 minutes. Lysis was quenched with 10mL of cold 
IMDM and cells pelleted the same as before. Cells were resuspended in cIMDM for 
counting. 
 
2.2.7.2 Spleen for antigen presenting cells 
Mice were sacrificed by CO2 asphyxiation and spleen excised and placed in plates with 
IMDM on ice. Under sterile conditions spleens were places in 3mL spleen digestion 
buffer (2.1.2.2) and mechanically dissociated and incubated at 37ºC for 30 minutes. 
Cells were then passed through a 70µm cell strainer and washed through with IMDM. 
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Cells were pelleted at 419 x g for 4 minutes. Pellet was resuspended in 4 mL Red Blood 
Cell Lysis buffer for 4 minutes. Lysis was quenched with 10mL of cold IMDM and cells 
pelleted the same as before. Cells were resuspended in cIMDM for counting. 
 
2.2.7.3 Lungs 
Mice were sacrificed by cervical dislocation and lungs were excised and placed in plates 
with IMDM on ice. Lungs were finely cut and incubated in 5mL of lung diction buffer 
at 37ºC for 60 minutes. Digested tissue was passed repeatedly through an 18-gauge 
needle then passed through a 70µm cell strainer and washed through with IMDM. 
Cells were pelleted at 419 x g for 4 minutes. Pellet was resuspended in 4 mL Red Blood 
Cell Lysis buffer for 4 minutes. Lysis was quenched with 10mL of cold IMDM and cells 
pelleted the same as before. Cells were resuspended in flow buffer for counting.  
 
2.2.7.4 Thymus 
Mice were sacrificed by CO2 asphyxiation and thymi excised and placed in plates with 
IMDM on ice. Under sterile conditions thymi were dissociated by crushing with the 
plunger from 2mL syringe through a 70µm cell strainer and washed through with 
IMDM. Cells were pelleted at 419 x g for 4 minutes. Cells were resuspended in flow 
buffer for counting. 
 
2.2.7.5 Lymph Nodes 
Mice were sacrificed by CO2 asphyxiation (pTh2 auricular draining LN) or cervical 
dissociation (mediastinal LN) and LNs excised and placed in plates with IMDM on ice. 
Under sterile conditions LNs were dissociated by crushing with the plunger from 2mL 
syringe through a 70µm cell strainer and washed through with IMDM. Cells were 
pelleted at 419 x g for 4 minutes. Cells were resuspended in flow buffer for counting. 
 
2.2.7.6 DynaBead CD4 isolation 
5x107 cells from single cell suspensions from the above processing were spun down at 
419 x g for 4 minutes and resuspended and incubated in isolation buffer with 25µL of 
αCD4 antibody (from the Dynabeads CD4 positive isolation kit, 2.1.2.2) for 10 minutes 
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on ice. These cells were washed with isolation buffer, pelleted and resuspended in 
isolation buffer with 75µL Dynabead mix was added and incubated rolling and tilting 
for 15 minutes at 4ºC. Bead bound cells were gathered to one side of the tube using 
magnets and the remaining suspended cells were aspirated away. Bead bound cells were 
resuspended in isolation buffer and then magnetic separation was repeated. Bead bound 
cells were resuspended in 1mL release buffer and incubated rolling at tilting for 10 
minutes at room temperature. Tubes were placed on the magnet again and suspended 
CD4+ T cells were removed by pipette. These cells were pelleted, resuspended in 
cIMDM and then prepared for culture. 
 
2.2.7.7  Macs bead CD11c isolation 
107 cells from spleens digested as in 2.2.7.2 were pelleted down at 419 x g for 4 minutes 
and resuspended and incubated in 100µL of αCD11c for 15 minutes on ice. Cells were 
washed in isolation buffer and spun down and resuspended in 1mL isolation buffer. 
Samples were run on the AutoMACs separator using a POSSEL programme for the 
positive selection of CD11c+ cells. Collected cells were pelleted and resuspended in 
cIMDM for counting. 
 
2.2.7.8 Blood 
Blood was collected via tail vein bleeding, and collected in Alsever’s solution. Cells were 
pelleted at 630 x g and supernatant aspirated. Pellets were resuspended in H2O for 30 
seconds then adding equal volume of 1.8% w/v NaCl solution quenched the lysis. Cells 
were re-pelleted and resuspended in flow buffer for counting. 
 
2.2.7.9 Skin 
Ears were excised and the ventral and dorsal halves of the pinna split using tweezers 
and mechanically dissociated then incubated in skin digestion buffer for 1 hour shaking 
at 150rpm at 37ºC. Digested tissue was worked through 80µm stainless steel mesh with 
the plunger from a 1mL syringe. Cells were washed through with flow buffer. Cells were 
washed twice with flow buffer and resuspended in flow buffer for counting. 
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2.2.8 Th cell polarisation culture 
24 well plates were coated overnight at 4ºC with 300µL/well of 1µg/mL αCD3 (2C11) 
diluted in dPBS. On day 0 plates were washed twice with IMDM and 106 splenocytes 
or 2x105 Dynabead enriched CD4 T cells in a 1mL total volume of the appropriate 
stimulatory media were plated. Half the media was replaced with appropriate feed 
media on days 3 and 4. 
On day 5 cells were harvested spun down at 419 x g for 4 minutes. Cells were 
resuspended in cIMDM with 100U/mL IL-2 and plated on uncoated 24 well plates at 
106  cells/well to rest. Half the media was replaced daily from day 6-10 with cIMDM 
with 200U/mL IL-2. On day 11 cells were harvested again and plated in media 
containing 100U/mL of IL-2 and 1:50 αCD28 (37.51) on plates that had been coated 
overnight with 10µg/mL αCD3 at 4°C30.  
 
2.2.8.1 Th0 media 
Stimulation Media 
αIL-4 (11B11) 10µg/mL 
 αIFN-γ (AN-18) 10µg/mL 
αCD28 (37.51) 1:50 
 
Feed media 
IL-2 200U/mL 
IL-4 2000U/mL 
 
2.2.8.2 Th2 media 
Stimulation Media 
IL-2 100U/mL 
IL-4 1000U/mL 
αCD28 (37.51) 1:50 
 
Feed media 
IL-2 200U/mL 
IL-4 2000U/mL 
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2.2.8.3 Carboxyfluorescein succinimidyl ester (CFSE) staining 
Stock CFSE was diluted in dPBS to 0.5µM then added to single cell suspension in dPBS 
at a ratio of 1:4 cell suspension : diluted CFSE solution. Cells were incubated for 5 
minutes protected from light at room temperature. Adding an equivalent volume of 
FBS quenched staining. Cells were pelleted at 419 x g for 4 minutes and washed twice 
in cIMDM.302 Cells were then be used for culture. 
 
2.2.8.4 Antigen processing cell – OTII cell culture 
APCs from digested spleens (2.2.7.2) were incubated for 30 minutes with 10nM ISQ 
peptide in cIMDM at 37ºC.291 APCs were washed with IMDM twice, and then 
resuspended in cIMDM. APCs were mixed in a ratio of 1:1 with Dynabead isolated 
CD4 T cells (2.2.7.6) from OTII mice and cultured in the presence of 100U/mL IL-2 
and 1000U/mL IL-4. Half the media was replaced on day 3 with feed media containing 
200U/mL IL-2 and 2000U/mL IL-4. 
For restimulation on day 3 spleens were digested (2.2.7.2) and CD11c+ cells isolated via 
AutoMACs (2.2.7.7). CD11c+ cells were incubated for 30 minutes with 10nM ISQ 
peptide in cIMDM at 37ºC. These cells were then washed in IMDM and resuspended 
in cIMDM containing 200U/mL IL-2 and 2000U/mL IL-4. Half of restimulated wells 
media was replaced with the CD11c+ cell suspension. 
 
2.2.9 Enzyme-linked immunosorbent assay (ELISA) 
Nunc Maxisorb 96 well plates were coated with 100µL of the appropriate coating 
antibody and incubated overnight at 4ºC. Plates were washed by submersion into a 4L 
bucket containing dPBS and 0.05% Tween-20 Sigma-Aldrich New Zealand Ltd 
(Auckland, NZ, P2287), excess liquid was removed from the wells by smacking the 
inverted plate on a pile of paper towels. Plates were blocked with 10% FBS in dPBS 
solution for 2 hours at 37ºC. Samples were serially diluted in 10 fold dilution steps with 
10% FBS in d solution. Standards were serially diluted across 11 wells in 2 fold steps in 
the same 10% FBS in dPBS solution. Block was washed from the plates and 100µL of 
samples and standards were incubated in the plates overnight at 4ºC. Samples and 
standards were washed out and the 100µL of the appropriate biotin bound detection 
antibody was added to the plates. Detection antibodies were washed out and 100µL of 
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streptavidin horse radish peroxidase diluted in 10% FBS in dPBS solution and 
incubated for a further hour at 37ºC. Plates were washed and developed with 100µL of 
a 1:1 mix of TMB A and B substrates, and development was stopped with 100µL of 1M 
H2SO4. Absorbance was read at 450nm on the Versamax Microplate reader.  
 
2.2.9.1 IL-4 ELISA 
Capture antibody – 11B11 (2µg/mL) 
Detection antibody - αIL-4-biotin (2µg/mL)  
 
2.2.9.2 IgE ELISA 
Capture antibody – 6HD5 (5mg/mL) 
Detection antibody – R1E4-biotin (3µg/mL) 
 
2.2.10 Flow cytometry staining and analysis 
2.2.10.1 Surface staining 
1.5x106 cells (or 2x106 cells for ILC analysis) were transferred into 5mL polystyrene 
round bottom tubes through 70µm gauze, and cells were pelleted at 419 x g for 4 
minutes. Cells were resuspended in 50µL of αCD16/32 (2.4G2) and cells were 
incubated for 5 minutes on ice. 50µL of the fluorophore bound antibody cocktail was 
then added to the tubes that were incubated for another 30 minutes on ice. Staining was 
stopped by the addition of 4mL of flow buffer and spun down. For secondary staining 
pellets were resuspended in 100µL of secondary antibodies diluted in flow buffer and 
incubated on ice for 15 minutes prior to washing. Samples were resuspended in 125µL 
flow buffer and prior to analysis 125µL of DAPI solution was added to each tube. 
 
2.2.10.2 Intracellular staining (ICS) 
1.5x106 cells (or 2x106 cells for ILC analysis) were transferred into 5mL polystyrene 
round bottom tubes through 70µm gauze, and cells were pelleted at 419 x g for 4 
minutes. Cells were resuspended in 1 mL diluted LIVE/DEAD fixable blue in dPBS 
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and incubated for 30 minutes at 4ºC. Cells were pelleted and stained as per 2.2.10.1. 
After surface staining and washing pellets were resuspended in 1mL of diluted 
Fixation/Permeabilization buffer (from FoxP3 Transcription Factor Staining buffer set) 
and incubated for 30 minutes at 4ºC protected from light. Cells were washed once with 
1x-diluted Permeabilization solution, pelleted then resuspended and incubated in 
100µL 1x-diluted Permeabilization solution with intracellular staining antibody at room 
temperature overnight. Cells were washed twice with 1x-diluted Permeabilization 
solution then finally resuspended in 250µL of flow buffer. 
 
2.2.10.3 IL-4 extracellular capture assay 
106 ells from culture (2.2.8) were collected and washed in 20mL of cold cIMDM then 
pelleted at 300 x g for 10 minutes. Pallets were resuspended in a 1:10 mixture of the IL-
4 catch reagent from the Mouse IL-4 secretion assay detection kit (Miltenyi Biotec 
Bergisch, Germany) diltued in cIMDM and incubated on ice for 5 minutes. 20mL of 
pre-warmed IMDM was added to the cells and cells were cultured rolling and tilting for 
45 minutes at 37°C. Cells were repelletted and washed twice in cold flow cytometry 
buffer. Cells were then stained as per 2.2.10.1 with the IL-4 detection antibody from the 
Mouse IL-4 secretion assay detection kit added to the staining cocktail. 
2.2.10.4 Acquisition 
Flow Cytometry data was acquired using a BD LSRII special order research product 
(SORP) and a BD LSR Fortessa with a unique laser arrangement specifically modified 
for optimal detection of AmCyan (Blue Violet 445nm laser with 504/12 filter). Both 
machines were running BD FACSDiva software. Cytometer setup and tracking was 
performed daily to ensure machines were calibrated. See appendix for laser and 
detector configurations (Table 8-1). 
2.2.10.5 Compensation 
For accurate compensation single stain controls were stained at the same time as surface 
staining (2.2.10.1). The appropriate anti-mouse or anti-rat/hamster Ig, κ/Negative 
control compensation beads were singly stained with antibodies conjugated to the same 
fluorophores as those used in the experimental staining cocktails. A mouse anti-human 
CD45-AmCyan antibody was used as a single stain control for the AmCyan-IL-4 
fluorescent reporter. Splenocytes processed as in 2.2.7.1 from eGFP and DS-Red 
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constitutively expressing mice were used as single stain controls of GFP-IL-4, and DS-
Red-IL-13 fluorescent reporters. Compensation was applied using the automatic 
compensation wizard in the FACSDiva software. 
 
2.2.10.6 Fluorescence activated cell sorting 
Cells were sorted by the staff of Hugh Green Cytometry Core on a FACSVantage cell 
sorter, using DIVA software (Becton-Dickinson, Mountain View, CA, USA). 
2.2.10.7 Analysis of flow cytometry data 
 Data was analysed using FlowJo software (Tree Star, Ashland, Oregon, USA). 
Compensation was reviewed by observing each single stain control against every other 
collected channel and confirming there was no over or under compensation applied. 
Singlets were selected for by gating for cells on the diagonal in FSChight by FSCarea and 
SSChight by SSCarea plots. Dead cells were excluded by gating on DAPI- cells. For 
specific gating on each leukocyte population see appendix. For gating upon populations 
where there was no clear division between positive and negative cells fluorescence 
minus one (FMO) controls were used to determine where background staining in each 
channel was and where gates should be set. 
2.2.11 Statistical analysis 
Data were graphed and analysed in Graphpad Prism 5.0. Statistical analyses used are 
stated in figure legends and p<0.05 was considered as significant. In comparisons 
between two similarly-sized groups, Student’s t-test was used. Analyses examining a 
single parameter of three or more groups were compared with One-way ANOVA with 
Tukey’s post-test. For experiments examining two or more groups, Two- way ANOVA 
with Bonferroni’s post-test were used. Repeated measures tests were used in cases in 
which the same biological sample was compared. Unless otherwise stated, symbols 
represent individual samples and error bars represent mean ± the standard error of the 
mean (S.E.M.). 
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3 Mechanisms regulating 
expression of IL-4 by 
CD4+ T cells 
3.1 Introduction 
IL-4 production by CD4+ T cells is critical for Type 2 immune responses and while they 
have been studied for over 25 years the mechanisms that regulate IL-4 expression remain 
obscure. This chapter will introduce and characterise a new reporter mouse strain and 
explores how Th2 cells regulate their expression of IL-4, including what signals affect the 
proportions of Th2 cells expressing IL-4 mono- and bi-allelically, and the importance of 
IL-4 to in vivo Th2 generation.  
To study the allelic nature of IL-4 expression two strains, the human CD2 (huCD2)289 
and the GFP227 IL-4 reporter mice strains have been crossed in this laboratory to allow 
the reporting of which IL-4 allele a Th2 cell is actively transcribing from. Utilising this 
system mono- and bi-allelically expressing Th2 cells can be identified, characterised and 
tracked over time. This chapter explores the nature of signals that drive production of IL-
4 from both as opposed to one allele and how stable these phenotypes are. 
IL-4 reporter mice have provided significant insight into the regulation of Th2 cytokine 
production, however the available knock-in reporter systems have many caveats that can 
potentially affect the Th2 and Type 2 immune responses that they are reporting. Most 
knock-in reporter mice systems, such as the GFP and huCD2 IL-4 reporter mice 
 78 
previously available to this laboratory, disrupt the production of the reported gene. To 
ensure that the protein being reported remains available to influence immune responses in 
vivo, experiments are traditionally performed in heterozygous mice allowing protein 
production from the WT allele. However mice with only one WT IL-4 allele have been 
found to have deficiencies in Type 2 immune responses. A lack of one IL-4 allele 
decreases the amount of IgE generated in response to N. brasiliensis infection by half31 and 
causes a ten-fold decrease in OVA-specific IgE in response to OVA/alum immunisation 
(Unpublished data Marcus Robinson). 
IL-4 has been shown to be not required for the generation of Th2 cells31. However the 
role of this cytokine in Th2 expansion is less clear. Previous data by Van Panhuys et al. 
generated using heterozygous and homozygous knock-in reporter mice had been difficult 
to interpret because IL-4 is allelically expressed, with the majority of in vivo expression 
being mono-allelic. It was assumed that in the heterozygous GFP/IL-4 mice there would 
be a proportion of IL-4 expressing cells that were reporter negative while every Th2 cell 
induced to express IL-4 in the GFP/GFP mice would be GFP+. If IL-4 were dispensable 
for Th2 induction then in both the GFP/IL-4 and GFP/GFP mice the same total number 
of Th2 cells would be present. However because GFP would only mark the Th2 cells 
expressing from the reporter and not the WT allele in the GFP/IL-4 mice, these mice 
should have roughly half the number of reporter positive cells than the GFP/GFP mice. 
Due to the fact that both strains of mice had equal numbers of GFP+ CD4+ T cells, I 
interpreted this to indicate that IL-4 present only in the heterozygous GFP/IL-4 mice 
expanded the total Th2 cell population. So while only half the potential IL-4 expressing 
cells would be reporting via GFP expression, the IL-4 driven expansion of the total Th2 
cell population means that the number of GFP+ cells would be comparable between the 
GFP/IL-4 and GFP/GFP strains31. Before this thesis no tools were available to 
independently measure IL-4 induction in IL-4 WT, heterozygous and knock-out mice. 
A new transgenic IL-4 and IL-13 reporter system has been generated in an attempt to 
identify cells expressing IL-4 and IL-13 while avoiding the issues arising from the knock-in 
reporter systems that disrupt the parental alleles. In this chapter I will seek to characterise 
the new transgenic reporter mice, comparing them to current reporter system and other 
measures of IL-4 production. I will also investigate whether a third allele inserted 
transgenically into the genome is under allelic regulation as the parental genes are. Finally 
using the new reporter system as a read out of Th2 cell generation, the role of IL-4 for iv 
vivo Th2 cell generation and expansion will be measured. 
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3.1.1 Aims 
The following experiments characterised the mechanisms that regulate IL-4 expression. 
To do this I validated and used multiple IL-4 reporter models to identify which IL-4 
alleles CD4+ T cell were producing from. In vivo and in vitro models were used to induce 
CD4+ T cell IL-4 production, and huCD2, GFP and AmCyan IL-4 reporter expression 
measured and compared to assess the allelic regulation, and requirements for IL-4 on the 
expansion of Th2 cells. Specifically these experiments aimed to: 
• Compare the three IL-4 reporter systems and measure their effectiveness for 
identifying IL-4 production 
• Evaluate conditions which affect mono- and bi-allelic IL-4 expression 
• Assess if clones maintain the same allelic phenotype 
• Measure the impact of partial and total IL-4 deficiency on in vivo Th2 induction. 
 
3.2 Results 
3.2.1 Analysis of IL-4 and IL-13 expression validates the 4C13R 
reporter mice 
The 4C13R reporter mouse reports IL-4 and IL-13 expression through the production of 
the fluorescent molecules AmCyan and DS-Red respectively. These transgenic reporter 
mice were created to avoid significantly affecting the expression of the WT IL-4 and IL-
13 alleles. To test this 4C13R splenocytes were stimulated in Th2 differentiating 
conditions, rested and restimulated. Stimulation was achieved by plating cells on αCD3 
coated plates, in the presence of IL-2 and IL-4 to drive Th2 differentiation. The cells were 
plated in media containing IL-2 but on uncoated plates to rest. During the αCD3 driven 
restimulation no IL-4 was added allowing measurement of the IL-4 secreted by the cells 
during the 12 hours of culture with αCD3. Antibodies against the IL-4Rα (CD124) were 
added to the culture to inhibit receptor mediated uptake of IL-4. The proportions of 
CD4+ T cells that were positive for IL-4 and IL-13 via intracellular cytokine staining 
(ICS) were also compared after 6 hours of restimulation (Figure 3.1a). The proportion of 
CD4+ T cells that were positive for ICS IL-4 and IL-13 were found to be lower in cells 
from 4C13R compared with WT (Figure 3.1b). When the amounts of IL-4 released by 
restimulated cells from WT and 4C13R mice were compared by ELISA, a trend of 
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slightly less cytokine in the 4C13R cultures was observed, but never a statistically 
significant difference (Figure 3.1c). 
A very important readout of in vivo IL-4 production is IgE antibody class switching, so I 
tested that the 4C13R reporter mice did not have deficiencies in IgE that had been 
observed in the other IL-4 knock-in reporter mice31. To test this, mice were infected 
subcutaneously with 600 L3 N. brasiliensis, they were bled via the tail vein at the indicated 
days post infection and the serum levels of IgE assessed via ELISA. As had been seen with 
in vitro IL-4 production, lower IgE serum levels were observed in 4C13R mice compared 
with WT but the differences were statistically insignificant (Figure 3.1d). 
Some minor deficiencies in Type 2 associated signalling and effector functions were 
observed using the 4C13R transgenic reporter mice however these were not as significant 
as those reported in the other reporter models31. Based on this data 4C13R reporter mice 
are able to mount reasonably normal Type 2 immune responses in terms of IL-4, IL-13 
and IgE production, making them an optimal model for identifying IL-4 and IL-13 
producing cells in an immune competent system.  
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Figure 3.1 - 4C13R mice demonstrate only slight deficiencies in Type 2 cytokine 
production. 
 a. Schematic demonstrating Th2 culture system. Plates were coated with anti-CD3 (αCD3) 
antibodies and cells plated in Th2 media containing IL-4, IL-2 and anti-CD28 (αCD28). On day 
5 the cells were moved to uncoated plates and rested in IL-2. On day 11 cells were restimulated in 
αCD3 coated plates in media with IL-2 and αCD28. b. Cells from 4C13R and C57Bl/6 mice 
were cultured in the Th2 culture system. During the day 11 restimulation monensin was added to 
the cultures. Cells were harvested at 6 hours after restimulation and intracellularly stained for flow 
cytometric analysis of CD4+ T cell cytokine expression. Bar graphs show mean ± S.E.M. n=3 in 
each group. Data are representative of two independent experiments. Statistics were calculated for 
each cytokine using Student’s t test * P < 0.05 ** P < 0.01 c. Cells from 4C13R and C57Bl/6 
mice were cultured in the Th2 culture system. During the restimulation αCD124 antibodies were 
added to block IL-4 uptake and media was taken from the cells at 12 hours post restimulation and 
IL-4 levels were measured by ELISA. d. IgE titres from 4C13R and C57Bl/6 mouse serum at 
various time points after subcutaneous N. brasiliensis infection. Plots show mean ± S.E.M. n=3 in 
each group. Data are representative of two independent experiments. Statistics were calculated for 
each cytokine using a two way ANOVA with Bonferroni multiple comparison post test. Bar 
graphs show mean ± S.E.M. n=3 in each group. Data are representative of two independent 
experiments. Statistics were calculated for each cytokine using Student’s t test ns = non significant. 
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Reporter Strain Number of 
IL-4 alleles 
Parental IL-4 alleles Transgene 
4C13R 3 IL-4/IL-4 AmCyan 
GFP/IL-4 2 GFP/IL-4 None 
huCD2/IL-4 2 huCD2/IL-4 None 
huCD2/huCD2 2 huCD2/huCD2 None 
huCD2/GFP 2 huCD2/GFP None 
4C13RxhuCD2/huCD2 3 huCD2/huCD2 AmCyan 
4C13RxGFP/GFP 3 GFP/GFP AmCyan 
4C13RxhuCD2/GFP 3 huCD2/GFP AmCyan 
Table 3-1 - Genotypes of IL-4 reporter mice strains 
Summary table indicating the status of IL-4 alleles in the IL-4 reporter mice used in this 
chapter.  
3.2.2 The different IL-4 reporter mice can be independently used 
to identify allelic expression by CD4 T cells 
In order to measure the relative reporting kinetics by CD4+ T cells from established IL-4 
reporter strains, the GFP and huCD2 knock-in reporter mice and the new transgenic 
4C13R reporter strain, primary Th2 cultured and restimulated splenocytes were analysed 
for reporter expression. Splenocytes from IL-4 heterozygous huCD2/IL-4 and GFP/IL-4, 
and IL-4 deficient huCD2/huCD2 and huCD2/GFP were stimulated in the Th2 culture 
system (Figure 3.2a). All three of the reporter systems displayed similar induction kinetics 
for IL-4 reporting, with reporter positive cells being observed 2 days after plating on 
αCD3 and peak production being reached on day 3 or 4 of culture. The resolution phases 
were also very similar, with GFP and huCD2 dropping to baseline on day 11 just prior to 
restimulation, while AmCyan contracted faster, dropping to baseline by day7 (Figure 
3.2b). A far greater percentage of CD4+ T cells expressed huCD2 than GFP or AmCyan, 
raising some concern that there may be some preferential expression of the allele carrying 
huCD2 over the IL-4 or other reporter allele. However when the reporter expression in 
the double reporter CD4+ cells that carried both the huCD2 allele (Figure 3.2c) and the 
GFP allele was measured (Figure 3.2d), it was found that expression of each of these 
alleles were nearly identical in these cells compared to cells that only carried one of each 
of the alleles. Therefore while the alleles were expressed at different levels across the 
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CD4+ T cell population the presence and expression of huCD2 did not effect the 
expression of the GFP allele and vice versa. 
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Figure 3.2 – 4C13R IL-4 reporting displays similar kinetics to knock-in reporter 
mice in vitro. 
a. huCD2 and GFP expression by splenic CD4+ T cells from Balb/c, huCD2/IL-4 mice, 
GFP/IL-4 and huCD2/huCD2 and 4C13R mice at day 3 of the Th2 culture system. Plots 
are representative of triplicates and more than 4 experiments b. Proportion of CD4+ T cells 
expressing reporters from the indicated reporter mouse strains throughout the full time 
course of the Th2 culture system including 12 hour restimulation at day 11. Plots show mean 
and S.E.M. n=3 in each group. Data are representative of two independent experiments. c. 
Proportion of CD4+ T cells expressing huCD2 from the huCD2/IL-4 and huCD2/GFP 
reporter mouse strains throughout the time course of the Th2 culture system. Plots show 
mean and S.E.M. n=3 in each group. Data are representative of two independent 
experiments. d. Proportion of CD4+ T cells expressing GFP from the GFP/IL-4 and 
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huCD2/GFP reporter mouse strains throughout the time course of the Th2 culture system. 
Plots show mean and S.E.M. n=3 in each group. Data are representative of two independent 
experiments. 
 
CD4+ T cells from the huCD2/GFP mice stimulated on αCD3 in the presence of Th2 
polarising media presented a consistent pattern of reporter expression, with cells 
expressing a singular reporter allele (mono-allelic) or both huCD2 and GFP alleles (bi-
allelic) (Figure 3.3a). This expression profile was also seen when an IL-4 extracellular 
capture reagent was used on stimulated, IL-4 heterozygous, huCD2/IL-4 cells. 
Extracellular capture reagents are dual antibody reagents, an IL-4 specific antibody, 
bound via a biotin linker to a CD45 binding antibody. The CD45 antibody binds the 
capture construct to the haematopoietic cells, and the αIL-4 antibody collects any IL-4 
secreted by the bound cell These cells can then be probed with another IL-4 binding 
antibody conjugated to a fluorescent tag which can be detected by flow cytometry303. 
Using this tool with the huCD2/IL-4 cells, mono and bi-allelic IL-4 expression could be 
detected (Figure 3.3b). As had been seen in the huCD2/GFP cells, the proportion CD4+ 
T cells expressing huCD2 was much higher than the proportion marked by the IL-4 
capture reagent. However, unlike GFP, the IL-4 capture reagent positive cells were more 
evenly distributed between the mono-allelic and bi-allelic expressing populations. 
Intracellular staining for IL-4+ CD4+ T cells from splenocyte cultures restimulated for 6 
hours on day 11 of the stimulation and rest culture system demonstrated further the allelic 
expression of IL-4.  The IL-4 heterozygous mice, huCD2/IL-4 and GFP/IL-4 had less 
than half the proportion of IL-4+ CD4+ T cells compared with WT cells, while the 
homozygous knock-out reporters huCD2/huCD2 and huCD2/GFP had no IL-4 (Figure 
3.3c). ELISAs of supernatants from cultures restimulated for 12 hours also demonstrated 
decreased levels of secreted IL-4 from the heterozygous cells (Figure 3.3d).  
These data demonstrate that IL-4 is expressed allelically and this can be detected via the 
use of reporter systems, and while the reporters are expressed independently of each other 
the relative reporting frequencies of each reporter are different. Due to the allelic nature 
of IL-4 expression, the replacement of an IL-4 allele by a reporter means less total IL-4 is 
produced and there are fewer IL-4 producing cells, as some are expressing the reporter 
construct rather than wild type IL-4. 
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Figure 3.3 - IL-4 expression is under allelic control.  
a. Reporter expression by huCD2/GFP CD4+ T cells cultured for 3 days in the Th2 culture 
system. Plot is representative of greater than five experiments b. huCD2 and IL-4 expression by 
huCD2/IL-4 CD4+ T cells assessed by use of the IL-4 extracellular capture reagent. Plot is 
representative of n=3 from two independent experiments. c. Proportion of IL-4 secreting CD4+ T 
cells assessed by ELISPOT. Cells were harvested at day 10 of the Th2 culture and restimulated in 
ELISPOT plates coated with αIL-4 and αCD3 antibodies. Plots show mean and S.E.M. n=2 in 
each group. Data are representative of two independent experiments. Statistics were calculated 
using One-way ANOVA with Bonferroni’s multiple comparisons post-test * P < 0.05 ** P < 0.01 
*** P < 0.001 **** P < 0.0001 d. Concentration of IL-4 in the media after 12 hours of 
restimulation on day 11 of the Th2 culture. Plots show mean and S.E.M. n=2 in each group. Data 
are representative of two independent experiments. Statistics were calculated using One-way 
ANOVA with Bonferroni’s multiple comparisons post-test * P < 0.05 ** P < 0.01 *** P < 0.001 
**** P < 0.0001 
 
3.2.3 T cell receptor stimulation affects IL-4 allelic expression 
profiles by CD4+ T cells 
I utilised the Th2 inducing culture system to evaluate the mechanisms that controlled the 
allelic expression pattern of IL-4 by CD4+ T cells. T cells receive several critical 
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differentiation driving signals once in culture, predominantly through their TCR 
interacting with the plate bound αCD3, with secondary signals through co-stimulation 
with αCD28 and finally IL-4 and IL-2 acting through their cognate receptors driving 
differentiation towards a Th2 phenotype. Cultures were set up to test which signals were 
controlling the CD4+ T cell differentiation into Th2, and if any of these particular signals 
preferentially drive bi-allelic as opposed to mono-allelic expression. Previous work has 
demonstrated the requirements for IL-430 and IL-2222 for optimal Th2 differentiation in 
vitro, so Th2 cultures were assessed on day 3 to test the effects of feeding with additional 
cytokines and/or co-stimulation added to the culture on days 1 and 2 after plating. It was 
found that the allelic expression pattern of the CD4+ T cells was totally unaffected by the 
addition of cytokines after the first day of plating, even in the unfed group, where half of 
the culture volume was replaced with media without stimulatory cytokines or antibodies 
daily (Figure 3.4). From this data it can be deduced that cells either receive all the signals 
they require for full Th2 differentiation and set allelic expression during the first day of 
culture, or the amount of cytokines and antibodies used maximally drove Th2 
differentiation and the allelic pattern I observed was what this maximal stimulation would 
always induce.  
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Figure 3.4 – IL-4 allelic expression patterns are unaffected by feeding regime.  
a. Reporter expression by huCD2/GFP cells 3 days after plating onto αCD3 in Th2 media. On 
days 1 and 2 half the media was removed and replaced with complete media containing the 
indicated cytokine and antibody mixes. Bar graph show mean and S.E.M. n=2 in each group. 
Data are representative of two independent experiments. Statistics were calculated individually for 
each strain using One-way ANOVA with Bonferroni’s multiple comparisons post-test with no 
significant difference. 
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To determine the role of TCR activation on allelic expression, a titration of the 
concentration of αCD3 that coated the stimulation plates was undertaken, limiting the 
amount of stimulation the CD4+ T cells received through their TCRs. When cultured in 
differentiation neutral conditions (Th0), with antibodies to neutralise the polarising 
cytokines IL-4 and IFN-γ, there was very little reporter expression detected at any αCD3 
concentration (Figure 3.5a). Of the positive cells there were almost no bi-allelic cells, and 
even proportions of mono-allelic huCD2 and GFP positive cells (Figure 3.5b). The 
concentration of αCD3 had a profound effect on IL-4 reporting by CD4+ T cells cultured 
in Th2 conditions, with an increase in reporter expressing cells correlating with increasing 
αCD3 concentrations (Figure 3.5a). The proportion of reporter bi-allelism increased with 
the amount of TCR stimulation, with an associated decrease in the proportion of mono-
allelic GFP+. Of the reporter expressing CD4+ T cells there was no change in the 
proportion of mono-allelic huCD2+ cells across the concentration range of αCD3 (Figure 
3.5b). Therefore bi-allelic reporting increases with increased stimulation through the 
TCR, and the observed decrease in mono-allelic GFP+ indicates that as the αCD3 
concentration increases, the majority of CD4+ T cells expressing this allele are expressing 
IL-4 using both alleles.  
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Figure 3.5 - Anti-CD3 concentration affects reporter expression and bi-allelism.   
a. and b. Representative plots and graphs of the proportion of reporter expression by 
huCD2/GFP cells from plates coated with a range of αCD3 concentrations, indicated above, at 
day 3 of the Th2 culture or Th0 culture systems. For Th0 cultures, cells were plated in media 
containing IL-2 and αCD28, αIL-4 and αIFN-γ antibodies in the media.  Bar graphs show mean 
and S.E.M. n=3 in each group. Data are representative of two independent experiments. 
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The scarcity of mono-allelic GFP+ CD4+ T cells observed in cultures with relatively high 
levels of overall reporter expression led to further investigation of the specificities of the 
IL-4 reporter systems. While green fluorescent protein is expressed intracellularly, the 
huCD2 reporter in translocated to the cell surface, allowing the reporter-positive cells to 
be identified by staining with fluorescently tagged monoclonal antibodies. As the reporter-
positive cells are expressing the huCD2 molecules on their surface I hypothesised that the 
protein could be transferred to other cells not expressing the reporter allele themselves. 
To test this huCD2 IL-4 reporting splenocytes were cultured with and without 
carboxyfluorescein succimidyl ester (CFSE) labelled wild-type (WT) splenocytes in Th2 
conditions. Two days after beginning the culture, cells were harvested and stained with 
the full antibody cocktail including the huCD2 specific antibody. Doublets were excluded 
and gates set based upon the background of stained huCD2 and CFSE labelled WT 
CD4+ T cells cultured alone. A small percentage of CFSE labelled cells from the mixed 
culture that had acquired huCD2 could be detected (Figure 3.6a). This was not due to 
nonspecific staining as this population was missing from the single cultured cells that were 
stained with the same antibody cocktail.  
To confirm that transfer of CFSE to huCD2 expressing cells was not occurring, the mixed 
culture system was repeated with cells that constitutively expressed intracellular enhanced 
GFP (eGFP). Again an appearance of huCD2 expression was detected on cells that did 
not carry the huCD2 allele (Figure 3.6b). The transfer of huCD2 was also observed 
between co-cultured cells from huCD2 expressing cells (on a Balb/c background) and 
C57Bl/6 cells, identified by their differing MHC class II haplotypes (data not shown). It 
appeared that the transfer of huCD2 could occur within a short period of time. In one 
experiment huCD2 expressing and eGFP cells, that had been cultured individually, were 
mixed just prior to staining and a population of eGFP and huCD2 positive cells was 
detected, though at roughly half the proportion compared to cells that were cultured 
together for the 2 days (data not shown). Therefore huCD2 can transfer to cells which are 
not actively expressing the huCD2 allele, which can partially explain why the huCD2 
reporter appears to mark such a high percentage of CD4 T cells in Th2 culture, and why 
there is such a preponderance for GFP+ cells to be bi-allelic from cultured huCD2/GFP 
splenocytes. However, at most, only 5% of the non-huCD2 carrying cells were observed 
becoming positive for huCD2, so transfer of the reporter protein must be considered but 
does not completely explain the much higher proportions of huCD2 expressing cells 
compared with the other reporter systems.  
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Figure 3.6 - huCD2 can be transferred between cells in culture.  
a. huCD2 expression on WT splenocytes labelled with CFSE and unlabelled huCD2/huCD2 
splenocytes cultured for 2 days in the Th2 system either by individually or mixed together. Plots 
representative of triplicates from two independent experiments. b. huCD2 expression on eGFP 
splenocytes and huCD2/huCD2 splenocytes cultured for 3 days in the Th2 system either by 
individually or mixed together. Plots representative of triplicates from two independent 
experiments. 
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3.2.4 Allelic IL-4 expression patterns are not maintained by 
restimulated CD4+ T cells 
Utilising the double reporter mice allowed further research into the phenomena of allelic 
expression of IL-4 by Th2 cells. Mono-allelic expression could be explained by a 
restriction in available transcriptional machinery, limiting the alleles a cell can transcribe 
into mRNA. Alternatively the cells could actively silence alleles through epigenetic 
regulation and dense packing of the DNA at key sites along a particular allele304. If the 
cells were controlling their allelic expression by epigenetic changes it would be likely that 
the cells, and their progeny, would maintain their allelic profile, even after resting and 
restimulation. To test this theory huCD2/GFP splenocytes were stimulated for 5 days in 
Th2 conditions, then CD4 T cells were sorted based upon their reporter expression into 
four populations, reporter negative (huCD2-GFP-), GFP positive (huCD2-GFP+), huCD2 
positive (huCD2+GFP-) and double positive (huCD2+GFP+) (Figure 3.7a). The cells were 
then plated on uncoated plates in IL-2 supplemented media and rested them for 10 days, 
until they were no longer expressing detectable reporter, at which point they were 
restimulated for 6 hours and their reporter expression assessed (Figure 3.7b). Regardless 
of the reporter profile the cells expressed on day 5 of culture, after restimulation all 
populations demonstrated the same pattern of expression (Figure 3.7c). The only notable 
difference was that cells that were reporter negative at the time of sorting had a lower 
proportion of total reporter positive cells upon restimulation (Figure 3.7d). This indicated 
that clones of Th2 cells did not maintain a memory of previous allelic expression and the 
IL-4 allele that a clone expresses can be reset after rest and restimulation.  
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Figure 3.7 - Sorted populations do not retain their IL-4 allelic patterns upon 
restimulation.  
a. Experimental schematic. Cells were cultured in the previously described Th2 system 
for 5 days then sorted into four CD4+ T cell populations based upon their reporter 
expression. The cells were then rested in uncoated plates with IL-2 containing media until 
day 17 when reporter expression had dropped to background. Cells were then 
restimulated for 12 hours and reporter expression analysed. b. Representative plots of 
reporter expression by the 4 restimulated populations. c. Proportions of restimulated 
CD4+ T cells expressing huCD2, GFP or both reporters. d. Proportion of the reporter 
expressing cells that are huCD2, GFP or dual reporter positive. Bar graphs show mean 
and S.E.M. n=3 in each group. All data is representative of two independent experiments. 
3.2.5 Expression of the 4C13R transgenic IL-4 reporter is 
allelically regulated 
The 4C13R reporter mice were created utilising transgenic technology with the intention 
that the endogenous parental IL-4 and IL-13 genes would remain untouched and 
available for normal cytokine transcription. However the uncontrolled insertion of the 
transgenic construct could mean that the transgenic alleles do not receive the same 
transcriptional enhancement, or regulation, as the parental alleles. Knowing that the 
expression of IL-4 is controlled allelically it remained to be seen if AmCyan, the 
transgenic IL-4 reporter, would also be under allelic restriction. If the transgenic allele 
had escaped regulation, then every cell that expressed IL-4 using either of the parental 
alleles would also express AmCyan. However if AmCyan was also under allelic regulation 
then a similar pattern of expression as the cells from the double knock-in reporter 
huCD2/GFP would be observed, with some cells expressing AmCyan, or a parental allele 
mono-allelically, and some expressing bi-allelically AmCyan and the parental IL-4 allele. 
To test if AmCyan was expressed allelically mice carrying the 4C13R construct were 
crossed with mice that were homozygous for either the huCD2 or GFP reporters on their 
parental IL-4 alleles. The resulting offspring carried the 4C13R construct, one WT 
parental IL-4 allele and one knock-in reporter allele, either huCD2 or GFP, making these 
mice triple allelic for the IL-4 locus. These reporter mice were then used to test the 
reporter expression by CD4+ T cells in both the Th2 culture, and the pTh2 assay, which 
involves intradermal HDM injection into the ears of IL-4 reporter mice and the reporter 
expression by CD4+ T cells in the auricular draining LN assessed 7 days later.  
When 4C13RxhuCD2/huCD2 CD4+ T cells were cultured in Th2 conditions the 
reporter pattern was remarkably similar to the huCD2/GFP cells. The majority of 
reporter positive CD4+ T cell mono-allelically expressed huCD2+, while almost all the 
AmCyan+ cells were bi-allelic and also expressing huCD2. AmCyan+ CD4+ T cells from 
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Th2 cultured 4C13RxGFP/GFP were almost equally split between the mono-allelic and 
bi-allelic populations, with slightly more in the bi-allelic population (Figure 3.8a). House 
dust mite responsive CD4+ T cells from the pTh2 assay presented different expression 
patterns. The 4C13RxhuCD2/huCD2 cells had the majority of the reporter positive 
being mono-allelically AmCyan+, and an even proportion of mono-allelic huCD2+, and 
bi-allelically expressing cells. Reporter expression by 4C13RxGFP/GFP CD4+ T cells in 
the pTh2 assay showed equal proportions of both the mono-allelic populations and the bi-
allelically expressing cells (Figure 3.8b). 
To assess the allelic expression of AmCyan against WT IL-4, the IL-4 extracellular 
capture reagent was used on Th2 cultured 4C13R CD4+ T cells. Th2 CD4+ T cells that 
were singularly expressing AmCyan or IL-4 could be detected alongside a population of 
bi-allelic Th2 cells (Figure 3.8c). As a control to test the specificity of the extracellular 
capture reagent Th2 cultured cells from IL-4 sufficient CD45.1 congenic mice were 
mixed with CD45.2 expressing IL-4 deficient cells. The populations could be 
distinguished based upon their congenic expression of CD45 so the mixed cells were 
treated with the IL-4 capture reagent and then analysed to check that only the IL-4 
sufficient cells were marked positive by the reagent. The extracellular capture reagent was 
very specific, only staining the IL-4 sufficient CD45.1+ cells and not the IL-4 deficient 
cells (Figure 3.8d). These data show that the expression of AmCyan, despite being a 
transgenic reporter of IL-4, was also under allelic control. Moreover the expression of 
AmCyan more closely resembles the GFP reporter system than the huCD2 reporter. 
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Figure 3.8 – Expression of the 4C13R transgenic IL-4 reporter is under allelic 
control.  
a. Reporter expression by 4C13RxhuCD2/huCD2 and 4C13RxGFP/GFP CD4+ T cells on day 
3 of the Th2 culture system. Bar graphs show mean and S.E.M. n=3 in each group. Plots are 
representative of two independent experiments b. Reporter expression by 
4C13RxhuCD2/huCD2 and 4C13RxGFP/GFP CD4+ T cells from the draining LN on day 7 of 
the pTh2 assay. Bar graphs show mean and S.E.M. n=3 in each group. Plots are representative of 
two independent experiments.  c. Representative plot of AmCyan and IL-4 expression by 4C13R 
CD4+ T cells on day 3 of the Th2 culture system assessed by use of the IL-4 extracellular capture 
reagent. d. Control experiment for IL-4 extracellular capture reagent, IL-4 sufficient CD45.1+ 
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CD4+ T cells were cultured in the Th2 culture system with IL-4 deficient CD45.1- CD4+ T cells. 
All plots are representative of n=3 in each group. Plots are representative of two independent 
experiments 
3.2.6 Triple allele IL-4 reporter system indicates the special 
nature of bi-allelically expressing CD4+ T cells 
Three independent reporters of IL-4 expression were available, two knocked into the 
parental IL-4 alleles and one transgenic reporter. A cross of all three of the reporter 
systems was established to test what effect a third allele would have on the generation of 
mono and bi-allelically expressing CD4+ T cells. Splenocytes from triple reporter mice 
were stimulated in the Th2 culture system and the mice were also subjected to the pTh2 
assay. CD4+ T cells were identified and four populations defined by their expression of 
two of the IL-4 reporters were identified. These populations were defined as reporter 
negative, single reporter positive or double positive. The expression of the third IL-4 
reporter was then assessed from each of these four populations. In both assays cells 
expressing two of the reporter alleles (double positive) were more likely to express a third 
allele regardless of which reporters were assessed (Figure 3.9). The only point of note was 
that the AmCyan-GFP+ cells were just as likely to express huCD2 as the AmCyan+ GFP+ 
double positive cells. These double positive cells also had a higher median fluorescent 
index (MFI) for the third reporter compared to the singular or reporter negative 
populations (Figure 3.9). From these data bi-allelic expressing cells were more likely, and 
more capable of utilising a third IL-4 allele. 
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Figure 3.9 - Qualities of multi-allelically IL-4 expressing cells elucidated by use of 
triple reporter mice.  
(a. b.) Reporter expression of CD4+ T cells from 4C13RxhuCD2/GFP reporter mice at day 3 of 
the Th2 culture system. CD4+ T cells were defined into 4 populations using 2 of the reporters and 
then a. the MFI and b. the proportion expressing the third reporter was analysed for each 
population. (c. d.) Reporter expression of draining LN CD4+ T cells from 4C13RxhuCD2/GFP 
reporter mice at day 7 of the pTh2 assay. CD4+ T cells were defined into 4 populations using 2 of 
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the reporters and then c. the MFI and d. the proportion expressing the third reporter was 
analysed for each population. 
3.2.7 IL-4 is not important for the expansion of Th2 cells in vivo 
The transgenic 4C13R reporter mice enabled measurement of the induction of IL-4 
expressing Th2 cells independently of the parental alleles.  Crossing these mice to GFP 
IL-4 reporter strains allowed the generation of reporter mice that were heterozygous 
deficient (4C13RxGFP/IL-4) and homozygous IL-4 deficient (4C13RxGFP/GFP) as well 
as the original IL-4 WT (4C13R) strain. Using AmCyan as an independent read out of 
IL-4 producing Th2 cells, these strains of mice allowed the effect of decreased IL-4 
availability on the expansion of Th2 cells to be assessed. The various strains of mice were 
challenged with house dust mite via the pTh2 model and the AmCyan expression by the 
dLN CD4+ T cells assessed on day 7 after intradermal injection.  
The percentage of CD4+ T cells that expressed AmCyan appeared to titrate with the 
availability of WT IL-4 alleles; significant difference was observed between the WT 
4C13R strain and both the heterozygous an homozygous deficient strains, but the 
difference between the 4C13RxGFP/GFP and 4C13RxGFP/IL-4 strains was not 
significant (Figure 3.10a). The numbers of AmCyan+ CD4+ T cells did not differ between 
the three strains (Figure 3.10b). This indicated that the lack of IL-4 had no effect on the 
expansion of Th2 cells (as marked by AmCyan expression) within the dLN. The apparent 
decrease in the proportion of AmCyan+ CD4+ T cells in the IL-4 deficient mice 
correlated with a non-significant expansion in the total number of CD4+ T cells (Figure 
3.10c). These data indicates that IL-4 is not required for the generation and expansion of 
Th2 cells within the draining LN, however as the proportion of Th2 cells was decreased 
in the absence of IL-4, IL-4 may play a role in inhibiting the expansion of other CD4+ T 
cells during the LN response. 
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Figure 3.10 – IL-4 is not required for the expansion of IL-4 producing CD4+ T cells. 
4C13R reporter mice on a WT (IL-4/IL-4), heterozygous GFP/IL-4 and homozygous deficient 
GFP/GFP backgrounds were challenged with the pTh2 assay, 200µg of HDM was injected 
intradermally into the ears of each mouse and LN responses on day 7 assessed by flow cytometry. 
a. Percentage of AmCyan expressing CD4+ T cells per LN. b. Number of AmCyan expressing 
CD4+ T cells per LN. c. Total number of CD4+ T cells per LN from the challenged strains.  Bar 
graphs show mean and S.E.M. n≥4 in each group. Data are representative of two independent 
experiments. Statistics were calculated using One-way ANOVA with Bonferroni’s multiple 
comparisons post-test ** P < 0.01  
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3.3 Discussion 
In this chapter I characterised a novel reporter mouse for monitoring the expression of 
IL-4, comparing and contrasting it with the currently available IL-4 reporter systems. I 
then utilised crosses of these reporter mice strains to observe, and measure what affects 
IL-4 expression by Th2 cells, and how IL-4 signalling controls Th2 cells differentiation 
and expansion in vivo. It was found that the 4C13R transgenic reporter system is an 
effective reporter of Th2 induction, however because AmCyan, like the parental alleles, is 
under allelic regulation not every cell expressing IL-4 expressed AmCyan. Despite this the 
reporter could be used to demonstrate that bi-allelically expressing cells were likely to be 
expressing a third transgenic allele and that IL-4 had little effect on the induction and 
expansion of Th2 cells within the reactive LN. 
Allelic expression of genes, including IL-4, IL-5 and IL-13 has been widely reported225, 226 
but in the case of the Type 2 cytokines little is understood about what mechanisms 
regulate the restricted expression of these genes. Previous work focussing on the allelic 
nature of IL-4 demonstrated that antigen concentration correlated with increased bi-
allelism, however these studies used heterozygous huCD2/IL-4 reporter mice, which 
meant the results were difficult to interpret288. The same study found the proportion of 
IL-4 producing CD4+ T cells correlated with antigen dose, so with greater amounts of 
stimulation more IL-4 was secreted into the culture. Autocrine or paracrine signalling by 
IL-4 on the stimulated CD4+ T cells may affect the capability of a cell to express IL-4 bi-
allelically. By using IL-4 deficient huCD2/GFP reporter mice in Th2 conditions where 
the amount of IL-4 was consistent, the analysis of the role of TCR stimulation on bi-
allelism was possible (Figure 3.5). I found that bi-allelism correlated with the amount of 
TCR stimulation independently of IL-4, indicating that the limiting factor that regulates 
allelic expression can be controlled via pathways downstream of the TCR.  
Whether the allelic pattern of IL-4 expression displayed by a particular CD4+ T cell is 
maintained through time and through subsequent proliferation cycles has been addressed 
by several publications with varying interpretations. Experiments assessing the long term 
allelic expression of Th2 clones isolated via limiting dilution or sorting indicated that 
clones maintained a similar allelic pattern over many rounds of stimulation.227, 288 
Conversely, sorting and restimulation of recently differentiated Th2 cells found that these 
cells did not maintain their sorted allelic phenotype. Upon restimulation the proportions 
of cells expressing cytokine using each allele were similar regardless of their sort 
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phenotype227. These experiments were undertaken in models there IL-4 is secreted, either 
using heterozygous reporter mice or mice with PCR identifiable single nucleotide 
polymorphisms in their IL-4 alleles305. The role of IL-4 on allelic maintenance is unknown. 
Furthermore in systems where intracellular IL-4 staining was compared to reporter to 
identify allelically producing cells, cells were harvested at different times to assess 
expression by reporter or intracellular staining227. Using the huCD2/GFP reporter mice 
allowed allelic maintenance to be assessed independently of IL-4 and to accurately 
identify mono and bi-allelic cells simultaneously post restimulation (Figure 3.7). The 
culture model was most similar to publications assessing recently activated Th2 cells, and 
consistent with these publications, I found that regardless of the phenotype at sort, all 
populations had very similar allelic expression after restimulation. These data are at odds 
with the observations using clones and may indicate that there are two phases regulating 
allelic expression. Together this indicates there may be an initial flexible stage during 
which the allelic phenotype of a cell may be changeable, but upon multiple stimulations 
the phenotype becomes set and inherited by the subsequent daughter cells.  
The use of transgenic reporter mice was intended to allow identification of cytokine 
expressing Th2 cells without effecting the parental IL-4 or IL-13 alleles. The IL-4 
reporting of Th2 stimulated 4C13R CD4+ T cells followed similar kinetics to the GFP 
and huCD2 reporter systems (Figure 3.2) and despite being a transgenic reporter is also 
under allelic regulation (Figure 3.8). This was an unexpected result; I had hypothesised 
that the random insertion of the transgenic construct into the genome would mean that 
the AmCyan allele might be missing some of the regulatory elements that mediate the 
expression of the parental IL-4 alleles within the Th2 locus. Two interpretations are 
available for the fact that the AmCyan construct is under allelic control. Either allelism is 
controlled by a limited availability of transcriptional machinery that are shared between 
the parental and transgenic alleles, or that the regulatory elements that regulate the 
accessibility of the IL-4 allele are also present and active within the transgene construct. 
The triple reporter mice highlighted an interesting phenomenon in that a cell that was 
expressing cytokine from two alleles was very likely to be expressing the third allele as well. 
This indicated that in bi-allelically expressing cells there was excess of the required factors 
for allelic expression, either transcription factors or mechanisms controlling 
transcriptional access (Figure 3.9). Unfortunately these experiments were insufficient to 
allow identification of the mechanisms controlling allelic expression, but they do highlight 
the fact that transgenic reporters are under similar control to parental IL-4 alleles. 
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Therefore the 4C13R reporter cannot be used to identify every IL-4 expressing CD4+ T 
cell, though it remains a useful reporter for measuring changes in IL-4 expression at the 
population level.  
The decrease in proportions but not numbers of AmCyan+ CD4+ T cells in the IL-4 
deficient mice (Figure 3.10) indicates that while IL-4 may not effect Th2 cell expansion it 
may play a role in the proliferation of other CD4+ T cell subsets, and in the absence of 
IL-4 signalling these subsets are allowed to expand. This was supported by the increase, 
albeit non significant, in numbers of CD4+ T cells in the absence of IL-4. This data 
supports previous work using the GFP/IL-4 and GFP/GFP reporter mice to assess the 
generation of IL-4 expressing Th2 cells in the absence of IL-4 during N. brasiliensis 
infection, where the induction of IL-4 reporting Th2 cells occurred if there was IL-4 
available or not. However my data does not marry with the previous observations 
between the number of GFP+ cells in the GFP/IL-4 and GFP/GFP mice. With IL-4 
independent Th2 expansion, it would be expected that GFP/IL-4 mice would have less 
GFP+ cells than the GFP/GFP mice. Although the total numbers of Th2 cells should be 
the same in both strains, some of the cells in the GFP/IL-4 mice would be GFP- as they 
would be expressing mono-allelically from the WT IL-4 allele. It is not clear from these 
experiments why a greater number of GFP+ cells than expected in the GFP/IL-4 mice 
has been reported with N. brasiliensis infection. However in a model of keyhole limpet 
hemocyanin induced airways inflammation there was a non-significant difference between 
the GFP/IL-4 mice and GFP/GFP mice indicating there may be a model-biased 
requirement for IL-431. Further experimentation utilising the tools that I developed for 
this project will confirm the role of IL-4 in in vivo Th2 cell activation across a range of 
models. 
3.4 Conclusions 
In this chapter I assess the mechanisms that regulate IL-4 expression and the role of IL-4 
in the expansion of Th2 cells in vivo, this was achieved by utilising various IL-4 reporter 
mice. The 4C13R transgenic reporter mouse is a useful tool for identifying IL-4 
producing populations in an immune competent system. However, the allelic regulation 
of IL-4 expression, which also affects the 4C13R AmCyan reporter allele, means 
interpretations made using this tool must take into account some limitations. The kinetics 
of AmCyan expression is similar to knock-in IL-4 reporter mice, and as with the other 
strains not all Th2 cells that are induced to produce IL-4 will be marked by AmCyan 
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expression. The fact that the proportion of bi-allelically expressing cells increases with 
increased TCR stimulation indicates that the mechanisms that mediate the allelic 
regulation of IL-4 are directly under the control of the TCR. The lack of maintenance of 
the allelic phenotype by restimulated CD4+ T cells also indicates that, at least with limited 
cycles of stimulation, there is plasticity in the allele that a CD4+ T cell can express from.  
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4 IL-13 production by 
CD4+ T cells is regulated 
separately to IL-4 
4.1 Introduction 
The functions of IL-13 have been widely studied with well-characterised roles in 
allergies191, 192, fibrosis12 and helminth expulsion198, and putative roles in many diseases 
from breast cancer306, lymphomas307 and glioma308 to myocarditis309 and regulation of 
glucose metabolism310. Despite many of the functions having been elucidated the 
mechanisms that regulate IL-13 expression by CD4+ T cells are not fully understood. In 
this chapter I utilise the novel IL-4 and IL-13 transgenic reporter mice to address the 
different signals that induce IL-4 and IL-13 expression by CD4+ T cells.  
IL-4 expression has been used as an indicator for Th2 cell differentiation and thus much 
is known about the signals that induce IL-4 production from activated CD4+ T cells. 
Both IL-4 and IL-13 have been previously detected being produced by the same 
restimulated CD4+ T cells226, so it has been assumed the signals that drive IL-4 are the 
same that drive IL-13. In this chapter I have compared IL-4 and IL-13 expression by in 
vitro differentiated Th2 cells, and have found that the expression of IL-13 is under 
differential control to IL-4. 
IL-13 expression by CD4 T cells is directly dependent upon GATA3 expression, and 
unlike IL-4, the ability to express IL-13 is lost if GATA3 is knocked out of already 
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differentiated Th2 cells84. The level of GATA3 expression has been used to explain the 
phenomena whereby only CD4+ T cells in the lung, but not in the LN of a N. brasiliensis 
infected animal express IL-13311. I have further investigated the absence of IL-13 
expression from the murine LN using the immune competent dual cytokine reporter 
mice. Utilising FTY720, which targets sphingosine-1 phosphate receptors on 
lymphocytes and inhibits their egress from secondary lymphoid tissues312, the effects of 
tissue location and migration on inducing IL-13 expression by CD4+ T cells have been 
assessed.  
4.1.1 Aims 
These experiments assessed the expression of IL-13 by Th2 differentiated CD4+ T cells, 
the induction of expression both in vitro and in vivo, and the mechanisms controlling this 
expression in a range of models. Using the 4C13R reporter mice I assessed the factors 
required for activated CD4+ T cells to begin expressing IL-13 and compared these to 
IL-4 production. Specifically these experiments aimed to: 
• Assess the timing of IL-13 expression by CD4+ T cells activated in vivo and in 
vitro 
• Use in vitro models to measure the effects of exogenous cytokines, resident tissue 
of the CD4+ T cells and amount of TCR stimulation on the induction of IL-13 
• Compare the expression of IL-13 by lung and LN residing CD4+ T cells both in 
primary and secondary immune responses 
• Assess the effects of inhibiting LN egress on CD4+ T cell IL-13 expression in 
lungs and LN 
 
4.2 Results 
4.2.1 Th2 differentiated CD4+ T cells begin expressing IL-4 and 
IL-13 at different times in vitro 
Consistent IL-4 expression kinetics had been observed in the previously described Th2 
culture system using all three of the available IL-4 reporter models, with CD4+ T cells 
dependably expressing reporter molecules on day 2 of culture (Figure 3.2) The kinetics 
of CD4+ T cell IL-13 expression was similarly assessed during the Th2 culture system 
using cells from the 4C13R reporter mice. When these cells were analysed for reporter 
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expression daily during the culture it was noted that IL-13 reporting through DS-Red 
expression was not detected until day 4 of the culture (Figure 4.1a). Furthermore IL-13 
reporting cells were not all simultaneously expressing IL-4; in fact the majority of IL-
13+ cells were reporter negative for IL-4 (Figure 4.1b) indicating that multiple Th2 
populations can be identified.  
Using cells from the 4C13R reporter mice it was found that IL-13 expression is delayed 
until 2 days after IL-4 in the Th2 culture system. Unlike the traditional view of 
simultaneous expression of IL-4, IL-13 and IL-5 by Th2 cells, populations of cells only 
expressing single cytokines were detected alongside dual positive populations. This 
demonstrates significant difference between CD4+ T cell expression of IL-4 and IL-13. 
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Figure 4.1 - AmCyan and DS-Red are expressed at different times in vitro.  
a. Proportion of CD4+ T cells expressing AmCyan, DS-Red or both reporters during the course 
of the Th2 culture system (as described in Figure 3.1a). Plots show mean ± S.E.M. n=3 in 
each group. Data are representative of two independent experiments. b. Representative plots 
showing AmCyan and DS-Red expression by CD4+ T cells on the indicated days, gated on Live 
CD3+ CD4+. Plots are representative of many experiments.  
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The Th2 stimulation culture protocol mandated feeding the cultures by removing half 
the volume and replacing it with fresh media and cytokines on day 3. I hypothesised 
that the supplementing of the Th2 culture system on day 3 was inducing IL-13 
expression by day 4. To check if the addition of cytokines was causing IL-13 expression, 
the Th2 culture system was modified, initially stimulating the cells on day 0 in Th2 
conditions then changing how the cultures were fed on day 3. Feeding with IL-2 alone 
on day 3 slightly increased the proportion of IL-13 reporting cells, and feeding everyday 
with IL-2 and IL-4 decreased it, compared with the standard feeding regime of IL-2 
and IL-4 on day 3 (Figure 4.2a). However not feeding with any cytokines on day 3 
made no significant difference to the IL-13 reporting proportion on day 4 compared to 
normal conditions. This means that addition of cytokines on day 3 was not the signal 
that induced IL-13 reporting from the CD4+ T cells on day 4 (Figure 4.2a). 
There has been indication by some publications that IL-1 family cytokines may drive 
differentiation of the different T helper cell phenotypes, with IL-1 associated with Th17 
function, IL-18 with Th1 and IL-33 with Th2267. Furthermore it has been shown that 
IL-33 induces strong IL-13 expression from ILC2s253. In light of this I tested if IL-33 
could effect IL-13 expression by CD4+ T cell. IL-33 was added to the Th2 culture 
system at a concentration of 10µg/mL, an amount able to induce responses by other 
cultured cell types313. It was found that IL-33 did not change the kinetics or the 
magnitude of IL-4 or IL-13 induction by CD4+ T cells in the Th2 differentiation culture 
system (Figure 4.2b). 
Another possibility was that non-CD4+ splenocytes in the culture were signalling, either 
via cell-cell contact or by producing cytokines that will initiate IL-13 expression by the 
CD4+ T cells in culture. These cells could themselves be responding to the IL-4 within 
the culture, promoting the production of signals which would drive IL-13 expression by 
the CD4+ T cells. To test whether other cells are required for the IL-13 expression 
reporter expression by CD4+ T cells was analysed in a total splenocyte Th2 culture or 
by CD4+ T cells enriched by magnetic bead isolation prior to culture in the Th2 system. 
Enriched CD4+ T cells did still express both IL-4 and IL-13 with the same kinetics as 
those cultured with other splenocytes, however the proportion of IL-4 and IL-13 
reporter positive cells was lower in the enriched cultures (Figure 4.2c).  
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Figure 4.2 – Neither feeding with Th2 culture cytokines, adding IL-33 nor 
enriching for CD4 induces earlier IL-13 induction.  
a. Proportion of CD4+ T cells expressing DS-Red at day 4 of the Th2 culture system from 
cultures fed on day 3 with the indicated cytokine mixes, IL-2 + IL-4 day 3 is standard Th2 
culture conditions. Bar graph shows mean ± S.E.M. n=3 in each group. Data are representative 
of two independent experiments. Statistics were calculated for each cytokine using One way 
ANOVA with Dunnett’s multiple comparisons test * P < 0.05 b. Proportion of CD4+ T cells 
expressing AmCyan and DS-Red cultured in the Th2 system with or without the addition of 
10μg/mL IL-33. c. Proportion of CD4+ T cells expressing AmCyan and DS-Red from total 
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splenocytes or enriched CD4+ T cells cultured in the Th2 system. Plots show mean ± S.E.M. 
n=3 in each group. Each graph is representative of three independent experiments. Statistics 
were calculated for each cytokine using two way ANOVA with a Bonferroni multiple 
comparisons post test. ** P < 0.01 **** P < 0.0001 comparing AmCyan+ samples. #### P < 
0.0001 comparing DS-Red+ samples. 
 
IL-13 and IL-4 are differentially expressed with IL-13 consistently being expressed 2 
days after IL-4 in the Th2 culture system. This delayed expression was unaffected by 
cells being fed, or not, with IL-2 and IL-4 on previous days of culture. IL-33, known for 
inducing IL-13 expression from other cell types, did not effect the induction of IL-13 by 
newly differentiated CD4+ T cells in naïve splenocyte cultures. Although other 
splenocytes were not required for IL-4 or IL-13 expression in the Th2 culture system 
their absence led to diminished proportions of reporter positive CD4+ T cells.  
4.2.2 Sustained or multiple TCR engagements are required for 
IL-13 expression by CD4+ T cells 
In the Th2 cultures described above, splenocytes were harvested from mice that had 
received no experimental manipulations (naïve). As these mice are kept in only specific 
pathogen free, and not antigen free, conditions they have circulating populations of 
previously activated, memory CD4+ T cells, the majority of which have responded to 
antigens from commensal microbiota or diet314. Whether these previously activated cells 
would report IL-4 or IL-13 expression differently from true naïve CD4+ T cells had not 
been established. To assess this CD4+ T cells were sorted from the spleens of mice based 
upon their expression of CD44 and CD62L. Naïve CD4+ T cells express high levels of 
CD62L, allowing egress from the high endothelial vessels (HEVs) into lymphoid 
structures. They express low levels of CD44 until stimulated by binding of their TCR to 
their cognate antigen. Once activated CD4+ T cells express high levels of CD44, and 
levels remain high as the cells transition to memory cells315, 316. Populations of CD4+ T 
cells were sorted from the spleens of naïve mice using the cell surface molecules CD44lo 
CD62Lhi to define naïve CD4+ T cells (Figure 4.3a). A second population was sorted on 
CD44hi CD62Llo; this population represented antigen-experienced cells though using 
CD44 and CD62L was insufficient to distinguish between activated effector cells and 
memory cells (Figure 4.3a). The naïve and antigen experienced CD4+ T cells were 
cultured in the Th2 culture system and their reporter expression assessed. It was found 
that 24 hours after plating, a small population of antigen experienced CD4+ T cells 
were AmCyan positive; this was earlier than AmCyan expression had been previously 
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detected in the Th2 cultures with unsorted splenocytes (b). 2 days after plating the 
proportions of CD4+ T cells reporting IL-4 expression were similar between naïve and 
antigen experienced cells. The antigen experienced cells did not increase their IL-4 
reporting after day 2 while naïve cells more than doubled the levels of reporting by day 
3, and stayed high on day 4 (Figure 4.3b). IL-13 reporting was higher in the antigen 
experienced cells on all days. Significant IL-13 reporting was also measured from 
antigen experienced cells from day 1 of culture, earlier that the day 4 when it was 
previously detected from unsorted splenocytes and the naïve cells (Figure 4.3b). One 
caveat in these experiments was that lower levels of IL-4 and IL-13 reporting were 
measured that were seen in experiments with unsorted splenocytes. This may be due to 
the lack of other splenocytes as in Figure 4.2c or because the cells are not as healthy 
after being sorted. 
From these data, cells that had been previously activated in vivo were able to express 
Th2 cytokines faster that naïve cells when stimulated in vitro. Although antigen 
experienced cells presented higher proportions of IL-13 reporters, naïve cells had higher 
proportions of IL-4 reporter positive cells at the later time points. 
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Figure 4.3 - Previously activated/memory cells express DS-Red earlier in vitro 
than naïve cells.  
a. Representative plots of CD4+ T cells from splenocytes pre-sort and the two post-sort 
populations defined naïve and antigen experienced based upon expression of CD62L and 
CD44. b. Proportion of CD4+ T cells expressing AmCyan and DS-Red from the two post-sort 
populations during the Th2 culture system. Plots show mean ± S.E.M n=3 in each group. Each 
graph is representative of two independent experiments. Statistics were calculated for each 
cytokine using two way ANOVA with a Bonferroni multiple comparisons post test. * P < 0.05 
** P < 0.01 *** P < 0.001 comparing AmCyan+ samples. # P < 0.05 ## P < 0.01 comparing 
DS-Red+ samples. 
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The longitudinal effects of TCR stimulation on IL-4 and IL-13 expression by CD4+ T 
cells was assessed by culturing cells for varying lengths of time on αCD3 in Th2 
conditions. Each day after the initiation of the culture, some cells were removed from 
αCD3 and transferred to wells with Th2 conditions but no αCD3. The reporter 
expression on day 4 of culture by cells removed from TCR stimulus was compared to 
cells cultured for the full four days on αCD3. The proportion of cells that were 
reporting IL-4 increased with the number of days the cells were exposed to αCD3 
before removal (Figure 4.4a). Cells cultured on αCD3 for the complete four days had a 
significantly greater proportion expressing IL-13 reporter compared with cells removed 
from stimulation at any point prior to day 4 (Figure 4.4b). 
It was found that in vitro Th2 differentiated CD4+ T cells will express IL-4 after only a 
brief stimulation in Th2 conditions, even if TCR stimulation is removed though longer 
stimulation does lead to increased proportions of IL-4 reporting cells. IL-13 however 
required continuous stimulation for its optimal expression, with rested cells only 
expressing IL-13 reporter slightly above background levels on day 4. These data further 
demonstrate the significant differences in the mechanisms controlling the expression of 
these two cytokines. 
 
 
 
  
 117 
 
Figure 4.4 - Sustained TCR stimulation is required for IL-13 expression.  
Proportion of CD4+ T cells expressing a. AmCyan and b. DS-Red on day 4 of the Th2 culture 
system. Cells were cultures in Th2 conditions in αCD3 coated plates for the indicated number 
of days, then moved to uncoated plates and rested in Th2 media (IL-2 and IL-4). Dashed lines 
indicate background reporter based upon cultured cells from non-transgenic littermates. Plots 
show mean ± S.E.M. n=3 in each group. Data are representative of three independent 
experiments. Statistics were calculated for each group using One way ANOVA with Tukey’s 
post test *** P < 0.001 
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Whilst a consistent pattern of reporter expression was observed by αCD3 stimulated 
CD4+ T cells in the Th2 culture system, it remained unknown if this pattern would be 
replicated by CD4+ T cell stimulated in a more physiological way by antigen loaded 
APCs. An antigen specific system was designed where 4C13R reporter mice were 
crossed with TCR transgenic OT-II mice. OT-II mice have been transgenically 
modified so that approximately 80% of their CD4 T cells expressing the TCR specific 
for the OVA peptide ISQAVHAAHAEINEAGR (ISQ)291. CD4+ T cells from 
4C13RxOT-II spleens were mixed with digested splenocytes that had been pulsed with 
a range of ISQ concentrations. The APCs from the digested spleens endocytosed the 
ISQ peptides and loaded them on their MHC II molecules317 allowing presentation to, 
and stimulation of the 4C13RxOT-II CD4+ T cells. It was found that 4C13RxOT-II 
CD4+ T cells expressed IL-4 reporter when stimulated with ISQ pulsed APCs (Figure 
4.5a), and similar kinetics were observed as had been seen with the αCD3 Th2 culture 
systems (Figure 4.1) with no IL-4 reporter being detected prior to day 2 of culture. 
There was a dose response with the proportion of cells stimulated to report IL-4 similar 
with 1µM and 10µM pulsed APCs. Slightly higher levels were maintained on day 4 by 
the 1µM pulsed cells. CD4+ T cells cultured with 0.1µM ISQ pulsed APCs expressed 
much lower proportions of IL-4 reporter, while none was detected from cells cultured 
with the 0.01µM ISQ pulsed and unpulsed APCs (Figure 4.5a). No IL-13 reporting by 
CD4+ T cells cultures with APCs pulsed with any concentration of ISQ was detected at 
any time point, even day 4 when IL-13 reporting was previously observed with the Th2 
culture system (Figure 4.5b).  
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Figure 4.5 - APC presentation does not induce IL-13 expression by CD4+ T cell.  
Proportion of antigen specific 4C13RxOT-II CD4+ T cells expressing a. AmCyan and b. DS-
Red, when stimulated on day 0 with digested splenocytes pulsed with various concentrations of 
ISQ peptide. Plots show mean ± S.E.M. n=3 in each group. Plots are representative of two 
independent experiments. 
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Splenic DCs only have an approximate 3 day lifespan in vivo318 and in culture greater 
than 80% of the DCs die within 48 hours319, removing antigen presentation and TCR 
stimulation for the CD4+ T cells. To test if the lack of continued stimulation was the 
reason for the lack of IL-13 expression, as seen previously in Figure 4.4, extra APCs 
were added on day 3 of the culture and then IL-13 expression assessed on day 4. 
Cultures were plated on day 0 with 4C13RxOT-II CD4+ T cells and ISQ pulsed or 
unpulsed APCs. On day 3 added to some wells were ISQ pulsed CD11c+ cells sorted 
via magnetic beads from digested spleens with or without antibodies that inhibit MHC 
II binding to CD4+ T cell TCR. The addition of ISQ pulsed APCs further increased 
the proportion of reporter positive CD4+ T cells in a MHC II dependent manner, as 
blocking antibody inhibited this increase (Figure 4.6a). Addition of ISQ pulsed APCs on 
day 3 was sufficient to induce significant IL-13 reporting by the 4C13RxOT-II CD4+ T 
cells 24 hours after their addition to the culture (Figure 4.6b). This IL-13 induction was 
also dependent on MHC II interactions as the blocking antibody diminished the 
proportion of IL-13 reporter positive cells by approximately 84%. 
From these experiments it was discovered that IL-13 is more likely to be expressed, and 
expressed sooner by cells that have been previously activated. In in vitro models IL-13 
was not expressed by cells that had been removed from αCD3 antibody TCR 
stimulation on any day before day 4. Furthermore APC stimulated CD4+ T cells did 
not express IL-13 either. IL-13 production could be induced from APC stimulated cells 
with the addition of extra peptide loaded APCs on day 3 of culture, and the expression 
was dependent upon MHC II interactions. 
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Figure 4.6 – Addition of extra peptide loaded APCs induces CD4+ T cell IL-13 
expression in a TCR dependent manner.  
a. Representative flow plots and proportion of antigen specific 4C13RxOT-II CD4+ T cells 
expressing b. AmCyan and c. DS-Red on day 4. Cells were stimulated on day 0 with digested 
splenocytes pulsed with ISQ peptide, ISQ pulsed DCs added day 3 of culture with or without 
αMHC-II antibodies. Plots show mean ± S.E.M. n=3 in each group. Plots are representative of 
two independent experiments. Statistics were calculated for each group using One way 
ANOVA with Tukey’s post test ** P < 0.01 *** P < 0.001 ns = not significant. 
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4.2.3 Tissue specific CD4+ T cell cytokine expression patterns 
are not observed with in vitro stimulation 
To assess the expression of IL-4 and IL-13 reporters in vivo, 4C13R dual reporter mice 
were infected with 550 N. brasiliensis subcutaneously and the reporter expression by 
CD4+ T cells assessed in the mediastinal LN and lung at various time points post 
infection. Previous studies that compared IL-4 and IL-13 expression by LN and lung 
CD4+ T cells during N. brasiliensis infection used knock-in reporter mice which have 
deficiencies in their abilities to produce IL-4 and IL-13 which may have unintended 
consequences on Th2 responses311. 4C13R transgenic reporter mice are capable of 
mounting a normal immune response as their parental IL-4 and IL-13 genes are 
untouched, it was unknown if the same pattern of reporter expression would be detected 
using this system as has been previously reported.  
7 days post subcutaneous infection 4C13R reporting CD4+ T cells in the lung expressed 
both IL-4 and IL-13 reporters (Figure 4.7a). Interestingly, reporter positive cells were 
detected at 2 days post infection and at this time point the parasites have only been in 
the lung for a maximum of 36 hours. These cells were notably IL-4 and not IL-13 
positive. By day 7 IL-13 reporting was detectable but still a lower proportion of CD4+ T 
cells expressed IL-13 than the IL-4 reporter, while the proportions of IL-4 and IL-13 
reporting CD4+ T cells were fairly equal at day 9 post primary infection (Figure 4.7b).  
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Figure 4.7 - Lung CD4+ T cells express both AmCyan and DS-Red in response to N. 
brasiliensis infection.  
a. Representative plots and b. proportion of lung CD4+ T cells expressing AmCyan and DS-
Red at the indicated days post primary subcutaneous infection with 550 L3 N. brasiliensis. 
Dashed lines indicate background based upon non-transgenic CD4+ T cells. Plots show mean ± 
S.E.M. n≥2 in each group. Plots are representative of two independent experiments. 
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The 4C13R reporter mice were used to determine if previous reports of LN CD4+ T 
cells limiting their expression of IL-13 could be replicated311. As had been seen by the 
lung CD4+ T cells there were robust IL-4 reporter expression by CD4+ T cells in the 
mediastinal LN, though the expression at day 2 was marginal and not significantly more 
than background. There was no significant IL-13 reporter expression detected at any 
time point (Figure 4.8a). To assess if this was a phenomenon specific to CD4+ T cells 
resident in the mediastinal LN or to all LN CD4+ T cells, 4C13R mice were subjected 
to the pTh2 assay whereby mice were challenged with an intradermal injection of 
HDM and reporter expression in the auricular draining LN assessed on days 3 and 7. 
Repeating the pattern of reporter expression displayed by N. brasiliensis responding 
mediastinal LN CD4+ T cells, HDM responding CD4+ T cells in the pTh2 assay did 
not express detectable IL-13 reporter, while a large proportion reported IL-4 (Figure 
4.8b). The 4C13R reporter mice replicated the previously demonstrated lack of IL-13 
expression by activated LN Th2 cells, while lung tissue CD4+ T cells were able to 
produce both IL-4 and IL-13, IL-13 is expressed later than IL-4 by these cells but 
eventually equal proportions of cells expressed each of the cytokines by day 9 post 
infection.  
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Figure 4.8 - LN CD4+ T cells do not express DS-Red.  
a. Plot of day 7 and proportions of CD4+ T cells expressing AmCyan and DS-Red in the 
mediastinal LN 2, 7 and 9 days after primary subcutaneous infection with 550 L3 N. brasiliensis. 
Dashed lines indicate background based upon non-transgenic CD4+ T cells. Plot shows mean ± 
S.E.M. n≥2 in each group. Plot is representative of two independent experiments. b. Plot of day 
7 and proportions of CD4+ T cells expressing AmCyan and DS-Red in the auricular draining 
LN 4 and 7 days after intradermal injection in the ear of house dust mite. Dashed lines indicate 
background based upon non-transgenic CD4+ T cells. Plot shows mean ± S.E.M. n≥4 in each 
group. Plots are representative of two independent experiments. 
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Taking these results into consideration I hypothesised that CD4+ T cells resident in the 
lung may be phenotypically distinct from the LN CD4+ T cells, and that they may be 
primed towards expedited IL-13 production. To assess this CD4+ T cells were isolated 
from the lung and their reporter expression compared to CD4+ T cells from the spleen 
in the Th2 culture system. CD4+ T cell IL-4 and IL-13 reporting followed similar 
patterns regardless if the cells were from the lung or spleen, with IL-4 detected on day 2 
and IL-13 on day 4 (Figure 4.9a). The only difference was a slightly lower percentage of 
IL-4 reporting CD4+ T cells from the lung than spleen on days 2 and 3 of culture. 
Hence lung CD4+ T cell were not any more likely to express IL-13 than cells from 
lymphoid tissues.  
CD4+ thymocytes were also compared to CD4+ T cells from the spleen in the Th2 
culture system. Using CD4 expression to isolate cells from the thymus will extract not 
only newly matured CD4+ T cells but also double positive thymocytes in the process of 
becoming mature T cells, although many of the double positive cells will rapidly die in 
culture (Figure 4.9b). In a Th2 differentiating culture CD4+CD8- thymocytes express 
both IL-4 and IL-13; IL-4 possessed similar kinetics as spleen CD4+ T cells, though at a 
lower proportion until day 4. Interestingly low levels of IL-13 expression could be 
detected on day 2, 2 days before spleen derived CD4+ T cells become IL-13 reporter 
positive (Figure 4.9b). Therefore thymocytes can produce Th2 associated cytokines in 
Th2 culture, and the early IL-13 reporter expression may indicate a difference in 
activation potential between thymocytes and peripheral T cells.  
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Figure 4.9 – In vitro Th2 differentiated CD4+ T cells from LN and lung display the 
same pattern of cytokine reporting.  
a. Proportion of CD4+ T cells enriched from spleen and lungs that express AmCyan and DS-
Red during the Th2 culture system. b. Proportion of CD4+ T cells enriched from spleen and 
thymus that express AmCyan and DS-Red during the Th2 culture system. Plots show mean ± 
S.E.M. n=3 in each group. Each graph is representative of two independent experiments. 
Statistics were calculated for each cytokine using two way ANOVA with a Bonferroni multiple 
comparisons post test. **** P < 0.0001 comparing AmCyan+ samples. ## P < 0.01 ### P < 
0.001 comparing DS-Red+ samples. 
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Considering that in vitro CD4+ T cells needed multiple interactions with APCs to induce 
IL-13 expression, it was thought that a secondary infection with a pathogen could 
potentially induce stronger IL-13 responses from LN CD4+ T cells than seen in primary 
infection. 4C13R reporter mice were infected with 550 N. brasiliensis, allowing the 
infection to progress naturally, with the mice clearing the infection by day 14 post 
infection124. Mice were left until day 30 post primary infection to allow their immune 
responses to contract, and then reinfected subcutaneously with another dose of 550 
larvae. The secondary CD4+ T cell responses in the lung and the mediastinal LN were 
analysed. Of the reporting cells, both in the lung and the few detected in the LN, there 
were populations that expressed one cytokine or both IL-4 and IL-13, with the dual 
expressing populations less frequent than either of the single producing populations 
(Figure 4.10a). Total proportions of lung CD4+ T cells expressing IL-4 or IL-13 
reporters were similar throughout the time points assessed, while there was still more 
IL-4 than IL-13 reporting CD4+ T cells in the mediastinal LN (Figure 4.10b). Again 
robust reporter positive cells were detected in the lung at 2 days post infection, but LN 
responses were also detectable at this time point of the secondary infection. Comparing 
secondary to primary at day 6 of infection, the peak of secondary responses, there was 
approximately a 13-fold increase in the number of IL-13 reporting cells in the lung, and 
approximately 30-fold increase in the LN. Therefore despite more IL-13 producing cells 
being detected, they are still far less frequent than IL-4 reporting CD4+ T cells in the 
secondary LN. 
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Figure 4.10 - Secondary infection leads to increases in IL-13 reporting CD4+ T 
cells compared with primary infection.  
a. Representative plots and b. proportions of lung and mediastinal LN CD4+ T cells expressing 
AmCyan and DS-Red at various time points after a secondary subcutaneous N. brasiliensis 
infection. Plots show mean ± S.E.M. n≥3 in each group. Each graph is representative of two 
independent experiments.  c. Number of DS-Red+ CD4+ T cells in the lung and LN at day 6 
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post primary and secondary infection. Bar graphs show mean ± S.E.M. n=3 in each group. 
Data are representative of two independent experiments. Statistics were calculated for each 
cytokine using Student’s t test * P < 0.05  
 
4.2.4 FTY720 blockade of LN egress affects both IL-4 and IL-13 
expression by CD4+ T cells 
The mechanism inhibiting IL-13 expression within the LN remained unclear. I 
hypothesised that Th2 cells within the LN responded to antigen and began expressing 
IL-4 but do not receive sufficient exposure to antigen in the correct context within the 
LN to induce IL-13 expression. When the Th2 cells migrate from the LN to effector 
tissue where they are exposed to antigen again they are permitted to express IL-13. To 
test this theory reporter expression by CD4+ T cells within the mediastinal LN and lung 
of N. brasiliensis infected 4C13R mice treated with the sphingosine-1 phosphate receptor 
agonist FTY720 was assessed. FTY720 causes down regulation of sphingosine-1 
phosphate receptor 1 on T cells and leads to sequestration within secondary lymphoid 
organs and inhibition of migration to the periphery. Treatment was begun on day 1 
post subcutaneous infection as it has been shown that FTY720 can inhibit migration of 
APCs to the LN320, 321, which could effect the T cell priming therefore the treatment 
was delayed to allow migration of antigen loaded APCs to the LN. 
Treatment affected IL-4 reporting by the CD4+ T cells in both the LN and the lung, 
though there was no significant decrease in the percentage of CD4+ T cells that were 
AmCyan+. There was a decrease in the number of IL-4 reporting lung CD4+ T cells 
when treated with FTY720 (Figure 4.11a). In the LN FTY720 treatment led to an 
increase in the numbers and percentages of CD4+ T cells expressing the IL-13 reporter 
(Figure 4.11b). Although there was an increase in the percentage of CD4+ T cells that 
were DS-Red+, the number in the lung was not altered by treatment. This indicated 
either that the IL-13 expressing CD4+ T cells within the lung do not require migration 
through the LN for activation, or LN activated CD4+ T cells that go on to express IL-
13 in the lung are not sequestered by treatment with FTY720. In summary 
sequestration of T cells within the LN did induce increased IL-13 expression by LN 
CD4+ T cells, however treatment did not lead to the expected decrease of IL-13 
reporting cells within the lung, indicating that in vivo cytokine regulation may be more 
complicated than originally thought.  
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Figure 4.11 – Inhibition of LN egress with FTY720 has differential effects on IL-4 
and IL-13 during N. brasiliensis infection.  
a. Numbers and proportions of IL-4 reporting AmCyan+ CD4 T cells within the LN and the 
lung on day 9 after a subcutaneous N. brasiliensis infection with and without FTY720. b. 
Numbers and proportions of IL-13 reporting DS-Red+ CD4+ T cells within the LN and the 
lung on day 9 after a subcutaneous N. brasiliensis infection with and without FTY720. Bar graphs 
show mean ± S.E.M. n≥3 in each group. Data are representative of two independent 
experiments. Statistics were calculated for each cytokine using Student’s t test * P < 0.05 ** P < 
0.01  ns = non significant. 
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4.3 Discussion 
In this chapter I aimed to characterise the mechanisms that mediate CD4+ T cell 
expression of IL-13, and compare them to those that regulate IL-4 production. IL-4 has 
traditionally been a marker of Th2 cell however results from this work have highlighted 
the fact that IL-4 and IL-13 are not regulated together, with significant temporal and 
spatial differences in their expression, indicating that the use of IL-4 as an identifier of 
Th2 cells may be a limiting approach. Despite IL-4 and IL-13 being structurally similar 
cytokines the different biologic functions they mediate in vivo potentially explain the 
disparity in their expression by CD4+ T cells.  
The delay of IL-13 expression observed in vitro complements the previously published in 
vivo data that CD4+ T cells in the LN do not express IL-13. The paper by Liang et al. 
inferred that it was insufficient expression of GATA3 that prevented IL-13 expression 
by LN CD4+ T cells, and that Th2 cells migrated out of the LN before GATA3 levels 
were high enough to induce IL-13. Tfh cells however remain within the LN and express 
IL-4. It was proposed that the master transcription factor Bcl-6 inhibited high 
expression of GATA3, keeping the levels too low to permit IL-13 expression by Tfh 
cells311. Due to technical difficulties I could not assess Bcl-6 levels in the cultured cells so 
whether low levels of this transcription factor in the newly differentiated Th2 cells 
inhibited IL-13 expression remains to be determined. LN CD4+ T cells express Bcl-6 
within two cycles of proliferation98, and while there is a brief peak of Bcl-6 expression by 
CD4+ T cells in Th1 culture it has not been assessed whether this occurs similarly in 
Th2 cultures322.  
Whilst Bcl-6 restriction of GATA3 expression might play a role in inhibiting IL-13 
expression by LN Th2 cells323, the data that sustained or multiple TCR engagement is 
required indicates a further level of control. It has been shown that Th2 inducing 
adjuvants, compared with Th1 adjuvants, decrease the amount of time a CD4+ T cell 
interacts with DCs in the reactive LN, partially through diminished co-stimulatory 
receptor expression on the DCs89. Potentially this decreased interaction time also 
provides an in vivo regulatory mechanism for inhibiting IL-13 expression within the LN. 
Further studies utilising multiphoton microscopy could shed light whether limited CD4+ 
T cell-DC interactions are contributing to the prevention of IL-13 expression within the 
LN. 
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 I used FTY720 in an attempt to see if trapping CD4+ T cells within the LN would 
induce expression of IL-13, or if they required transit to the lung before they could 
produce the cytokine. The increase in IL-13 expressing CD4+ T cells within the 
FTY720 treated LN could indicate that the Th2 cells trapped in the LN were there long 
enough, and stimulated frequently enough to induce IL-13. Interestingly the decrease in 
the number of IL-4 reporting CD4+ T cells was unexpected; if FTY720 was trapping 
the cells within the LN and increasing the amount of stimulation the cells were receiving 
(as was my inference from the IL-13 data) then why the number expressing IL-4 
dropped remains unclear.  
I had predicted that FTY720 treatment would decrease the number of CD4+ T cells 
that entered the lung from the LN, and as expected the total number, and the number 
of AmCyan+ CD4+ T cells were decreased in the treated lungs (Figure 4.11). 
Surprisingly the number of IL-13 reporting cells was not altered. IL-13 expression by, 
and the requirement for, lung-resident CD4+ T cells in protective immune responses 
against N. brasiliensis has been measured previously134. These studies observed a decrease 
in the total amount of IL-13 secreted by restimulated whole lung cells from FTY720 
treated mice, however this could be due to decreased activation of other IL-13 
expressing populations such as ILC2s. The discovery that CD4+ T cell IL-13 expression 
may occur without the requirement of LN migration is novel and potentially has far 
reaching consequences for both parasitic infection and allergies. 
4.4 Conclusions 
I have shown that CD4+ T cell expression of IL-13 is differently regulated compared to 
IL-4. These experiments have demonstrated temporal and spatial regulation of IL-13 
compared to IL-4 by recently activated CD4+ T cells. IL-13 is expressed much later 
than IL-4 in Th2 differentiating culture, and within the LN CD4+ T cells do not express 
IL-13 at all. By inhibiting egress of the CD4+ T cells from the LN during N. brasiliensis 
infection IL-13 expression can be induced. LN trapping of CD4+ T cells however does 
not change the number of IL-13 expressing CD4+ T cell within the lung indicating that 
IL-13 expression can potentially be activated outside of lymphoid tissue. I have 
discovered that IL-13 is differentially expressed to IL-4 and while these cytokines are 
related, they are under the control of very different regulatory mechanisms. These data 
can inform future studies particularly those aiming to specifically target IL-13 in an 
attempt to inhibit its pathogenic roles in allergic and fibrotic diseases. 
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5 Innate immune cells of 
the skin display divergent 
expression of Type 2 
cytokines 
5.1 Introduction 
The skin offers a physical barrier to exclude potential pathogens and it contains many 
resident populations of immune cells that mediate rapid responses to breaches in the 
barrier and attacks by opportunistic infections. Inappropriate immune responses in the 
skin can alter function and structure of the tissue as is seen in skin inflammatory 
disorders including psoriasis324 and atopic dermatitis325. The immune components that 
facilitate the pathology of these skin diseases are not fully characterised and this chapter 
attempts to focus on two immune cell types and their contributions to skin immune 
responses.  
Populations of ILCs have been identified in other barrier sites including the gut254 and 
lungs116 however prior to this study whether a skin resident population exists, and what 
functions these cells might have had not been assessed. I have described a novel 
population of dermal resident ILCs discovered in collaboration with researchers from 
the Centenary Institute in Sydney265, and I have assessed the function of these cells in a 
range of inflammatory models. 
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MC903, also known as calcipotriol, is a derivative of the vitamin D3 metabolite 
calcitriol and is traditionally used as a treatment for psoriasis326. Topical, daily 
application of MC903 causes localised skin inflammation that in a mouse 
phenotypically reproduces the salient characteristics of atopic dermatitis, with hyper-
proliferation of keratinocytes, infiltration of immune cells into the dermis and oedema at 
the treated site. The pathology is dependent upon TSLP and is associated with 
increased serum IgE and Th2 responses, though the pathogenic changes in the skin are 
independent of antibody or T cell responses as they can occur in Rag1-/- animals.297 In 
this chapter I have described ILC responses during the MC903 model then 
characterised basophil responses, assessing their cytokine production during treatment 
and the factors that mediate their activation and recruitment. Together these data assess 
the contributions to skin inflammation by two cell populations, one resident and one 
recruited and compared their differential responses and cytokine expression patterns. 
5.1.1 Aims 
In this chapter I aimed to characterise a population of novel innate immune cells within 
the skin and assess their responses in a range of inflammatory conditions. IL-4 and IL-
13 producing cells in the skin were characterised using reporter mice and, utilising the 
MC903 model of skin inflammation, I compared the responses of ILCs and basophils. 
Specifically these experiments aimed to: 
• Characterise the dermal innate lymphoid cells (dILCs)  
• Compare IL-13 production by dILCs in mice across a range of ages and in 
inflammatory conditions 
• Assess the susceptibility of skin immune cells to antibody depletion 
•  Measure basophil responses in a vitamin D analogue driven model of skin 
inflammation. 
5.2 Results 
5.2.1 Dermal innate lymphoid cells are a distinct population of 
skin resident immune cells 
Roediger et al. discovered a population of cells within the skin that phenotypically 
resembled ILCs, it was decided that I would assess the potential role of these cells in 
models of Type 2 inflammation of the skin265. A gating strategy was defined to identify 
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the dermal ILC (dILC) population of the skin. To prepare a single cell suspension for 
flow cytometry the skin needed to be digested with a buffer containing type IV 
collagenase and DNase type I and then ground through a metal mesh. Using CD45 to 
identify the haematopoietic cells that make up roughly 5% of the digested skin cell 
suspension, lymphoid cells were identified by CD90 expression and myeloid cells 
excluded using CD11b. To exclude T cells and NK cells from the innate lymphoid gate, 
cells identified as CD3-, NK1.1- and CD2- were gated on (Figure 5.1a). This population 
of non-T, non-NK lymphoid cells, making up around 2.5% of the CD45+ cells in the 
skin (Figure 5.1b), were classified as the dermal innate lymphoid cells (dILCs).  
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Figure 5.1 - dILCs are a unique population of skin immune cells.  
a. Gating scheme identifying dermal innate lymphoid cells (dILCs). b. Proportion that different 
cellular populations make up of CD45+ cells within the total ear skin of naïve mice. Bar graphs 
show mean ± S.E.M.  n≥8 in each group. Data was pooled from 4 independent experiments.  
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The dILCs were phenotyped by flow cytometry for various cell surface molecules, 
looking for expression of ILC related receptors and ensuring the lack of expression of 
molecules associated with other cell populations (Figure 5.2). Almost all the dILCs 
expressed CD44 and the majority of cells were positive for CD69 and the IL-7R 
(CD127), variable levels of Sca1 (Ly6E) and inducible T cell costimulator (ICOS) were 
also detected, all cell surface molecules previously described to be expressed by ILCs251. 
Expression of CD11a, CD34, CD95 and CD103 were also detected. It has since been 
shown that CD103 expression was limited to dermal ILCs, it was not detected on ILC 
populations from any other tissue265. A population of IL-33R+ (T1-ST2) and a low 
percentage of CD25+ (IL-2Rα) cells were also observed. Both receptors had been 
associated on ILC2s in other tissues allowing them to response to IL-33 and IL-2253. 
dILCs were found to be negative for the myeloid associated cell surface molecules 
CD11c, CD80, CD86, the canonical eosinophil molecule siglec F, antibody receptors 
FcεRI and CD16/32 (FcγRII and FcγRIII), CD154 (CD40Ligand), CD152 (CTLA-4), 
mast cell expressed stem cell growth factor receptor CD117 (C-Kit), T cell co-receptors 
CD4 and CD8, Gr1 (Ly6C/Ly6G), KLRG1 and CD121b (IL-1Rb). Notably IA/IE 
(MHC class II) was not detected which had been measured on populations of ILCs in 
other tissues254.  
Using this gating strategy I was able to specifically identify a novel population of skin 
cells that appear to resemble ILCs, although they express many of the common ILC 
associated cell surface molecules they were not clearly positive for all markers 
traditionally associated with ILC2s. 
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Figure 5.2 - dILCs have a phenotype characteristic of ILCs from other tissues.  
a. Histograms demonstrating expression of a range of cell surface molecules on dILCs gated as 
in Figure 5.1a. Gates are set upon isotype controls and numbers indicate percentage of dILC 
population that fall within the gate. Plots are representative of triplicates and two independent 
experiments.  
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5.2.2 IL-13 is constitutively expressed by dermal innate 
lymphoid cells 
dILCs in the skin of 4C13R mice were assessed at baseline for their expression of IL-4 
and IL-13 and a population of DS-Red expressing cells reporting IL-13 expression were 
identified in naïve skin (Figure 5.3). The DS-Red cells were all CD45+ and CD90+ and 
the majority of DS-Red+ cells were from the CD3- and NK1.1- population. Some minor 
expression from the CD3hi NK1.1hi cells was detected as well, although this population 
is smaller than the CD3- NK1.1- DS-Red+ cells (Figure 5.3a). When dILCs were 
specifically gated a population of cells were consistently observed with higher DS-Red+ 
expression than background (Figure 5.3b), however these cells did not report any IL-4 
expression as there was no detection of AmCyan above background (Figure 5.3c). 
It was noted that the age of the mouse made a large difference on the proportion of 
dILCs that were IL-13 reporter positive (Figure 5.4a). Very young mice less than 4 
weeks of age had about 66% of their dILCs expressing DS-Red while older mice, 
between 4 and 8 weeks, had about 44% DS-Red+ dILCs. A further non-significant 
reduction in the proportion of IL-13 reporting dILCs was observed in mice older than 8 
weeks of age (Figure 5.4b).  
Thus despite a low proportion of dILCs expressing T1/ST2 (IL-33R) and CD25 (IL-
2Rα), receptors usually associated with ILC2s, a proportion of the dILCs expressing the 
IL-13 reporter were detected. This indicated that at least some dILCs are of a group 2 
phenotype in naïve skin. Furthermore I found that the proportion of the dILCs that 
constitutively express IL-13 decreases as the mice mature. 
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Figure 5.3 - dILCs constitutively express IL-13 but not IL-4.  
Representative plots of DS-Red expression on a. Total lymphocytes (CD45+CD11b-CD90+) 
and b. dILCs from ear skin from 4C13R and non-transgenic littermate control mice. Plots are 
representative of many experiments. c. Representative plots of AmCyan expression on dILCs 
from ear skin of 4C13R mice. Plots are representative of greater than five independent 
experiments. 
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Figure 5.4 - IL-13 expression varies with age.  
a. Representative plots of DS-Red expression on dILCs from 2 week and 16 week aged mice. b. 
Proportion of ear skin dILCs expressing DS-Red from mice grouped into three groups based 
upon age. Graph shows mean ± S.E.M. of each group. Groups contain at least seven replicates. 
Data are representative of two independent experiments. Statistics were calculated using 
Kruskall-Wallis with Dunn’s post-test, **p<0.01, ***p<0.001 
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5.2.3 dILCs only display minor responses in models of skin 
inflammation 
IL-13 can contribute to fibrosis and pathology of atopic dermatitis12, 327 so we 
hypothesised that dILCs could contribute to models of skin inflammation through their 
production of IL-13.  Mice were treated to assess dILC responses in a skin specific 
model of inflammation, a model that induces the Type 2 associated IgE antibody. 
However the model required optimisation to meet our ethical guidelines and 
inflammatory requirements.  Mice were treated with MC903 at the same concentration 
as the original publication, 4nmol of MC903 dissolved in ethanol per ear daily297. The 
ear skin of these mice clearly became inflamed, with the ears becoming thickened from 
dermal infiltration of inflammatory cells as well as hyper-proliferation of keratinocytes, 
the mice became ill by day 7 of treatment, with visible hunching, loss of sleekness to the 
fur and by day 9 all the mice had to be culled as their weight loss was greater that 
ethical cut offs. I found that the 17-day model could not be ethically replicated in our 
laboratory using the same concentration described in the original publication.  
To assess the limits of the MC903 model mice were treated with a titration of the drug, 
treating groups of mice on both ears with 4, 2 or 1nmol MC903/ear/day, and also 
treating one group with 4nmol daily on one ear and ethanol on the other, all these 
treatments were compared to mice treated daily on both ears with ethanol. Regardless 
of the concentration of MC903 used to treat, the mice ears thickened at an equal rate 
(Figure 5.5a). The ears that were only treated with ethanol, even when the contralateral 
ear was receiving MC903, did not show any thickening (Figure 5.5c). However as 
observed in the original experiments mice treated on both ears with 4nmol 
MC903/ear/day succumbed the quickest to the sickness caused by MC903 treatment 
(Figure 5.5b). This was followed by the mice receiving 4nmol/day to a single ear, which 
lost weight at a similar rate to the mice receiving 2nmol/ear/day on both ears (both 
groups of mice received a total of 4nmol/day). Mice receiving 1nmol/ear/day only 
began losing weight on day 15 of treatment and all mice in this group survived to the 
day 17 time point with massive ear swelling (Figure 5.5a and b). 
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Figure 5.5 - Calcipotriol (MC903) causes inflammation and thickening of skin 
tissue.  
a. Ear thickness measurements of Balb/c mice treated with 10μL/side of ear (20μL/ear) daily 
with different concentrations of MC903 or ethanol control. b. Weights of mice undergoing 
treatment with MC903. Pictures taken of the mice treated on the left ear with 4nmol/ear 
MC903 and on the right ear treated with ethanol on c. day 6 and d. day 12 of treatment. Each 
time point contains two mice, four ears. 
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Massive ear thickening, and survival of the mice until at least until day 17, could be 
achieved if the dose of MC903 was dropped to a quarter of what was originally 
published297. Due to the fact that similar thickening was measured at day 7 with all the 
doses trialled, I decided to treat with the highest dose trialled, 4nmol/ear/day MC903 
as I reasoned that high doses would be most likely to generate responses from the dILCs. 
The model chosen was to measure the responses of dILCs using the original 
4nmol/day/ear regime at day 7 of treatment.  
dILC responses to MC903 treatment were minimal, with no difference in their total 
number between a 7 day ethanol and 4nmol/ear/day treated ear (Figure 5.6a). The 
proportion dILCs constituted of live (Figure 5.6b) and CD45+ cells (Figure 5.6c) were 
diminished in the MC903 treated skin. These data indicated that dILCs were not 
infiltrating into the skin or proliferating in response to treatment, in fact decreased 
proportions indicated that other immune cells were increasing in the skin. Treating 
4C13R mice with MC903 allowed measurement of the IL-13 reporting from the dILCs. 
MC903 treatment caused increased numbers (Figure 5.6d) and a statistically 
insignificant increase in proportions (Figure 5.6e) of DS-Red+ dILCs in the ear skin 
above ethanol treated mice. So although there appeared to be slight increases in the 
activation of dILCs in response to MC903, there was no increase in cell number and 
the changes observed were not significant so it did not appear that dILCs are very 
responsive to MC903 treatment. 
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Figure 5.6 - ILCs only show moderate responsiveness in a MC903 model of skin 
inflammation.  
Comparing ear skin responses of MC903 treated and ethanol control 4C13R mice at day 7 of 
treatment. Measuring; a. numbers of dILCs. b. proportion of dILC of total live cells, c. 
proportion of dILCs of CD45+ cells, d. number of DS-Red+ dILCs and e. proportion of dILCs 
expressing DS-Red. Bar graphs show mean ± S.E.M.  for each group. Data are representative 
of two independent experiments. Statistics were calculated for each group using Student’s t test 
* P < 0.05 ** P < 0.01 *** P < 0.001 ns = non significant. 
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dILC did not respond to MC903 in any detectable way, so other inflammatory stimuli 
were tested to see if these could effect dILC numbers. I hypothesised that the 7 days of 
the MC903 model may be too long and early dILC responses were be being missed. So 
I decided to look at early responses after tape stripping or intradermal injection of 
HDM, IL-33 or TSLP. Tape stripping required repetitively sticking tape to the ears of 
the mice and pulling it off298, the process was repeated 20 times on each ear, removing 
the cuticle and causing considerable inflammation. The dILC responses 24 hours after 
treatment were assessed. No differences were found in the numbers of dILC or their 
proportion of CD45+ cells (Figure 5.7a). When the dILCs responding 24 hours after 
intradermal injection of HDM were assessed, similar patterns were observed as with 
MC903 treatments. HDM injection reduced the proportion of CD45+ cells made up by 
the dILCs but the total numbers of dILCs per ear did not change between PBS and 
HDM injection, indicating that while HDM induced some inflammation it wasn't 
causing dILCs proliferation (Figure 5.7b). So in the 3 inflammatory systems assessed 
dILCs were not observed responding in changes in cell number. 
ILCs have been reported to respond strongly to a range of cytokines, particularly the 
barrier-derived cytokine IL-25, IL-33 and TSLP328. I hypothesised that dILCs would 
also respond to recombinant cytokine, so IL-33 and TSLP were injected intradermally 
into 4C13R mice and dILC responses assessed 24 hours later. No changes in the 
proportion of CD45 or numbers of dILCs were observed, nor in the proportion of 
dILCs expressing DS-Red compared to the contralateral ears injected with PBS (Figure 
5.7c). So unlike ILCs from the lungs or intestines, dILCs did not seem to respond very 
rapidly to direct cytokine treatment. 
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Figure 5.7 - dILCs show marginal responses to various inflammatory stimuli.  
a. Proportion of CD45, and numbers, of dILCs in untreated and tape-stripped Balb/c mice 24 
hours after treatment. b.  Proportion of CD45, and numbers, of dILCs in response to 
intradermal injection of PBS or HDM in Balb/c mice 7 days after treatment. c. Proportion of 
CD45, and numbers of dILCs, and proportion of DS-Red+ of dILCs 24 hours in the ears of 
4C13R mice after intradermal injection of the cytokines IL-33 or TSLP compared to 
contralateral ears treated with PBS. All graphs show mean ± S.E.M.  for each group. Data are 
representative of two independent experiments. Statistics were calculated for each group using 
Student’s t test to compare against the relevant control **** P < 0.0001 ns = non significant. 
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From these experiments it can be interpreted that dILCs are a quiescent skin resident 
cell population, not responding via proliferation or IL-13 expression to a range of 
inflammatory models or to direct cytokine injection. Depletion of dILCs would allow 
assessment of their contribution to inflammatory models such as MC903 in ways that 
hadn’t yet been detected. MC903 induced inflammation and ear thickening had been 
documented to be T cell independent and occur in Rag-/- mice297, so if CD90+ cells 
could be depleted from the skin of a Rag1-/- mouse, the role of dILCs could be assessed, 
NK cells would also be depleted but this could be controlled for with NK cell specific 
depletion. However I found that regular antibody depletion protocols didn't deplete 
dILCs. The abilities of antibodies to penetrate certain tissues and to deplete cells were 
assessed by treating mice intraperitoneally with 0.2mg αCD4 (GK1.5) or 1mg αCD90 
(30H12) and then assessed the detectable CD90+ cell in the skin, auricular draining LN 
and spleen 48 hours later (Figure 5.8). There was marked decrease in the detectable 
CD90+ cells in the spleen with αCD4 treatment and a total loss from the spleen with 
αCD90. In the LN there was no difference with GK1.5 treatment though αCD90 
caused an almost 10 fold decrease in the detectable CD90+ cells. In the skin no effect of 
the antibody treatments was observed, no masking of the CD90 staining or any 
apparent depletion. Although antibody could reach and deplete cells from the spleen, 
and to a lesser degree the LN, 1mg of αCD90 was insufficient to affect the ear skin cells; 
the lack of masking indicates the antibodies were not even able to reach the cells in this 
tissue (Figure 5.8). 
In summary dILCs were not detected responding in any significant way to any of our 
inflammatory models or application of recombinant cytokine. While they did report 
constitutive production of IL-13 no changes in this cytokine expression were measured 
so no obvious role for this IL-13 expression could be inferred. Furthermore, it was 
found that dILCs were resistant to antibody depletion compared to cells from the spleen 
of LN, this meant inflammatory responses in the absence of dILCs could not be 
accurately assessed. 
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Figure 5.8 - ILCs of the skin are resistant to antibody depletion.  
a. Representative flow plots of Live, CD45+ cells from the ear, auricular draining LN and 
spleens of mice 24 hours after receiving 0.2mg GK1.5 (αCD4), 1mg 30H12 (αCD90) or 
remained naïve. Plots are representative of two independent experiments each n=3. 
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5.2.4 Basophils respond to TSLP induced by MC903 treatment 
by producing IL-4 
During the analysis of dILC responses I had observed an expansion of CD45mid cells in 
the ears of MC903 treated mice (Figure 5.9a and b). These cells were found to be 
positive for CD49b (DX5), FcεRI, and extracellular IgE their lack of expression of 
detectable C-kit confirmed their status as basophils (Figure 5.9a),. Recent publications 
had indicated that high levels of TSLP led to haematopoiesis of a population of 
basophils329. Knowing that the MC903 treatment caused increased serum levels of 
TSLP297 I hypothesised that TSLP signalling was causing increased systemic basophilia 
and migration into the skin. To test the systemic basophilia, basophil numbers and 
proportions of haematopoietic cells were analysed in the blood of mice treated on both 
ears with 4nmol MC903 or ethanol daily for 7 days. Unexpectedly the proportion of the 
CD45 expressing haematopoietic cells in the blood that were basophils decreased, this 
drop was also associated with a decrease in the number of basophils per mL of blood in 
the MC903 treated compared with ethanol treated mice (Figure 5.10a). I interpreted 
this drop in circulating numbers to indicate that the cells were likely migrating into 
tissues in response to treatment. To determine if the accumulation of basophils in the 
skin was treatment specific mice were treated for 7 days on one ear with 4nmol/ear 
MC903 and ethanol on the other ear, and basophil numbers and their proportion of 
CD45+ cells in the ear skin (Figure 5.10b) and auricular draining LN (Figure 5.10c) 
were analysed. As observed previously, there were increased basophil numbers and 
proportions in the skin of MC903 treated ears and also increases in the LN from the 
treated side over the ethanol control ears or LN. The decreased levels of basophils in 
the blood of treated mice also correlated with infiltration of basophils into the skin and 
draining LN of mice but only specifically into the draining LN or the skin treated with 
MC903. 
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Figure 5.9 - Basophils migrate to the skin in response to MC903 treatment.  
a. Representative plots of skin cells from ears treated for 7 days with MC903, pre-gated 
upon singlets then live cells. The first plot shows a CD45mid population of cells staining 
positive for IgE; this population also stains positive for FcεRI and DX5, are SSClo and is 
negative for C-kit. Gating is based upon FMO controls. b. Number, and c. proportion of 
CD45+ of basophils in ears of mice treated with 4nmol/ear/day of MC903 for 4 or 7 days.  
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Figure 5.10 – Basophils migrate specifically to the site of treatment and the 
draining LN. 
Proportions of CD45+ and numbers of basophils in a. blood, b. ear and c. auricular draining 
LN on day 7 of MC903 treatment. a. Mice had been treated on both ears with either 
4mol/ear/day of MC903 or ethanol. b. and c. mice received 4nmol/ear/day MC903 on one 
ear and ethanol on the other ear. All graphs show mean ± S.E.M.  for each group. Data are 
representative of two independent experiments. Statistics were calculated for each group using a 
Student’s * P < 0.05 ** P < 0.01. 
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One characteristic of G4 GFP IL-4 reporter mice is that basophils constitutively express 
GFP330, so I decided to utilise this as an extra identifying marker of basophils in the 
various MC903 treated tissues. Using this technique an interesting phenomenon was 
noted in the treated mice. A population of basophils could be detected expressing 
higher GFP (GFPhi) than naïve basophils (Figure 5.11a). This was consistent with 
observations from our group whereby basophils in the lungs from N. brasiliensis infected 
huCD2/GFP mice began expressing huCD2 and also increased their GFP MFI, to 
indicate they had begun expressing IL-4 (331and unpublished data). Furthermore TSLP 
elicited basophils have been shown to produce very high levels of Type 2 associated 
cytokines particularly IL-4329, 332, so the proportions of basophils expressing high levels 
of GFP in the ear, LN and blood of GFP/IL-4 mice were analysed. A proportion of 
basophils in all three MC903 treated tissues began expressing GFP at a higher level 
than basophils in ethanol treated mice indicating they had begun expressing IL-4 
(Figure 5.11b). IL-4 reporting was confirmed by looking at the reporter expression of 
basophils in the blood of 4C13R mice treated with MC903 for 7 days. A population of 
AmCyan expressing basophils could be detected reporting IL-4 expression. Interesting 
no DS-Red expressing basophils were detected indicating specific induction of IL-4 but 
not IL-13 expression (Figure 5.11c). 
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Figure 5.11 - MC903 elicited basophils produce IL-4 but not IL-13.  
a. Representative plots, b. proportion of basophils and c. numbers of GFPhi basophils in ear, 
auricular draining LN and blood of mice receiving on both ears either 4nmol/ear/day MC903 
or ethanol for 7 days. d. AmCyan and DS-Red expression of basophils in the blood of 4C13R 
and non-transgenic control mice after 7 days of MC903 treatment. All graphs show mean ± 
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S.E.M.  for each group. Data are representative of two independent experiments. Statistics were 
calculated for each group using a Student’s * P < 0.05 *** P < 0.001 ns = not significant. 
 
 
TSLPR knock-out mice on a GFP IL-4 reporter background (GFP/GFP, so IL-4 
deficient) were used to test my hypothesis that the basophilia, and increased IL-4 
production by the basophils was dependent on TSLP.  Comparing MC903 driven 
basophil responses in GFP/GFP mice with WT TSLPR (TSLPR+/+) to TSLPR knock-
out mice (TSLPR-/-) demonstrated tissue specific responses. Blood basophil numbers 
were higher in TSLPR-/- mice, but they were decreased in the LN compared with 
TSLPR+/+ mice (Figure 5.12a). Unexpectedly there was no difference in number of 
basophils in the ear between the two strains of mice (Figure 5.12a). In all three tissues 
looked at a total lack of GFPhi induction by basophils from TSLPR-/- mice was observed 
(Figure 5.12b).  
So I identified basophils as strong responders to MC903 exposure, although there was 
no measurable increase in basophil numbers in the blood, their migration into the ear 
skin and LN were measured in a treatment site-specific manner. MC903 treatment 
induced increased IL-4 reporting from basophils within all three tissues and this was 
dependent upon TSLPR signalling. 
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Figure 5.12 – TSLPR signalling is required for basophil IL-4 expression and 
migration to the LN.  
a. Total numbers and b. proportion that are GFPhi of basophils in blood, ear skin and auricular 
draining LN of mice receiving on both ears either 4nmol/ear/day MC903 or ethanol for 7 days. 
All graphs show mean ± S.E.M.  for each group. Data are representative of two independent 
experiments. Statistics were calculated for each group using a Student’s * P < 0.05 ** P < 0.01 
*** P < 0.001 **** P < 0.0001 ns = not significant. 
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5.3 Discussion 
In this chapter I aimed to characterise a novel population of dermal resident innate 
lymphoid immune cells and observe their responses in a number of inflammatory 
conditions. I assessed the cytokine production of the dILCs and other immune cells 
found within inflamed skin using the IL-4 and IL-13 reporter mice. dILCs were found 
to have muted expansion and cytokine reporting responses but, treatment with MC903 
induced cytokine production and migration of basophils into both the skin and the 
draining LN. How these cells contribute to pathogen specific immune responses has yet 
to be determined but these studies offer vital information about the immune cells of the 
skin and their cytokine responses. 
The immune network in the skin is a carefully regulated system with cells inhabiting 
specialised sites in order to best carry out their functions. dILCs reside within the 
dermal layer of the skin, a position where they can have contact with DC subsets, 
macrophages, resident memory T cells and mast cells, but not with the dendritic 
epithelial T cells (DETCs) or Langerhans cells in the epidermis.333 Imaging studies 
performed by Roediger et al. utilising multiphoton imaging found that the dILCs were 
the only cells in the skin of Rag1-/- mice that expressed CXCR6. Utilising Rag1-/-
xCXCR6-GFP reporter mice two patterns of dILC movement were observed; active 
migration through the dermis and extended periods of remaining static. Through the 
use of bone marrow chimeras and other reporter mice they were able to show that the 
dILCs did not interact with DCs but did migrate towards mast cells, and halt their 
movement when in the close vicinity of a mast cell.265 These observations led to the 
hypothesis that dILCs might have a role in regulating dermal mast cell responses. 
IL-13 is one of the key cytokines produced by the group 2 ILCs; the IL-13 reporting by 
dILCs indicates that at least a proportion of the population are ILC2s (Figure 5.3). The 
fact that the proportion of dILCs expressing IL-13 in naïve skin was inversely 
proportional with age could indicate several things. It could indicate the signals that 
drive IL-13 expression by dILCs dissipates as the animal ages, or that there is a 
preferential outgrowth of other ILC populations that begin to outnumber the ILC2s. 
IL-13 expression in the skin is usually associated with fibrosis and inflammation as seen 
in systemic sclerosis334 and models of atopic dermatitis205, however its roles in naïve skin 
were unknown. Following the discovery that these cells report IL-13 and also interacted 
with mast cells the cytokine responses of mast cell cultures activated by receptor bound 
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IgE cross-linking in the presence of IL-13 were tested. IL-13 was found to inhibit mast 
cell cytokine release, potentially hinting at a role of dILCs as regulatory cells of the skin 
controlling IgE driven mast cell responses.265 This proposition potentially fits with the 
observation that atopy is most prevalent in young children335. The higher proportions of 
IL-13 expressing dILCs in younger animals could be acting to inhibit over-activation of 
mast cells in the skin in situations of high levels of circulating IgE in early life. The lack 
of IL-4 expression by dILCs is consistent with other reporters assessing cytokine 
expression by unstimulated ILCs directly ex vivo257. 
This study observed minimal expansion and changes in IL-13 reporting by the dILCs in 
a range of inflammatory conditions, however Roediger et al. found that dILCs would 
respond to IL-2. During experiments where mice were treated with IL-2 complexed 
with antibody (IL-2c) in an attempt to maintain adoptively transferred Tregs, it was 
noted that the dILCs expanded greatly. IL2c treatment of Rag1-/- mice induced strong 
dILC expansion associated with increases in ILC2 cytokines IL-5 and IL-13. These 
mice also spontaneously developed skin lesions populated by neutrophils, eosinophils 
and dILCs that were characteristically similar to lesions seen in atopic dermatitis 
patients.265 It is possible that in this study strong dILC responses were not registered as 
these experiments assessed early time points looking for direct dILC activation by 
damage or invading pathogens, while dILC activation may actually occur subsequent to 
the activation of the adaptive immune system. If dILCs do rely upon the IL-2 provided 
by T cells migrating to the site of inflammation then they could either act as supporting 
cells by producing extra cytokine to sustain inflammatory responses as may be the case 
in atopic dermatitis, or they could play a regulatory role. The production of cytokines 
such as IL-13 could counter the effects of other inflammatory cytokines such as IFN-γ336 
and IL-17337, while promoting healing and fibrosis336. 
I measured only marginal dILC responses in the skin of MC903 treated mice (Figure 
5.6), however papers published since this work was carried out have measured TSLP 
dependent ILC2 changes within the skin and draining LN338, 339. Furthermore it was 
found that antibody treatment was capable of depleting ILCs from the LN and this 
antibody depletion could diminish the MC903 driven ear thickening. Whether this 
study actually achieved depletion of ILC2s within the skin was not demonstrated, so 
either depletion was achieved and it was the absence of skin resident ILC2s that 
explained the decreased inflammation, or that the antibody sensitive LN ILC2s were 
critical to driving the MC903 inflammation. In either case there was significant enough 
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differences between this study and the one by Kim et al. to leave several questions 
unanswered in relation to the role of ILCs in MC903 inflammation. 
The MC903 model did highlight strong migratory responses, and IL-4 but not IL-13 
expression by basophils to the vitamin D3 analogue (Figure 5.9). IL-4 producing 
basophils in the skin have been associated with the alternate activation of skin 
macrophages, which can trap parasites as they migrate through the skin340. Siracusa et 
al. published a paper identifying a novel subset of basophils that respond to TSLP. 
These basophils expressed high levels of Type 2 cytokines and were quite different to 
traditional IL-3 elicited basophils, particularly in the repertoire of proteases they 
expressed and a notable lack of histamine. This paper also used the MC903 model and 
discovered TSLP dependent, and IL-3 independent, basophilia in the ear. In addition 
to my discovery that these basophils were also present, albeit in low number, and 
reporting high IL-4 expression in the draining LN of treated ears, Siracusa et al. found 
that basophil depletion decreased the amount of Type 2 cytokine produced by 
restimulated T cells from MC903 treated draining LNs. These data indicated that 
basophils might play a role in the generation or expansion of Th2 responses, in the 
draining LN.329 A subsequent paper published after the conclusion of this project 
evaluated the importance of TSLP elicited basophils in the induction of Th2 in the 
mesenteric LN during intestinal helminth infection and found these basophils required 
for optimal Th2 generation341. 
Conflicting reports exist proposing basophils are or are not required for the generation 
of Th2 cells in vivo. Th2 differentiation requires IL-4 in vitro however it was long thought 
Th2 cells were the only source for IL-4 in the LN so a chicken/egg causality dilemma 
existed as no obvious source of IL-4 was known that could switch activated CD4+ T 
cells to Th2342. The discovery of basophils within the reactive LN and also that 
basophils could express MHC II and co-stimulatory molecules made them an attractive 
candidate as cells that could present antigen and produce the IL-4 that would induce 
Th2 differentiation343, 344, 345, 346. Several studies claimed that basophils were more 
important than DCs at inducing Th2 cells, anti-FcεRI antibody targeting of basophils344, 
345 and limiting of MHC II expression to CD11c+ cells346 greatly diminished Th2 
generation. These papers were challenged however by the implementation of CD11c-
diptheria toxin receptor (DTR) depletion models, where by loss of CD11c expressing 
cells significantly inhibited Th2347. The further identification of FcεRI expressing 
inflammatory DCs which were both necessary and required for in vivo Th2 induction 
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brought into question the purity of the previously identified basophils that could present 
antigen, and provided an alternate explanation as to why FcεRI targeting antibody 
disrupted Th2 generation348. Despite these controversies recent developments of genetic 
based basophil depletion models have generated further contradictory data, which in 
some models indicate clearly no role for basophils, 349and others claiming basophils are 
required for optimum responses341, 350. While enough evidence exists that basophils can 
affect Th2 responses it remains uncertain if they truly do in vivo and if they do to what 
extent. Careful analysis using well characterised models and specific depletion models 
will educate Th2 researchers in the future. 
5.4 Conclusions 
This study acts as a foundation for future research into the roles of innate immune cells 
in the skin, particularly in relation to Type 2 immune responses. I characterised a novel 
cell type, the dILC and detected significant, age dependent, IL-13, but not IL-4 
reporting by these cells. While these cells appeared unreactive in the inflammatory 
models assessed, more in depth time course studies may discover as yet unrealised roles 
for these cells, particularly in light of the data that they strongly respond to IL-2 which 
can be produced by T cells. Basophils display a TSLP dependent cytokine response in a 
model of skin inflammation caused by treatment with an analogue of vitamin D3. These 
basophils tracked specifically to the treated area of the mouse and could also be 
detected within the LN; they produced IL-4 in a TSLP dependent manner but were not 
observed to be producing IL-13. Publications by other groups indicate these basophils 
may have a role in the induction of Th2 cell responses within the LN and further studies 
could determine if there is a link between epithelial cell derived TSLP, IL-4 producing 
basophils and the generation of atopic dermatitis. These data also demonstrate a further 
differentiation in Type 2 cytokine expression, with two distinct populations of cells each 
expressing IL-4 or IL-13 within the same tissue. While CD4+ T cells may differentially 
regulate their timing and location of expression, some cell types can selectively express 
only one of these cytokines. 
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6 Interplay of adaptive and 
innate immune responses 
mediate protection 
against Nippostrongylus 
brasiliensis  
6.1 Introduction 
Upon secondary exposure to the rodent hookworm N. brasiliensis WT mice mount 
protective immune responses, the nature of which have been widely characterised127, 132, 
134, 340, 351 but the exact mechanisms contributing to protection remain ambiguous. 
While much research has focused on the intestinal expulsion phase seen in late primary 
infection14, 73, 254, 352, 353, we have focused on the phenomena of protection, whereby 
worms are killed within the host by the immune responses, not simply expelled. As 
fewer worms arrive in the intestine in a secondary infection they must be trapped or 
killed in another site earlier during their transit of the host132. Traditionally infectious 
larvae are injected subcutaneously for experimental infections124. Using a technique 
comparing subcutaneous versus intravenous injection of larvae, other researchers in this 
lab established a model for identifying the location of the protective responses354. Larvae 
injected intravenously arrive in the lung within minutes and 2 days after infection, mice 
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that have previously received a primary infection have fewer surviving larvae in the lung 
than mice being infected for the first time. Comparing the number of surviving larvae in 
primed mice 2 days after infection either intravenously (where larvae can only be killed 
in the lung) or subcutaneously (where larvae can be killed in the skin while migrating to 
the lung as well) demonstrates that between 60-80% of protective responses occur in the 
lung354. Our lab has previously found the lungs to be a critical site for priming 
protective immune responses354, so in this chapter we have focused on immune 
mechanisms within the lung that mediate larval killing. 
Th2 cells are critical to protective responses, as are the cytokines that signal through 
STAT6132. Measurement of Type 2 cytokine expression has required the use of in vitro 
restimulation355 or knock-in reporter mice31, 311, the following data utilises the 4C13R 
IL-4 and IL-13 transgenic reporter system to identify and characterise the cytokine 
producing cells in the lung during infection in an immune competent environment. 
Using this reporter mouse, I have characterised lung ILC2 activation and cytokine 
contributions during primary and secondary infections. ILC2s have roles in expulsion of 
N. brasiliensis from the gut254 and also in mediating asthmatic responses257 and healing 
following viral infection in the lungs240, but prior to this study a direct role for ILC2s in 
protective responses against larvae in the lung has not been established. ILC2s act as 
sensors of barrier damage, responding to cytokines including TSLP338 and IL-33253 
released by injured epithelial cells356. IL-33 has also been shown to have a role in 
protective responses against N. brasiliensis with IL-33-/- mice having decreased protection 
against a secondary infection leading to greater numbers of larvae reaching the 
intestine353. This chapter assesses the roles of ILC2s in secondary infection and also in 
naïve mice treated with ILC2 stimulatory cytokines prior to infection.  
ILC2s have also been shown to interact with CD4+ T cells in several different ways. 
Both ILC2254 and ILC3357 populations express low levels of MHC II. Antigen 
dependent interactions between ILC3s and CD4+ T cell have been demonstrated to 
suppress CD4+ T cell responses due to the lack of co-stimulatory factors on the ILC3s357. 
ILC2s have been shown to support the generation of Th2 responses in response to N. 
brasiliensis infection and Th2 differentiation and proliferation in vitro358. ILC2s strongly 
respond to IL-2265, which largely derives from activated T cells. In this study we have 
assessed the interactions between CD4+ T cells and ILC2 responses in the lung during 
N. brasiliensis infection. 
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6.1.1 Aims 
I investigated how different immune cell populations contribute to trapping and killing 
of the N. brasiliensis larvae during the lung infectious phase. The responses of CD4+ T 
cells and ILC2s were analysed and the roles of Type 2 cytokines in activating lung 
macrophages, which are critically required for protection against the parasite, assessed. 
Specifically these experiments aimed to: 
• Identify innate lymphoid cells of the lung and characterise the IL-13 producing 
cells during a secondary infection. 
• Compare IL-13 production by ILC2s and CD4+ T cells and compare the 
contribution to protection by IL-4 and IL-13. 
• Measure CD4+ T cell roles in protection against reinfection and interactions 
with ILC2s 
• Test the ability of treatment with different cytokines to induce protective 
immune responses without priming or in secondary infection in the absence of 
CD4+ T cells.  
6.2 Results 
6.2.1 ILC2s contribute to IL-13 production in the lung during N. 
brasiliensis infection 
4C13R reporter mice were infected via i.v. injection with N. brasiliensis to assess cytokine 
expression by immune cells within the lung. As expected from previous reports, CD4+ 
T cells were significant producers of IL-13 but a population of CD3- CD4- cells 
expressing the IL-13 reporter DS-Red could also detected (Figure 6.1a). Based upon 
observations with skin resident dILCs expressing IL-13, I designed a staining panel to 
allow identification of ILC2s in the lung and assess their contribution to cytokine 
production (Figure 6.1b). By gating on CD45+ CD11b- CD3- NK1.1- B220- CD2+ 
CD90+ CD25+ a distinct population in the lung was identified. The majority of these 
cells express the ILC2 associated transcription factor GATA3 and the IL-33 receptor 
T1-ST2. Furthermore a small proportion of these cells expressed DS-Red, reporting IL-
13 production in the lung of naïve 4C13R mice similar, though to a lesser extent, to 
what had been seen from dILCs in the skin (Figure 6.1b).   
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Figure 6.1 - N. brasiliensis responsive DS-Red+ non-CD4 lymphoid cells in the 
lung are ILC2s.  
a. Identification of CD3-CD4- DS-Red expressing cells from the lung in primary and secondary 
N. brasiliensis infection. DS-Red gating based on WT cells. Plots are representative of multiple 
experiments. b. Gating scheme for identifying innate lymphoid cells from the lung, cells are 
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CD45+, CD3-. CD11b-, NK1.1-, B220-, CD25+, CD90+. Expression of GATA3, ST2 and DS-
Red by ILC2s from naïve mice is shown. 
 
STAT6 signalling is known to be important for providing protection during 
reinfection132, however the contribution of IL-13 to the protective immune responses 
has not been assessed. To begin I identified the major IL-13 producing populations in 
the lungs during the secondary infection. Cells were isolated from the digested lungs of 
4C13R mice 2 days after their secondary infection, and panels were designed 
specifically to minimise the background fluorescence in the DS-Red channel, allowing 
sensitive identification of basophils, ILC2s, CD4 and CD8 T cells, neutrophils and 
eosinophils by flow cytometry. Live cells were selected for and then gates encompassing 
all lung cells expressing DS-Red with a higher fluorescence than the background of an 
infected non-transgenic mouse were set (Figure 6.2a). Then the cell populations that 
made up the reporter positive population were determined. Approximately 40% of the 
IL-13 reporting cells were CD4+ T cells, 15% basophils and 25% ILC2s (Figure 6.2b). 
Via this gating method about 20% of the DS-Red positive cells were unaccounted for. 
This process was repeated for IL-4 reporter positive cells and I found that basophils 
made up the largest population of IL-4 expressing cells (~32%), followed by CD4+ T 
cells (~21%) and eosinophils (~9%) (Figure 6.2b). This was inconsistent with previous 
reports that at day 6 of infection, greater numbers of CD4+ T cells were producing IL-4 
than basophils in the secondary responses331, however the differences may be due to the 
earlier time point of day 2 post infection assessed here. Some of the ILC2s expressed IL-
4, (3% of the ILC2 population) although a small proportion, this did indicate the 
potential of ILC2s to make IL-4 under some conditions (Figure 6.2b). 
Concomitant experiments performed in our laboratory by Dr. Tiffany Bouchery 
addressed the role of lung macrophages in protecting against secondary infection. It was 
found that lung macrophages take on an alternately activated (M2) phenotype in a 
secondary infection, characterised by expression of Arginase and resistin-like molecule 
alpha (Relm-α) and the phosphorylation of STAT6354. To assess the sufficiency of M2 
macrophages to provide protection, bone marrow derived macrophages were cultured 
and pulsed overnight with IL-4 to drive an M2 phenotype. These cells were adoptively 
transferred intranasally delivering them to the lungs of naïve mice; these mice were then 
challenged with N. brasiliensis and the numbers of larvae in the lung were enumerated 2 
days post infection. It was found that adoptive transfer of M2 macrophages was enough 
 168
to induce protection, though transfer of LPS primed macrophages did not affect lung 
larvae numbers354.  
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Figure 6.2 - CD4+ T cells and ILC2s are the majority IL-13 producing cells during 
secondary infection.  
a. 4C13R mice were infected via i.v. with N. brasiliensis, and then reinfected 30 days later. 2 days 
after secondary infection lungs were harvested and digested and stained with a range of panels 
to identify immune cells producing IL-13 as reported by DS-Red. Total live cells were identified 
then all the DS-Red+ cells were gated on, gates based upon infected non-transgenic lung cells. 
From the DS-Red+ population; CD45mid CD200R3+, identified basophils, ILC2s by lineage- 
CD90+ CD25+, T cells as CD90+ CD3+ and CD4+ or CD8+. b. The composition of DS-Red+ 
and AmCyan+ cells in the lungs of secondary infected mice. Cells were gated as per a. and then 
the proportion that each cell type contributed to the reporter positive population was calculated. 
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Eosinophils were defined as Siglec F+ CD11c- SSChi and neutrophils as Ly6Chi Gr1hi. Bar graph 
shows a representative sample. Data is representative of greater than five independent 
experiments. 
 
We hypothesised that both IL-4 and IL-13 in the lungs are able to induce M2 activation 
of macrophages by signalling through STAT6 and these macrophages were providing 
protection through either direct or indirect mechanisms. To test the relative 
contribution of IL-4 and IL-13 an IL-13R blocking antibody was generously provided 
by AbbVie and used to treat WT and IL-4 deficient (GFP/GFP) mice a week before, 
and during the secondary infection. WT and IL-4 deficient mice had equal numbers of 
larvae at 2 days post primary infection, and there was no significant difference between 
the WT and IL-4 deficient mice 2 days post secondary infection (Figure 6.3a). Although 
not significant, there was a slight trend towards reduced protection in the IL-4 deficient 
mice. αIL-13R antibody treatment also made no difference to the larval number in 
secondary infected WT mice. Treatment of IL-4 deficient mice with αIL-13R antibody 
totally abrogated protection with these mice having the same number of larvae in the 
lung as primary infected mice.  
Through these experiments we have discovered that the STAT6 dependent protection 
against N. brasiliensis infection in the lung has redundancy. Single blockade of IL-4 or 
IL-13 signalling does not affect protection, however simultaneous blocking of both IL-4 
and IL-13 signalling led to total loss of protective mechanisms.  
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Figure 6.3 – Requirement for IL-4 or IL-13 signalling to maintain protection.  
a. Numbers of larvae recovered from digested whole lungs from wild type and IL-4 deficient 
mice 2 days after either primary infection or secondary infection with or without treatment with 
αIL-13 antibody the week preceding secondary challenge. Graph shows mean ± S.E.M. in each 
group. Data are from a single experiment. Statistics were calculated for each group using One 
way ANOVA with Bonferroni multiple comparisons post test ** P < 0.01 ns = not significant. 
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6.2.2 CD4+ T cells support ILC2 responses in secondary N. 
brasiliensis infection 
 The IL-4 producing cells in secondary infected lungs have been identified and their 
roles well characterised331, similarly the roles of IL-13 in gut expulsion181, 198, 359, 
however the contributions of IL-13 to protective responses in the lung has not been well 
studied. With recent publications indicating that ILC2s and CD4+ T cells interact, and 
that ILC2s may be critical for Th2 cell differentiation and activation358, I wished to 
measure the kinetics of the responses by these cell populations and their potential 
interactions. 
Initially the early responses of CD4+ T cell and ILC2s were assessed, the kinetics of 
cellular activation were measured during a time course between 24 hours and 48 hours 
post primary infection. The numbers of each of these cell types did not alter 
dramatically over the time course (Figure 6.4a). The proportions (Figure 6.4b) and 
numbers (Figure 6.4c) of DS-Red expressing ILC2s were consistently greater than IL-13 
reporter positive CD4+ T cells indicating that ILC2s were activated earlier than T cells 
in response to N. brasiliensis infection.  
As greater numbers of DS-Red+ ILC2s than IL-13 reporting CD4+ T cells were 
measured at 2 days after primary infection I compared their numbers 2 days after 
secondary infection and 30 days after a primary infection (primed). Very few DS-Red+ 
ILC2s or CD4+ T cells were found in the primed lungs, with a significant decrease in 
the number of IL-13 reporting ILC2s from 2 days post primary (Figure 6.4d). The lack 
of difference between primary and primed DS-Red expressing CD4+ T cells is likely 
explained by their cytokine response beginning and resolving between day 2 and day 30. 
In secondary infection both ILC2 and CD4+ T cell DS-Red responses were expanded, 
similar numbers of DS-Red+ cells from each of these populations were enumerated in 
the lungs. So based on these results, ILC2s respond faster than CD4+ T cells in the 
primary infection, the IL-13 reporting by both populations resolves by day 30 post 
primary infection but 2 days after secondary infection they respond quickly with equal 
numbers of DS-Red+ ILC2s and CD4+ T cells.    
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Figure 6.4 – ILC2s respond quickly to a primary N. brasiliensis infection and 
match T cell IL-13 responses in a secondary infection.  
a. total number , b. proportion expressing DS-Red and c. number of DS-Red expressing  
ILC2s and CD4+ T cells from digested whole lungs between 24 and 48 hours post primary i.v. 
N. brasiliensis infection. Graphs show mean ± S.E.M, n=3 in each group. Data is from 2 
independent experiments. d. Numbers of DS-Red expressing ILC2s and CD4+ T cell from 
digested whole lungs from mice 2 days after primary infection, 30 days post-primary (primed) 
and 2 days after secondary infection. Bar graphs show mean ± S.E.M, n=3 in each group. Data 
is from a 2 independent experiments. 
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CD4+ T cells are critically important for optimal protection, with mice that are deficient 
in CD4+ T cells such as MHC class II-/- having significantly reduced levels of 
protection132. To measure the importance of CD4+ T cells at different phases of 
infection, we used GK1.5 antibody to deplete CD4+ T cells prior to primary and 
secondary infection. The effectiveness of the antibody was tested and found that CD4+ 
T cells in the lung are totally depleted 24 hours after i.p. injection and a single 0.5mg 
injection was sufficient to maintain depletion for at least 3 days (Figure 8.2). Using this 
depletion technique the importance of CD4+ T cell for both priming and during the 
active protection phase could be assessed. CD4+ T cells were depleted 1 day prior to 
primary infection then the number of lung larvae 2 days after the secondary infection 
were compared to undepleted mice. CD4+ T cell depletion during primary infection did 
affect the number of surviving larvae in a secondary exposure with a significant increase 
in larval number compared with normal secondary infection (Figure 6.5a). However 
CD4+ T cells depleted 1 day before secondary infection found that there was no 
difference in protection, with normal low levels of larvae recovered from the depleted 
lungs. From this data it was evident that CD4+ T cells had a role in priming the 
protective responses, with their transient depletion during primary infection leading to 
sub-optimal protection in a secondary. However we found they were not required 
during the protective response, as their depletion just prior to reinfection had no effect 
on the number of recovered larvae. 
Another depletion method was trialled where CD4+ T cells were depleted a week before 
the secondary infection. To maintain the depletion a 0.5mg injection of GK1.5 
antibody was given 7 days before the secondary infection then a booster injection at day 
3 prior to infection, this regime ensured CD4+ T cell depletion was maintained in lung 
until 2 days post infection. Mice depleted for the week before secondary infection had 
an entire reversal of protection with high larval numbers equal to counts from primary 
infected mice (Figure 6.5a). So while the presence of CD4+ T cells during the secondary 
infection were not required for protection they do have a role in maintaining the 
protective environment, with a sustained absence leading to a loss of the protective 
responses they support.  
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Figure 6.5 – CD4 T cells are required for long term protection but are not effector 
cells of the immune response.  
a. Number of N. brasiliensis larvae in the lungs of mice 2 days post primary i.v. infection 
(Primary) and i.v. reinfection (Secondary), or after CD4+ T cell depletion before primary 
infection (Secondary – GK1.5 during primary), and 24 hours or 7 days before secondary 
infection (Secondary GK1.5 day-1 and Secondary GK1.5 day-7 respectively). Graph shows 
mean ± S.E.M. in each group. Data are representative of 3 independent experiments. Statistics 
were calculated for each group using One way ANOVA with Bonferroni multiple comparisons 
post test * P < 0.05  **** P < 0.0001 ns = not significant. 
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An increase in ILC2 number was observed between primary and secondary infection 
(Figure 6.4b). In secondary infected mice that had their CD4+ T cells depleted for 1 
week before infection a significant decrease in ILC2 numbers was recorded (Figure 
6.6a). CD4 depletion also led to a non-significant decrease in the number of DS-Red+ 
ILC2s(Figure 6.6b) and a decrease in their expression of CD25(Figure 6.6c).  
These data highlights the responses by CD4+ T cells and ILC2s to N. brasiliensis 
infection. CD4+ T cells are slower to respond than ILC2s in a primary infection but 
both populations can be detected producing cytokines at day 2 of a secondary infection. 
We have shown that CD4+ T cells are required to set up and maintain the protective 
environment, their long-term absence leading to a total loss of protection, but they are 
not required for the active protective mechanism. ILC2 numbers, and their activation 
based on DS-Red and CD25 expression, are dependent upon CD4+ T cells, with long 
term CD4+ T cell depletion leading to decreases in ILC2 responses.  
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Figure 6.6 - Secondary ILC2 responses are decreased in the absence of CD4 T 
cells.  
Number of a. total ILC2s and b. DS-Red expressing ILC2s and c. CD25 mean fluorescent 
index (MFI) of ILC2s from the digested whole lungs 2 days after secondary i.v. infection with or 
without treatment with αCD4 antibody (GK1.5) 7 days (Day-7) preceding the secondary 
infection. Bar graphs show mean ± S.E.M. n≥4 in each group. Data are representative of two 
independent experiments. Statistics were calculated for each group using Student’s t test * P < 
0.05 ** P < 0.01 ns = not significant. 
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6.2.3 ILC2 stimulating cytokines can induce protective immune 
responses in naïve mice 
With the evidence that ILC2s were quick responders to primary infection, and that 
CD4+ T cells were required for optimum ILC2 responses in the secondary infection, we 
wanted to assess the mechanisms activating ILC2s during infection. Barrier-derived 
cytokines have been implicated in ILC2 activation in response to N. brasiliensis252, 353. 
Previous work from our lab had shown that IL-25 was not important in the protective 
immune responses360 and as the IL-33R (ST2) had been detected on the lung ILC2s, 
along with the fact that IL-33-/- mice have deficient protective responses353. The role of 
IL-33 activated ILC2s in protection was assessed. We also selected IL-2 to be tested as 
an activator of ILC2s because the ILC2s expressed the IL-2Rα (CD25) and this could 
be a potential link between activated CD4+ T cells and ILC2 maintenance358. For 
efficient in vivo treatment with IL-2, IL-2 was complexed with its cognate antibody (IL-
2c), increasing the half-life and only allowing signalling through the high affinity CD25 
inclusive receptor301, 361. Lung ILC2 responses to these cytokines were tested by treating 
4C13R mice intranasally (i.n.) with IL-33 alone, or i.p. with either IL-2 blocking 
antibody or IL-2c, and assessed numbers of, and DS-Red expression by ILC2s 24 hours 
after treatment. We found that IL-33 alone, or with IL-2 blocking antibody, did not 
affect the numbers of ILC2s in the lung within 24 hours of treatment (Figure 6.7a) 
though both treatments did lead to expansion of the percentage expressing DS-Red 
(Figure 6.7b) and thus the number of these cells too (Figure 6.7c). As has been 
demonstrated in vitro362, IL-2c and IL-33 dual treated mice had increased numbers of 
ILC2s and significantly increased proportions and numbers of IL-13 reporting ILC2s to 
a level suggesting an additive interaction between these two cytokines on ILC2 
responses. From this we found that both IL-33 and IL-2c could rapidly activate ILC2s 
and led to their increased IL-13 production. 
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Figure 6.7 - Lung ILC2s are responsive to IL-33, IL-2c and combinations of 
cytokine.  
a. Number of total ILC2s and b. proportion of DS-Red expressing ILC2s and c. numbers of 
DS-Red expressing ILC2s from the digested whole lungs of naïve WT mice or mice treated 24 
hours prior with intranasal 0.5μg IL-33 with and without αIL-2 antibody (48 hours prior to 
harvest) or IL-2/αIL-2 antibody complex (IL-2c, 72 and 24 hours prior to harvest). Bar graphs 
show mean ± S.E.M. n≥3 in each group. Data are representative of three independent 
experiments. Statistics were calculated for each group using One way ANOVA with Tukey’s 
post test * P < 0.05 ** P < 0.01 *** P < 0.001 ns = not significant. 
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To determine if IL-33 driven expansion of ILC2s would be sufficient to protect against 
N. brasiliensis a model was established where naïve mice were treated i.n. with IL-33, 2 
days later challenged i.v. with 550 L3 larvae and lung larvae numbers were enumerated 
on day 2 post infection. CD4+ T cells were also depleted from an IL-33 treated group to 
assess the requirement for CD4+ T cells. IL-33 treatment alone induced protection 
against primary infection in naïve mice and depletion of CD4+ T cells with IL-33 
enhanced this protective response (Figure 6.8a). IL-33 treatment prior to primary 
infection led to increases in ILC2 numbers, intriguingly GK1.5 treatment abrogated the 
ILC2 expansion.  
The discovery that cytokine treatment could drive protective immune responses led Dr 
Tiffany Bouchery to compare the mechanisms involved in IL-33 driven protection to 
the mechanisms that mediate protection in secondary infection. As with secondary 
infection macrophages were expanded and were also critical to IL-33 driven 
protection354. When STAT6 and IL-4 deficient mice were treated with i.n. IL-33 and 
i.p. GK1.5 the IL-4 deficient mice were protected but the STAT6-/- were not, 
indicating that this IL-33 model, like secondary infection, required STAT6 signalling 
independent of IL-4354. This indicated that as in secondary infection, in the absence of 
IL-4 IL-13 could drive protective responses. Importantly it also ruled out the possibility 
of IL-33 directly activating a population of cells, such as M2 activated macrophages, 
that could provide protection against infection. Unlike in natural secondary infection 
IL-33 treatment was able to induce protection in Rag1-/- mice. 
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Figure 6.8 - IL-33 treatment can provide protection in the absence of CD4 T cells.  
a. Number of larvae and b. number of ILC2s from lungs 2 days post-primary N. brasiliensis 
infection of untreated mice (primary) and mice treated with 0.5μg IL-33 intranasally 2 days 
before infection with and without αCD4 antibody GK1.5 at the same time as IL-33 treatment. 
a. Plots show mean ± S.E.M. of each group. Data is pooled from 4 experiments. Statistics were 
calculated for each group using One way ANOVA with Tukey’s post test * P < 0.05 **** P < 
0.0001.   b. Bar graphs show mean ± S.E.M. n≥3 in each group. Data are representative of 
three independent experiments. Statistics were calculated for each group using One way 
ANOVA with Tukey’s post test * P < 0.05 ns = not significant.  
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I repeated the IL-33 protection model but replaced i.n. IL-33 with i.p. IL-2c. 
Treatment with IL-2c was sufficient to induce protective immune responses in the 
absence of CD4+ T cells (Figure 6.9a), and also expanded ILC2 numbers (Figure 6.9b). 
IL-2c treatment also induced protection in Rag1-/- mice. To assess if ILC2s were the IL-
2 responding cells that were mediating the protective immune responses, ILC2s were 
depleted with a regime requiring multiple treatments of αCD90 antibody in Rag1-/-. 
Treatment with 0.5mg of αCD90 antibody (30H12) daily for 5 days prior to infection, 
and the day after infection was sufficient to maintain depletion until 2 days after 
infection in most mice. Worms were collect by bronchial alveolar lavage for counting 
while lung tissue was digested to assess ILC2 depletion, only worm counts were included 
from mice where ILC2 numbers were reduced below 50% of undepleted mice. When 
this depletion was applied with IL-2c treatment to Rag1-/- mice that were subsequently 
infected with N. brasiliensis, protection was reversed (Figure 6.10c). This provided strong 
evidence that ILC2 populations were sufficient to provide protection when stimulated 
by cytokine.  
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Figure 6.9 - IL-2c activated ILC2s are required for protective responses. 
 a. Number of larvae and b. number of ILC2s from lungs 2 days post-primary N. brasiliensis 
infection of untreated WT mice (primary), mice treated with GK1.5 and intranasal IL-33 
(Primary + IL-33 + GK1.5) and mice treated with GK1.5 and i.p. IL-2c (Primary + IL-2c + 
GK1.5), antibody and cytokine treatments were given 2 days prior to infection. c. number of 
ILC2s from lungs 2 days post-primary N. brasiliensis infection of untreated Rag1-/- mice 
(Primary) or Rag1-/- mice treated with IL-2c and either isotype or αCD90 antibody 2 days prior 
to infection. All plots show mean ± S.E.M. of each group. Data are representative of two 
independent experiments. Statistics were calculated for each group using One way ANOVA 
with Tukey’s post test * P < 0.05 ** P < 0.01 *** P < 0.001 **** P < 0.0001.  
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Knowing that T cell independent protection could be achieved with IL-2c treatment, 
we decided to see if cytokine treatment could rescue the protection that is lost in a 
secondary infected mouse when CD4+ T cells are depleted 7 days prior to infection. 
The CD4+ T cells were depleted as before (Figure 6.5) and the mice treated with IL-2c 
every 2 days during the depletion. IL-2c treatment rescued the protection lost with 
CD4+ T cell depletion and actually led to increased protection compared to natural 
secondary infection (Figure 6.10a). The long-term IL-2c treatment also caused massive 
expansion of the ILC2s (Figure 6.10b). 
Therefore we found that the cytokines IL-33 and IL-2c cause rapid activation and 
eventual expansion of ILC2s, and these cytokines could induce T cell independent 
protection. The IL-2c driven protection was ILC2 dependent as depletion with αDC90 
abrogated the protection. Finally IL-2c treatment caused massive expansion of ILC2s in 
secondary infected mice that had their CD4+ T cells depleted, and this treatment was 
able to restore the protection despite the long-term absence of CD4+ T cells. 
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Figure 6.10 - Treatment with IL-2c rescues protection in the absence of CD4 T 
cells.  
Number of a. larvae and b. ILC2s from the digested whole lungs 2 days after primary infection, 
secondary infection with and without treatment with αCD4 antibody (GK1.5) 7 days (Day -7) 
preceding the secondary infection and secondary infected mice that received IL-2c every 2 days 
during the 7 day CD4 depletion period. Plots show mean ± S.E.M. n=4 each group. Data are 
representative of two independent experiments. Statistics were calculated for each group using 
One way ANOVA with Tukey’s post test * P < 0.05 *** P < 0.001.    
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6.3 Discussion 
The focus of this chapter was to elucidate the immune cells, and the signalling pathways 
employed by these cells, that are critical for protection against N. brasiliensis. The results 
I have found, alongside other research within this laboratory, are the first to 
conclusively show that CD4+ T cells and ILC2s contribute to protective responses in the 
lung by maintaining M2 activation of macrophages through the production IL-4 and 
IL-13. These cells and signalling pathways collectively mediate larval arrest and killing 
within the lung354. 
IL-13 production by ILC2s has been widely reported including in the lung in models of 
allergic airways inflammation271 and even N. brasiliensis infection358. Previous hookworm 
infection studies required in vitro culture and restimulation of lung cells to identify 
cytokine producers with intracellular staining358. By using the reporter mouse system to 
detect real time cytokine production directly ex vivo I have been able to make more 
direct interpretations about cytokine production by different cell populations. 
Identification of IL-13 reporting ILC2s as early as 12 hours post infection indicates 
these cells respond much faster than CD4+ T cells during the primary infection, though 
during a secondary infection robust cytokine production by day 2 post infection 
demonstrates rapid memory response of the CD4+ T cells (Figure 6.4). ILC2s consist of 
a much smaller population of cells when compared to total CD4+ T cells in the lung. 
Their relatively small numbers compared with other immune cell populations has often 
drawn debate as to how influential they could be to an immune response, particularly 
one that involves a strong CD4+ T cell response as well. The discovery that in a 
secondary infection there are similar numbers of IL-13 producing ILC2s and CD4+ T 
cells is evidence that when compared to antigen specific cytokine responses, ILC2s can 
contribute significantly to the overall response, though it remains to be assessed the 
relative amount of cytokine produced per cell from each of these populations. 
CD4+ T cells are required for optimal immunity, and adoptive transfer of CD4+ T cells 
from the lung of a previously infected host can convey protection354. In this study I have 
demonstrated a more nuanced role for these cells in protective responses. These data 
indicate that CD4+ T cells are not required for effector functions against the larvae as 
protection is maintained when CD4+ T cells are depleted only one day before infection. 
However, the importance of CD4+ T cells is exemplified by the loss of protection with 
longer term (seven day) depletion, indicating that CD4+ T cells are critical for 
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maintaining other effector cell populations capable of dealing with the invading 
parasites such as M2 macrophages. 
Seven day depletion of CD4+ T cells also resulted in decreased numbers of ILC2 and 
decreased IL-13 reporting ILC2s during secondary infection. Based on this evidence 
CD4+ T cells positively influence lung ILC2 responses in vivo. While it has been shown 
that ILC2s and CD4+ T cells can communicate through MHC II – TCR interaction, 
previous in vivo studies focussed on the effects of these interactions on the CD4+ T cell358. 
However it has been noted that adoptive transfer of MHC II-/- ILC2s leads to 
diminished expulsion of N. brasiliensis from the gut compared to transfer of WT ILC2s in 
a model where these ILC2s are the only IL-13 expressing cell type363. This study does 
not directly identify the nature of the CD4+ T cell ILC2 interaction within the lung but 
establishes a clear relationship whereby CD4+ T cells support ILC2, as well as M2 
macrophage responses. This may also explain why ILC2s cannot maintain M2 
macrophage phenotype in the absence of CD4+ T cells, as the ILC2s themselves are 
also missing a maintenance signal. Addition of IL-2c to the CD4+ T cell depleted mice 
rescued (actually expanded) ILC2 numbers and cytokine production, which led to 
maintenance of M2 macrophages and protective responses. IL-2 is released by activated 
T cells and is a potential communication signal between CD4+ T cells and ILC2s. It has 
been shown in vitro CD4 T cell derived IL-2 can activate ILC2s inducing strong 
cytokine production, however in these studies, a proliferative response from the ILC2s 
was not observed,. This may be due to limited amounts of IL-2 produced by CD4+ T 
cells, or the lack of a proliferation promoting accessory signal that is present in vivo363. A 
recently published paper has identified a population of lung resident ILC1s or ILC3s as 
a potential source of IL-2364, the responses of these cells during N. brasiliensis infection 
remain to be assessed but these cells could also be contributing to the activation of 
ILC2s through the production of IL-2. 
ILC2s in the absence of CD4+ T cells could not provide protection in a natural 
immunity setting, though when sufficiently stimulated with the cytokines IL-33 or IL-2, 
protective responses could be established in a T cell independent manner. It is of 
interest that protective responses established by IL-33 treatment were more efficient in 
the absence of CD4+ T cells.  Tregs have been shown to respond to IL-33365 and could 
potentially have an effect of diminishing protective immune responses, however a single 
observation using FoxP3-GFP reporter mice to identify Tregs demonstrated no 
significant increase of Tregs with IL-33 treatment (unpublished data). IL-33 has also 
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been implicated in driving a M2 macrophage phenotype directly366, however as the IL-
33 protective response required STAT6 signalling this ruled out the possibility of IL-33 
bypassing the IL-13 producing ILC2s and directly activating macrophages. As I had 
previously found in the skin, there were significant difficulties depleting ILC2s from the 
lung via antibody depletion methods; using the IL-33 model antibody treatment never 
established depletion of ILC2s to a level where their requirement for the IL-33 induced 
protection could be assessed.  
IL-33 is required for optimal ILC2 IL-13 expression in response to N. brasiliensis 
infection353, so it was expected that treatment with IL-33 would induce strong IL-13 
expression by the lung ILC2s. IL-33 has been shown to be required for secondary 
responses as well, however larvae counts were taken from the intestines so from these 
data it was unknown whether IL-33 was required for gut expulsion or protective 
responses earlier in the transit of the host353. While I haven’t been able to assess if IL-33 
is required, I have demonstrated that lung administration of IL-33 is sufficient to induce 
protective responses. Not only was IL-2c treatment able to stimulate ILC2 responses in 
the absence of CD4+ T cells and maintain protection in a secondary infection, IL-2c 
also stimulated protective immune responses in naïve mice in a T cell independent way. 
Unlike the IL-33 model, antibody depletion of ILC2s could be achieved with the IL-2c 
treatment, allowing the requirement of ILC2s in this model to be shown. This study is 
the first to demonstrate that ILC2s in the lung are sufficient to mediate protective 
responses against N. brasiliensis infection. 
A paper published during the course of this project came to similar conclusions 
regarding the role of IL-13 and M2 macrophages in protective responses, however this 
paper attributed the cellular source of IL-13 to neutrophils367. Ly6G targeting antibody 
depletion led to diminished M2 macrophage activation and protective responses, and 
neutrophils sorted from N. brasiliensis infected hosts had mRNA signals for IL-13 
expression. Co-culture of neutrophils from N. brasiliensis infected donors caused 
macrophages to display M2 characteristics, which could be blocked with the 
administration of IL-13 blocking antibodies367. Experiments performed by Dr Tiffany 
Bouchery in our lab have found that depletion with an antibody with a broader 
specificity, Ly6C/Ly6G specific Gr1 clone, had no effect on protective responses in this 
i.v. model of infection354. Furthermore I have not detected IL-13 reporting from 
neutrophils or any SSChi population in these experiments (data not shown). Depletion 
of neutrophils does affect protective responses when reinfection is administered 
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subcutaneously only 4 days after primary infection. In this model it is conceivable that 
rapidly recruited neutrophils play a role in protective responses in the skin354. Why such 
different requirements for neutrophils have been demonstrated between our study and 
the one carried out by Chen et al. remains unknown. 
Through adoptive transfer and depletion experiments run concomitantly with my work 
it was shown that M2 macrophages are both sufficient and required for protection 
against N. brasiliensis infection within the lung354. Macrophages initiate the M2 
programme after exposure to either IL-4 or IL-13; they express the IL-4Rα, IL-13RαI 
and cγ chains so are able to respond through both receptor complexes185, 368, 369. 
Through the production of IL-4 and IL-13 CD4+ T cells and ILC2s support M2 
macrophage generation and maintenance within the lung post infection, sustaining the 
M2 phenotype to protect from future parasitic infections. IL-4 deficient mice treated 
with αIL-13 antibody lost protection against reinfection indicating that these cytokines 
were the STAT6 dependent signal that drove protection. However the fact that both 
IL-4 deficient mice, and αIL-13 treated WT mice were protected in a secondary 
infection demonstrated strong redundancy in the system and, that the presence of either 
of these cytokines could sufficiently maintain M2 macrophage activation and the 
protective response. So while mechanisms exist for differentially regulating the 
expression of IL-4 and IL-13 in some cases their functions significantly overlap to the 
point that they are completely redundant, only when signalling by both cytokines is 
inhibited are the effects of their depletion observed.  
 
6.4 Conclusions 
I aimed to identify the key cells and signalling pathways that provide protection against 
reinfection by N. brasiliensis. M2 macrophages are both sufficient and required to 
provide protection and the phenotype of these cells is maintained by IL-4 and IL-13 
signalling, which CD4+ T cells and ILC2s are major producers of. There is almost 
complete redundancy in the protective responses maintained by IL-4 and IL-13. 
Depletion studies found that while CD4+ T cells were not effector cells they were critical 
for sustaining the long term protective environment by maintaining M2 macrophages. 
Although ILC2s expressed IL-13 they were not able to sustain protective responses in 
the absence of CD4+ T cells, this was partly due to the fact that their numbers and 
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activation were also diminished upon CD4+ T cell depletion, possibly due to a lack of 
IL-2 signalling. Exogenous IL-2 expanded ILC2s to a level where they could sustain M2 
macrophages and rescue protection in the absence of CD4+ T cells. IL-2 activation of 
ILC2s was also shown to be sufficient for protection in naïve mice, and IL-33 treatment 
similarly activated ILC2s and produced protective immune responses. This study 
demonstrated that IL-33 and CD4+ T cells, possibly through IL-2, support ILC2 
responses in the lung, and together Type 2 cytokine producing ILC2s and CD4+ T cells 
types maintain M2 activation of macrophages that mediate protection against N. 
brasiliensis reinfection. 
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7 General Discussion 
The purpose of the research outlined in this thesis was to increase our understanding of 
how the production of two key Type 2 cytokines, IL-4 and IL-13, are regulated by both 
CD4+ T cells and Type 2 associated innate cell populations. These mechanisms have 
been investigated by utilising a novel transgenic dual reporter mouse in the context of in 
vivo models of skin inflammation and parasitic infection, as well as in vitro culture. 
Specifically I sought to understand the role of TCR signalling on the allelic expression 
of IL-4, and for the first time independently assess the impact of IL-4 on CD4+ T cell 
IL-4 expression in vivo. I compared the mechanisms that control IL-13 expression by 
CD4+ T cells with those that control IL-4 expression. The expression of IL-4 and IL-13 
by basophils and a novel population of dermal ILCs was assessed in a model of atopic 
dermatitis. Finally I characterised the roles of Type 2 cytokine producing lymphoid 
populations in the lung in protection against infection by N. brasiliensis. The results of 
this study have highlighted significant differences in the mechanisms that regulate the 
expression of IL-4 and IL13; the following chapter will discuss the impacts of my 
findings in the context of the current literature. 
7.1.1 The allelic expression of IL-4 is controlled by multiple 
factors 
Cytokines including IL-2, IL-4 and IFN-γ have dose dependent effects when stimulating 
immune cells47, 222. The immune system must accurately regulate the amounts of these 
cytokines produced in vivo to limit negative consequences such as the inappropriate 
generation of IgE antibodies370. It has been suggested that stochastic mono-allelic 
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expression is an effective way for the immune system to limit the total amount of a 
cytokine that is produced, rather than modulating the amount produced by each 
individual cell371. It has been found that in strong Th2 optimising conditions only a 
small proportion of CD4+ T cells actually express IL-4, with a ~100 fold increase in Il4 
mRNA between IL-4 expressing and non-producing cells, despite their being similar 
GATA3 expression across the whole population372. The exact mechanisms which 
determine if, and from which combination of alleles, a CD4+ T cell will express IL-4 
remain unknown. The accessibility of the IL-4 allele has been suggested as a potential 
method for allelic regulation372. The results I have generated are in agreement with 
previous work from Guo et al. where by restimulation of cells can lead to reassignment 
of which IL-4 allele may be expressed by CD4+ T cells (Figure 3.7). This data indicates 
that it is unlikely to be epigenetic modulation that silences alleles in recently 
differentiated mono-allelically expressing cells. If epigenetic mechanisms were in effect it 
would be expected that daughter cells would maintain their allelic phenotypes during 
successive replication cycles, as has been seen with some mono-allelically expressed 
genes controlled epigenetically by clones of neural progenitor cells373. These data also 
refute the theory that bi-allelically expressing cells represent the more terminally 
differentiated Th2 effector cells. Sorted CD4+ T cells expressing both IL-4 alleles had 
the same pattern of mono- and bi-allelic cells upon restimulation as CD4+ T cells 
expressing mono-allelically or not expressing IL-4 at the time of sorting. This shows that 
at least in terms of their IL-4 expression even bi-allelically reporting cells remain plastic 
for a while after differentiation. 
Accessibility to DNaseI hypersensitivity sites HS-I and HS-III within the Il4 gene have 
been observed in both IL-4 producing and non-producing cells374, however only IL-4 
producing cells display increased accessibility to the HS-VA site 3’ to the 4th exon of the 
Il4 gene216. HS-VA has four binding domains for GATA3 and it has been proposed that 
binding of GATA3 to this site may be the stochastic event that determines IL-4 
expression371. While not measured in this thesis GATA3 stabilisation may explain the 
observed increase in bi-allelic expression with increasing TCR activation (Figure 3.5). It 
has been shown that TCR signalling stabilizes GATA3 expression partly through 
promoting Gfi1, which is down stream of the MAPK signalling cascade375, 376. Both IL-
4 and IL-13 are expressed allelically and it has been shown that there is no co-
ordination of expression between an IL-4 allele and the IL-13 allele on the same 
chromosome. However the conserved noncoding sequence 1 (CNS1) on the same 
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chromosome must be open, access is mediated by histone 3 acetylation, to permit 
expression of either cytokine. GATA3 has been shown to mediate access to the CNS1 
site and this may be another site via which increased levels of GATA3 can modulate the 
chance of bi-allelic expression.226 So with increasing level of TCR signalling there 
should be increased stabilisation and availability of GATA3, which potentially could 
mediate bi-allelic expression. It remains to be shown if bi-allelically positive cells have 
higher GATA3 levels or if modulating GATA3 availability effects the proportion of Th2 
cells expressing bi-allelically. 
The data I have generated agree with past observations that IL-4 expression is a 
stochastic process with a low probability of occurring within a given cell. When it does 
occur the majority of the time only one allele is expressed although there is consistently 
a population that express bi-allelically (Figure 3.3). The foremost theory on why IL-4 is 
under such control is that it fine-tunes the number of IL-4 expressing cells is more 
efficient than regulating the amount of IL-4 produced by every cell. Having the chance 
of a cell actually expressing IL-4 very low ensures that only few cells will be expressing it 
at any one time. This can be altered by variables including, exposure to cytokines, 
differential TCR engagement and co-stimulation. This theory however does not explain 
the role for bi-allelically producing cells. It is possible that these cells represent the 
population of cells that can express simultaneously both alleles through random chance, 
and that the factors that generally affect the number of IL-4 expressing cells also 
increase the possibility of any given cell expressing from both alleles. In argument 
against this theory are the observations from past members of this lab that bi-allelically 
expressing cells also express higher levels of activation-associated molecules 
(unpublished data – Helen Mearns). This could be interpreted to mean that the bi-
allelically expressing cells are a population of super-activated Th2 cells. It is possible 
that rather than random chance, bi-allelism can be induced by a particular combination 
of stimulatory signals, this theory is further supported by the observation that bi-
allelically producing cells are more likely to express the markers of Tfh cells in the 
reactive LN than mono-allelic cells (unpublished data – Helen Mearns). This makes it 
tempting to infer that signals that promote Tfh differentiation may also drive bi-allelic 
expression, however the Tfh master transcription factor Bcl-6 is known to inhibit 
expression of GATA3323 potentially conflicting with my earlier hypothesis that 
increased GATA3 could stabilise bi-allelic expression of IL-4. It remains unknown if bi-
allelic cells represent a differently activated population, and if this population has 
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specified roles in vivo, or if they are just cells which have initiated transcription from both 
IL-4 alleles by chance. Future work identifying extracellular markers of bi-allelic 
producing cells, or using multiple transgenic reporter systems will hopefully bring light 
to these questions. 
7.1.2 Transgenic reporter constructs are under similar 
regulation as parental alleles 
Reporter mice allow efficient identification, in real time, of cells expressing a protein of 
interest, however there are many caveats that have to been considered when 
interpreting data using these systems particularly if the protein is under allelic control. 
Many factors can affect the results garnered using these systems including; sensitivity of 
reporter detection, half life of the reporter, how insertion of the reporter has effected 
regulatory elements within the gene, and as seen with the huCD2 reporter mouse, the 
potential for non-specific transfer of reporter to other cells. However when these factors 
are considered and controlled for reporter mice can provide important information 
about the regulation of gene expression. 
Genes like Il4 are under such strong regulation, with few cells expressing the protein 
and of those the majority only expressing from one allele, therefore using heterozygous 
knock-in reporter mice leads to decreased numbers of cells expressing WT IL-4, and 
thus decreased the amount of IL-4 available to drive Type 2 immune responses. It was 
hoped that transgenic reporter mice might allow reporting while maintaining WT 
expression of the parental alleles, and potentially marking every cell that was producing 
IL-4. Unfortunately I discovered that despite probably being located in a random site 
outside of the Th2 locus, the transgenic IL-4 reporter remains under allelic control 
(Figure 3.8), meaning that it’s presence has a slight, non-significant effect on WT IL-4 
production. More importantly only a subset of IL-4 producing Th2 cells were marked 
by reporter. This phenomenon was exploited to assess some of the properties of allelic 
regulation, specifically that bi-allelically expressing cells have an increased propensity to 
express from a third allele (Figure 3.9). From this I inferred that these cells have an 
excess of factors that allow bi-allelic expression. While the allelic expression by the 
transgenic reporter has had its uses it means that quantification of IL-4 reporting cells 
will likely significantly underestimate the true number of IL-4 producing Th2 cells, as 
many of these will be expressing of the WT IL-4 alleles rather than the transgenic 
reporter. Even with this limitation the 4C13R reporter mouse is still an effective tool for 
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identifying which population of cells are expressing IL-4 or IL-13 and measuring 
proportional changes within these populations during Type 2 inflammation where close 
to WT cytokine is available to support the total response. 
7.1.3 Th2 IL-4 expression is independent of IL-4 signalling in 
vivo 
By using a transgenic reporter as an independent read out of IL-4 expression I was able 
to show that IL-4 expressing Th2 cells do not require IL-4 signalling for either their 
generation or later expansion within the LN (Figure 3.10). This further characterises IL-
4 as an effector cytokine of the Type 2 immune response rather than a differentiation 
driving cytokine as it has been thought of for decades. It also brings into question the 
role for LN basophils in the induction of Th2 immunity. The discovery that basophils 
can migrate to the reactive LN, express IL-4 and present antigen led to the theory that 
they may be what provides the initiating signal for Th2 differentiation377. As discussed 
in chapter 4 there are a range of conflicting publications showing that basophils are 
both important and not required for optimal Th2 responses. The limited role for IL-4 I 
have shown in this thesis somewhat diminishes their potential importance in generating 
Th2 responses. Both basophil numbers and their level of MHC II expression are 
significantly lower than B cells or DCs within the LN346, decreasing the chance of them 
presenting antigen to a cognate CD4+ T cell. While it is possible that basophil IL-4 may 
support early B cell responses, particularly as trending increases in basophils could be 
seen within the LN as early as day 4 of MC903 treatment, this link remains to be shown. 
Specific depletion experiments will provide light on the role of basophils in activating 
lymphoid cells within the LN. 
IL-4 did not appear to directly affect Th2 cells, however it may be important in 
suppressing other CD4+ T cell responses. The increased proportion of IL-4 reporting 
cells in IL-4 WT mice indicated the absence of IL-4 allowed expansion of other Th 
subsets. This correlates with results observed using IL-4Rα-/- mice where increased 
levels of T-bet mRNA are detected in the LN of IL-4 signalling deficient mice. The role 
of IL-4 in limiting the expansion of other CD4+ T cell subsets may be important in 
regulating downstream mixed or non-Type` 2 effector functions, as IL-4Rα-/- mice 
displayed increased mRNA for IgG2a isotype antibodies.83 
IL-13 is not expressed within the LN of mice (Figure 4.8) so utilising the pTh2 assay did 
not provide any data on the effect of partial or complete IL-4 deficiency on the 
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induction of CD4+ T cell IL-13 expression. IL-4 signalling increases the level of 
GATA3 expressed by the newly differentiated Th2 cells212, and with IL-13’s reliance 
upon high GATA384 for expression it would be expected that IL-4 availability would 
support IL-13 expression. IL-13 function can be observed in IL-4 or IL-4Rα deficient 
(genetically or antibody depleted) mice in models of allergic asthma355, pulmonary 
cryptococcosis378 and intestinal helminth expulsion156, though these responses are 
diminished, indicating that while IL-4 is not required for IL-13 it may play a role in 
optimal expression. My finding in this thesis that IL-4 deficient mice were still protected 
from N. brasiliensis infection in a IL-13 dependent manner also showed that sufficient IL-
13 expression to provide protection can be achieved in the absence of IL-4, though the 
source of this IL-13 was not assessed (Figure 6.3). Utilising the mice designed in this 
thesis with IL-13 reporting from a transgenic reporter construct crossed to IL-4 WT, 
heterozygous and deficient strains it will be possible to assess the role of IL-4 sufficiency 
to the expression of tissue IL-13 by CD4+ T cells. 
7.1.4 The expression of IL-4 and IL-13 is differentially regulated 
The 4C13R transgenic reporter mice allowed careful observation of the expression of 
IL-4 and IL-13 without the requirement of restimulation or intracellular staining, which 
led to the observation of consistently delayed expression of IL-13 after IL-4 (Figure 4.1). 
This along with the observations that APC stimulated CD4+ T cells in Th2 inducing 
conditions require multiple rounds of activation for IL-13 reporting, and the differential 
expression of IL-13 between LN and lung, led me to make several inferences on the 
regulation of IL-13 expression. There is little biological reason for IL-13 to be expressed 
within the mouse LN. The vast majority of cells within the mouse LN are T cells and B 
cells, which mostly have been shown to not express the IL-13RαI so cannot respond to 
IL-13179. Other than lymphocytes there are resident and migratory DC populations as 
well as sub-capsular macrophages, cells that can express the IL-13Rα1, but also the IL-
4Rα and the γc chain379, 380, so would also be able to respond to the IL-4 expressed by 
Th2 and Tfh cells within the LN81. So even the few cells that could respond to IL-13 
within the LN could just as likely respond to IL-4 via the higher affinity IL-4 receptor 
complex, so there appears to be little role for IL-13 within the murine LN. 
Conservation of IL-13 expression by Th2 cells until within the peripheral tissue is 
consistent with IL-13 mediating its effects in the tissue, not the LN, but the mechanisms 
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that eventually allow IL-13 expression are remain unclear. Multiple or sustained 
stimulations through the TCR in vitro are required (Figure 4.4 and Figure 4.6) and this 
may give hints to the in vivo situation as well. It is tempting to interpret this as indicative 
that Th2 cells receive a primary stimulation within the LN, enough to activate them 
and potentially turn on IL-4 expression; they then migrate to tissue sites where local 
APCs present antigen, providing a second restimulation and allowing IL-13 expression. 
Imaging studies refute the likelihood of this model though, with CD4 T cells 
demonstrated to have multiple interactions with DCs of varying durations within the 
LN over the first 3 days of stimulation381, so it is unlikely to be simply the number or 
length of stimulations that limits LN IL-13 expression.  
The DC phenotype may also be very important at inducing IL-13 expression from Th2 
activated CD4+ T cells. In the in vitro model, I used splenic CD11c expressing cells from 
naïve mice as the APCs to both activate and restimulate at day 3. It is plausible that the 
DCs presenting antigen within the reactive LN are phenotypically different to APCs 
within the tissue or naïve LN382, and the differences in cytokine production and co-
stimulatory molecule expression may limit LN DCs ability to induce IL-13 expression. 
As any potential IL-13 inducing signal that Th2 cells could receive from APCs within 
the tissue is probably absent in the enriched CD4+ T cell Th2 cultures, it is unlikely that 
tissue APCs are actively promoting IL-13 expression. The fact that the αCD3 
stimulation eventually induces IL-13 suggests that LN APCs, or something about the 
LN environment, may actively suppress IL-13 expression by the CD4+ T cells. This 
effect can be partially overcome with FTY720 treatment, which increases the 
proportion and number of IL-13 reporting CD4+ T cells in the LN but it remains to be 
found what is causing this increase of IL-13 reporting. Use of activated APCs or DCs 
from reactive LN in the in vitro model may indicate if it is a signal from the LN APC that 
is inhibiting IL-13 expression.  
The delay in IL-13 expression may be a CD4+ T cell intrinsic timing mechanism that 
inhibits IL-13 until a sufficient amount of time has progressed. For this to be true cells 
must have a way to measure time. One available mechanism is counting cycles of cell 
division. It has been previously shown that CD4+ T cell production of IL-2, IL-4 and 
IFN-γ expression is differentially regulated in terms of timing, which depends partially 
upon number of cell divisions383. Bird et al. demonstrated that cells stimulated without a 
polarising influence (αCD3 + αCD28 + IL-2) IL-2 production could be detected after 
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one day of activation before any proliferation of the cells; IFN-γ could be detected on 
day 2 in both undivided and proliferated cells, and it took at least 3 days and 4 divisions 
for cells to express IL-4. The regulation was dependent upon epigenetic changes at the 
cytokine gene loci that occurred with successive proliferation cycles. Drugs that 
increased either histone acetylation or cytosine demethylation led to increased 
proportions of cytokine positive cells and production by less proliferated cells.383 
However in the presence of Th2 polarising conditions IL-4 expression had been 
detected by unproliferated cells but it still required at least 48 hours of stimulation 
before IL-4 was detectable384 and our own unpublished data). To further complicate 
this, cells stimulated by antigen in the presence of IL-4 and L-mimosine, a drug that 
inhibits division by arresting cells in G1/S phase, could not express IL-4. Once L-
mimosine was washed from the culture and cells were restimulated, they could express 
IL-4, even before they had progressed through a round of proliferation384. So while 
division isn’t required, cell cycle inhibitors can inhibit IL-4 expression. It remains 
unknown if cell cycle inhibitors or treatments that increase acetylation, or 
demethylation would affect IL-13 expression. Experiments using reporters to accurately 
monitor cytokine and transcription factor expression along with dilution dyes and 
epigenetic analyses will shed further light on the elements which control expression of 
all the Type 2 cytokines. 
In mice, where the majority of lymphocytes do not express the IL-13Rα1 there is little 
requirement for IL-13 within the LN, however the expression of IL-13Rα1 by B cells in 
humans means there may be species specific differences in the regulation of IL-13 
expression179. IL-13 was first recognised as a human B cell activating cytokine that 
induced IgE class switching comparable to IL-4162. Therefore there are two possibilities, 
either in humans CD4+ T cell IL-13 expression is present in the LN providing a 
redundancy with IL-4 for driving of IgE isotype switching, or IL-13 remains absent in 
human LNs as seen in the mouse models. IgE is a very potent antibody, able to mediate 
systemic effects at serum titres much lower than the other antibody isotypes19. The 
immune system carefully regulates IgE expression120, as inappropriate production of 
IgE with specificities against innocuous antigens can lead to potentially fatal 
anaphylactic reactions137. Due to this fact it is feasible that IL-13 expression may be 
excluded from the human LN even though B cells are able to respond to it.  
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There is evidence available that human CD4+ T cells do not regulate IL-13 as mouse 
cells do. Restimulation of peripheral blood mononuclear cells from both adults and 
neonates induced rapid expression of both IL-4 and IL-13 mRNA, indicating that 
peripheral CD4+ T cells begin transcribing these cytokines simultaneously, though this 
doesn't mean they will translate both proteins together157. The Human Protein Atlas has 
measured some histological staining for IL-13 within the LN as well385. A clinical trial 
with the IL-13 blocking antibody has shown that IgE levels can be decreased by 
inhibition of IL-13 signalling386. The effects on IgE of IL-13 signalling measured in mice 
is considered to be indirect387, however as human B cells can respond to IL-13 the 
mechanisms via which IL-13 promotes IgE in vivo remain uncertain. It would be 
particularly interesting to assess if human Tfh cells expressed IL-13, as it has been found 
that IL-21, a cytokine produced by Tfh, potentiates human B cell responses to both IL-
4 and IL-13 and synergises with these cytokines to induce increased B cell 
proliferation388. In vitro studies assessing the time of protein production by stimulated 
naïve human CD4+ T cells should determine if IL-4 and IL-13 are as temporally 
separated by human CD4+ T cells as they are in mouse.  
In some situations there is significant overlap of IL-4 and IL-13 function, as observed in 
the case of lung protection against N. brasiliensis infection (Figure 6.3) however in other 
models IL-13 has been shown to have a critical non-redundant role188. The discoveries 
in this study that IL-13 is so differently regulated from IL-4 indicate that there are 
unrecognised pathways that distinctly control the expression of the Type 2 cytokines. 
Cytokines consistently co-expressed are not necessarily controlled via the same 
mechanisms, and careful characterisation of these mechanisms will lead to identification 
of specific targets to modulate individual cytokines as required.  
7.1.5 Innate immune cells associated with Type 2 display 
differential cytokine regulation 
This thesis investigated several types of innate immune cells and how they were 
responding to environmental cues that mediated their migration and expression of 
cytokines. Since this project a study has been published describing high levels of TSLP 
induced by MC903 treatment drew basophils from the blood into the site of treatment 
and the draining LN339. Kim et al. have reported a difference in the numbers of 
basophils entering the skin of TSLP-/- mice, which for an unknown reason I did not 
replicate in this study (Figure 5.12). However I did not observed systemic basophilia, in 
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fact basophil numbers and proportions in blood actually decreased in treated animals 
(Figure 5.10), assumedly due to migration from the circulation to the treated tissues and 
LN. TSLP is able to promote haematopoiesis of basophils, however this was shown in 
models where recombinant TSLP was administered or transgenic production was 
induced329. It may be that in natural TSLP inducing inflammation models there are two 
distinct signals, one that induces basophil haematopoiesis and drives systemic basophilia, 
and another, potentially TSLP, which mitigates basophil entry into tissue and LNs. This 
could explain why increased circulating basophils have been reported in N. brasiliensis 
infected TSLPR-/- mice compared with infected WT389. If decreased basophil numbers 
were observed in the lungs and LN of the TSLPR-/- mice this would argue strongly for 
TSLP generally working as a chemotactic agent. So MC903 treatment, with it’s 
localised impact, draws basophils to the draining LN via TSLP but apparently lacks the 
systemic signals present during helminth infection that promote haematopoiesis and 
systemic basophilia. The haematopoiesis-inducing signal absent from MC903 treatment 
may be IL-3. Giacomin et al. found antibody neutralisation of neither IL-3 nor TSLP 
alone caused any changes to circulating blood basophil number during Trichinella spiralis 
infection. αTSLP treatment of IL-3R deficient mice however prevented any increase in 
blood basophils. Furthermore αTSLP decreased the numbers of splenic and mesenteric 
LN basophils during Trichinella spiralis infection, while αIL-3 only caused a modest 
decrease in the number that arrived in the LN.341 While the role of TSLP, and TSLP 
elicited basophils, remain to be elucidated many of the cytokine deficient, and cell 
depletion tools are now available, so it is likely that this field will progress quickly over 
the next few years. 
I found that dILCs in the skin did to not show strong responses in any of the models of 
inflammation used in this paper, not even direct injection of the cytokine IL-33 or 
TSLP caused proliferation or changes in IL-13 expression. This is in particular conflict 
with two recent papers that have measured ILC responses using the MC903 model338, 
339. The first measured ILC responses but mostly in the draining LN and found they did 
expand in a TSLP dependent fashion. It was difficult to draw direct comparisons 
between the observations in this thesis because the paper measured LN ILC 
responses338. The second paper also using the MC903 paper measure dILC expansion 
within the skin between days 4 and 7 of treatment and found that IL-4 produced by the 
basophils was responsible for the ILC expansion. Adoptive transfer of TSLP elicited 
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basophils from WT, but not IL-4-/- donors were sufficient to induce atopic dermatitis 
and cause ILC expansion339. Why I did not replicate the observations made by these 
studies in this thesis is unknown. It seems unlikely that slight variations in MC903 
concentration would account for such differences in cell specific responses. This 
publication does seem to agree with my observation that ILCs do not directly respond 
to TSLP; Kim et al. demonstrated that it is TSLP activation of basophil IL-4 that 
modulates the ILC responses339. Similar to IL-2, TSLP signals through STAT5, and 
STAT5 has important roles in inducing IL-4 expression in CD4+ T cells. By expressing 
the TSLPR, along with calcium signalling pathway such as crosslinking of FcεRI bound 
IgE, basophils may use these signalling pathways as triggers for IL-4 production. 
The observations within this thesis that ILC populations within the skin are resistant to 
depletion and that lung ILC2 depletion can only be partially achieved is in 
disagreement with many publications. Various studies have reported the ability to use 
antibodies of various concentrations to deplete populations of ILCs from the skin 
draining LN,338, 390 lung240 and intestines248. One difficulty is that many of these studies 
use antibodies against Thy1 (αCD90 antibodies) or PC61 (αCD25), but continued to 
use CD90 or CD25 expression as a gating criterion for ILC identification236, 240, 274, 338. I 
found almost total CD90 masking in the lung and spleen (though not in the skin 
indicating restricted antibody access to the dermis), so careful analysis of ILC expressed 
molecules including CD25, KLRG-1 and CD127 were utilised to assess depletion, at 
best an approximate 50% reduction in ILC number was achieved in inflamed lungs 
(Figure 8.3). This was sufficient to see decreased efficacy in the IL-2c driven protection 
in Rag1-/- mice (Figure 6.9), and may explain why other publications can measure ILC 
dependent effects, despite insufficient depletion checks being performed. Why these cells 
are so resistant to depletion in unknown. It is possible they rarely circulate, the 
circulation and migration kinetics of ILCs have not been studied. If they were resident 
cells then the local immune cell populations would be relied upon to mediate antibody 
dependent cell-mediated cytotoxicity. Antibody-bound circulating populations can be 
picked up as they pass through the liver or spleen391. If there were a lack of appropriate 
cells, such as antibody responsive macrophages or NK cells within the tissue could mean 
that resident cells are not very likely to be depleted in situ and are relatively protected 
from antibody depletion. Using tools that allow tracking of cells, like the photos-
switching reporters392 will allow investigation into the migratory capabilities of ILCs and 
other depletion resistant populations. 
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ILC2s of the lung, unlike dILCs, rapidly responded to IL-33 treatment increasing their 
expression of IL-13 within 24 hours (Figure 6.7). ILCs are proposed to act as damage 
sensors and rapidly respond by production of proinflammatory cytokines IL-5 and IL-
13, and also damage control proteins such as amphiregulin, which mediate epithelial 
healing393. IL-33 is not the only factor known to stimulate ILC2 responses. IL-25 has 
also been implicated394, 395, and a recent publication identified prostaglandin D2 as a 
potent activator of ILC2s within the lung396. ILC2s within the lungs play dual roles; 
promoting inflammatory responses against invading parasites and in AHR models397, 
and through their support of M2 macrophages and epithelial healing via amphiregulin 
they also are critical to healing damaged and maintaining tissue function240. Why dILCs 
did not respond to IL-33 remains to be investigated as, albeit a small percentage, some 
of the dILC population were detected expressing the IL-33R (ST2) (Figure 5.2). It is 
possible that the dILCs represent a quiescent ILC population that respond to 
stimulation from other members of the immune system such as CD4+ T cells and 
basophils, and this study did not accurately assess their function at the correct time 
points to observe their responses. 
This thesis has identified several signalling pathways that mediate innate cell responses 
to varied inflammatory stimuli. These pathways are critical to the early functions of the 
Type 2 immune response and may play important roles in how the larger response will 
form over time. Understanding these early innate responses are just as important as 
characterising the later adaptive immune cell functions. 
7.1.6 CD4+ T cells support ILC2 responses  
One of the major findings of this thesis is that CD4+ T cells provide signals that support 
the maintenance of ILC2s within the lung after N. brasiliensis infection (Figure 6.6). The 
exact mechanisms that CD4+ T cells employ to communicate with ILCs are unclear but 
there are several candidates. In this thesis and related work, IL-2c was used to stimulate 
both skin and lung ILC responses to great effect. ILC2s responding to low dose IL-2 
treatments used in clinical trials to treat autoimmune diseases have been implicated in 
inducing systemic eosinophilia via IL-5398. Systemic IL-2c treatment leads to a strong 
proliferative and cytokine response from ILC2s and while it provides a useful model for 
measuring the capabilities of stimulated ILC2s it is likely unrepresentative of the true 
stimulatory signals ILC2s are receiving in vivo. IL-2 is only transiently expressed by most 
activated T cells, and though Th1 differentiated CD4+ T cells maintain IL-2 expression 
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longer than other T cell subsets399, Th1 cells are a rare population in N. brasiliensis 
infection84. In a natural setting ILC2s will likely be exposed to limited IL-2 for short 
times but they will be exposed to other activating stimuli. Similar to skin ILCs, ILC2s 
within the lung have been shown to respond to basophil derived IL-4400,. It is therefore 
feasible that ILC2s could respond to both basophil and Th2 derived IL-4, especially 
considering the relatively high numbers of IL-4 reporting CD4+ T cells during N. 
brasiliensis infection (Figure 4.7). IL-9 has also been shown to be a potent survival factor 
for ILC2 and required to maintain their numbers after N. brasiliensis infection. Using fate 
reporters (which mark every surviving cell that has at any point expressed IL-9) it was 
found the majority (>80%) of reporter positive cells were ILC2s, the remainder being 
CD4+ T cells74. This indicates that survival-promoting IL-9 may be working in an 
autocrine fashion. However fate reporters do not allow identification of cytokine 
producing cells in real time, and it was unknown which populations maintained their 
production of IL-9 long term. There is also the potential for direct communication 
between ILC2s and CD4+ T cells, expression of MHC II on the ILC2s can facilitate 
cell-cell interactions in vitro358, so it remains feasible that these exchanges could occur in 
vivo. These interactions could promote communication via other receptors, providing 
pro-survival and activation signals to the ILC2s.  
CD4+ T cells are required to maintain ILC2 responses in a secondary infection, though 
I have shown that cytokine stimulated ILC2s were able to generate protective immune 
responses in the absence of CD4+ T cells (Figure 6.8, Figure 6.9 and Figure 6.10). Early 
cytokine expression detected using the 4C13R transgenic reporter found that ILC2s 
were responding within 24 hours of infection, indicating that even to natural stimuli 
ILC2s show rapid activation. The question remains why these early responding ILC2s 
cannot provide protection against a primary infection. It is likely that while rapid, the 
larvae are still faster, exiting the lungs within 3 days of infection, not allowing enough 
time for the ILC2 produced IL-13 to switch on the anti-helminthic programming of a 
sufficient number of macrophages and other effector cells. It is also possible that, as is 
often an issue raised when regarding the relative importance of ILCs, there may simply 
be too few to respond sufficiently in a primary infection. I found the numbers of ILC2s 
are raised up to 30 days post infection and further expanded two days after a secondary 
infection in a CD4+ T cell dependent manner. The CD4+ T cell independent 
protection model required cytokine treatment two days prior to infection, effectively 
giving the ILC2s a head start to expand and drive anti-helminthic responses to prepare 
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the protective environment within the lung. Similarly, IL-2c treatment of CD4+ T cell 
depleted mice prior to secondary infection increased ILC2 number as well as cytokine 
production proving enough signal to maintain the protective immune responses 
generated during the primary infection.  
To date many of the roles of ILCs have been demonstrated in T cell independent 
models. In this thesis I have found that stimulated ILC2s are sufficient for both priming, 
and maintaining protective responses within the lung against N. brasiliensis. Due to their 
overlapping functions ILC2s and Th2 cells are often thought to be redundant, this study 
has found that both populations constitute significant proportions of the IL-13 
producing cells, and as seen with CD4+ T cell depletion, it is possible ILC2 depletion 
would also lead to decreases in the protective response. This thesis has lacked tools for 
specific targeting of ILC2s to determine their relative contributions to protective 
responses in a T cell sufficient host. Using such tools will elucidate if the early responses 
by ILC2s, and their contributions to cytokine production during a secondary infection 
are important at developing the overall immune responses.  
7.1.7 CD4+ T cells are the central mediator of Type 2 immunity 
Long term depletion of CD4+ T cells led to decreased protective responses against a 
secondary infection, however we have shown the presence of CD4+ T cells was not 
required during the protective immune response against N. brasiliensis (Figure 6.5). That 
CD4+ T cells aren’t required to directly effect the larval survival isn’t surprising; CD4+ 
T cells have not been reported to produce anything that could directly harm the larvae. 
The fact that they can be absent, and yet immune responses remain effective indicates a 
much less direct role for CD4+ T cells than was previously thought. Work done 
alongside of this thesis has shown that M2 macrophages are key effector cells that 
provide protection, and it is the phenotype of these cells that CD4+ T cells maintain 
through production of IL-4 and IL-13354. Previous studies have shown that M2 
macrophages require constant STAT6 dependent signalling to maintain their 
phenotype401, The loss of protection when CD4+ T cells are depleted for a week 
correlates with this. However the source of IL-4 or IL-13 in the short-term absence of 
CD4+ T cells is unknown. It is possible that ILC2s are not as sensitive to the loss of the 
support provided by CD4+ T cells, and are able to provide sufficient IL-13 to maintain 
M2 macrophages in the short term. Through this work we have confirmed that CD4+ T 
cells are critical to maintaining Type 2 immunity within the lung, and that these 
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responses can only be sustained for a short time in the absence of these central 
mediators. 
It has been shown using FTY720 to inhibit migration of CD4+ T cells from the LN to 
the lung, that lung resident populations of CD4+ T cells are able to respond to a 
primary infection and provide protection against a secondary infection134. The fact that 
tissue resident CD4+ T cells show a greater propensity for IL-13 expression that LN 
cells, and that inhibiting LN migration has no effect on the number for IL-13 expressing 
cells (Figure 4.11), indicates that these cells may account for the majority if not all CD4+ 
T cell derived IL-13 within the lung. In vitro stimulation found no preference for lung 
cells to express IL-13 compared with spleen derived CD4+ T cells (Figure 4.9), so it 
remains unknown what control IL-13 expression in vivo and if these lung resident cells 
represent a different population of CD4+ T cells primed to express IL-13 without 
needing activation in the LN. While it is known CD4+ T cells are critical to mediating 
Type 2 immunity, much about how they are activated, their kinetics of migration 
during inflammation and their regulation of effector function remain to be discovered. 
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Figure 7.1 - Summary of discoveries from this thesis in the greater context of 
Type 2 immune responses. 
a. Damaged epithelial cells release cytokines including TSLP and IL-33. TSLP acts systemically 
to induce IL-4 expression from basophils and migration of these basophils to the LN and tissue. 
IL-33 activates tissue resident ILC2s, which rapidly begin producing IL-13. DCs responding to 
epithelial derived cytokines become activated and migrate to the LN. b. Antigen loaded DCs 
present to CD4+ T cells in the LN and induce IL-4 independent Th2 differentiation. Increased 
levels of TCR engagement may increase the chances of a CD4+ T cell expressing IL-4 bi-
allelically as seen in vitro. B cells are the predominant IL-4 responding cell type within the LN. c. 
Several days after the LN CD4+ T cells begin expressing IL-4 tissue resident CD4+ T cell begin 
producing IL-13. FTY720 experiments indicate that most IL-13 expressing CD4+ T cells do not 
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migrate from the LN at all, suggesting in situ activation by DCs and other tissue resident APCs. 
d. IL-4 and IL-13 drive M2 activation of macrophages, and IL-13 responsive goblet cells 
increase their production of mucus. In the context of a helminth infection, maintenance of the 
alternately activated macrophages by CD4+ T cell and ILC2 derived IL-4 and IL-13 provides 
protection against subsequent infections. CD4+ T cells also support ILC2 responses potentially 
through the production of IL-2. Adapted from Allen and Maizels, 2011. 
 
 
 
 
 
 
7.1.8 Key Findings 
• The expression of IL-4 and IL-13 are differently regulated by CD4+ T cells and by 
Type 2 associated innate immune cells 
• The proportion of CD4+ T cells expressing IL-4 bi-allelically can be altered by 
modifying the level of TCR stimulation 
• IL-4 does not effect the generation or expansion of IL-4 producing CD4+ T cells in 
vivo 
• Expression of IL-13 by in vitro differentiated CD4+ T cells requires multiple TCR 
ligations and is consistently delayed compared with IL-4 
• Dermal innate lymphoid cells constitutively express IL-13, and skin migrating 
basophils in a model of atopic dermatitis express IL-4 in a TSLP dependent manner  
• When stimulated with exogenous cytokines group 2 innate lymphoid cells in the 
lung can promote and maintain CD4+ T cell independent protective immune 
responses against Nippostrongylus brasiliensis infection 
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7.2 Conclusions 
The principle aim of my thesis was to compare the regulatory mechanisms that control 
IL-4 and IL-13 expression. By demonstrating the differential expression of IL-4 and IL-
13 both in vivo and in vitro I have found that mouse Th2 cells carefully regulate the 
timing and the location of their cytokine production to tissue sites where the cytokine 
will be most effective. Both IL-4 and IL13 demonstrate redundancy in their influences 
on anti-helminthic immune responses, and though CD4+ T cells are large producers, 
cells of the innate immune system produce significant amounts as well. Basophils and 
ILC2s contribute to Type 2 cytokine production but show differential preferences in 
which cytokine they produce. Basophils generally produce IL-4 and ILC2s express IL-
13, this demonstrates that different populations can selectively regulate which cytokine 
they preferentially express. Innate lymphoid cells, although sharing much in common 
with CD4+ T cells are a distinct effector population, responding quickly to infection, 
and when sufficiently stimulated capable of influencing the greater Type 2 immune 
response though production of IL-13. CD4+ T cells control many facets of the Type 2 
immune response and their long-term depletion leads to significant abrogation of 
responses. Overall these data demonstrate significant regulation controlling the 
expression of IL-4 and IL-13, both within the CD4+ T cell population and between 
different innate cell populations. Despite some overlap in their functions, in some cases 
complete redundancy, the spatial and temporal regulation of IL-4 and IL-13 expression 
may allow the immune system to control cytokine specific effects during Type 2 
immune responses. Understanding these mechanisms will allow the development of 
treatments that can specifically target the expression of individual cytokines, either 
boosting their effects as may be desirable with an anti-hookworm vaccines, or inhibiting 
them to limit pathologies associated with atopic diseases. 
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7.3 Future Directions 
This study has assessed many aspects of IL-4 and IL-13 expression and function, 
however further experiments need to be carried out to precisely define the mechanisms 
that control the expression of these two cytokines. Below I have described some 
experiments that could be carried out to further advance the understanding of Type 2 
cytokine expression. 
To assess further the mechanisms that control allelic regulation of the IL-4 allele, in-
depth analysis of intracellular signalling pathways is required. The first target should be 
to measure the relative levels of GATA3 within mono- and bi-allelically expressing cells 
as such strong evidence exists that GATA3 facilitates Il4 gene transcription. If a link is 
found then chromatin immunoprecipitation (ChIP) followed by high-throughput DNA 
sequencing (ChIP-seq) could be utilised to assess which regions of the Th2 locus 
GATA3 is binding and if there are differences between the differentially expressing Th2 
populations. Unfortunately attributing functions to mono- and bi-allelically expressing 
cells is extremely difficult. In absence of a cell surface molecule that is differentially 
expressed, reporters that disrupt the expression of IL-4 are required to identify the 
mono- and bi allelic cells, and the decrease in available IL-4 may mask the actual 
functions these cells mediate. Transcriptome analysis may enable identification of 
molecules that could be used to delineate the differently expressing cells, and would 
allow functional studies within IL-4 sufficient cells. 
Utilising the 4C13R reporters crossed to IL-4 deficient mice (4C13RxGFP/IL-4 and 
4C13RxGFP/GFP strains) and looking at DS-red expression by tissue CD4+ T cells will 
allow assessment of IL-4 signalling on the expression of IL-13. Identification of GFP+ 
AmCyan+ CD4+ T cells will also allow correlation between bi-allelism and IL-13 
expression. Finally the 4C13RxGFP/GFP mice can be used to assess ILC2 responses in 
the absence of IL-4, to assess if IL-4 is a factor that supports ILC2 responses. 
Measuring GATA3 levels in vitro will also be important in understanding the delay in 
the expression of IL-13. Bcl-6 expression has been proposed as inhibitory for GATA3 
expression so inhibitors of Bcl-6 might instruct whether it is functioning to limit GATA3 
expression within our in vitro model. Potentially using treatments that drive global 
hyper-acetylation, or demethylation may also indicate if epigenetic factors are 
restricting IL-13 expression. Use of dilution dyes to measure proliferative cycles, and 
cell cycle inhibitors will assess if there is a requirement for proliferation that permits IL-
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13 production. The use of splenic DCs may also be promoting IL-13 expression, in vitro 
presentation by DCs from inflamed LNs will determine if the DC activation state plays 
a role in inducing IL-13 from the CD4+ T cells. A model is also available where 
transgenic CD4+ T cells are stimulated with 2 peptides of differing affinity. Using this 
model in vitro with APC driven Th2 activation will allow testing of how antigen affinity, 
antigen dose, DC activation state and accessory cytokines influence IL-13 induction. 
Several models allowing in vivo depletion of ILC2s have been developed; using these 
mice will elucidate the exact contributions of ILC2s in activating M2 macrophages and 
protection against N. brasiliensis infection. Adoptive transfer experiments of various gene 
knock-out CD4+ T cells may instruct via which signals CD4+ T cells use to sustain ILC2 
responses during Type immune responses. Finally using TSLP and IL-3 deficient mice 
will provide information on the roles of these cytokines in the haematopoiesis and tissue 
migration of basophils 
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8 Appendix 
8.1 Supplementary Data 
8.1.1 CD4+ T cell gating scheme 
 
Figure 8.1 – Panel for the identification of CD4+ T cells.  
a. CD4+ T cells are selected by Live NK1.1- CD3+ CD8- CD4+. In some experiments CD19 
was used to exclude B cells. 
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8.1.2 Cell Depletions 
8.1.2.1 Depletion of CD4+ T cells from the lung 
 
Figure 8.2 - CD4+ T cell depletion in the lung is maintained for 4 days around 
infection.  
a. Mice were treated with 0.5mg of antibody two days prior to N. brasiliensis infection then the 
CD4+ T cell population within the lung were assessed by flow cytometry two days post infection. 
Lung cells were stained with a cocktail including the RM4-4 αCD4 clone specific for a separate 
epitope than GK1.5. Plots are representative of many independent experiments. 
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8.1.2.2 Depletion of ILC2s from the lung 
 
Figure 8.3 – Panel for assessing lung ILC2 depletion with αCD90 antibody.  
a. In mice treated with αCD90, depletion of lung ILC2s was assessed by comparing the 
numbers of Live CD45+ Lineage- B220- CD127+ CD25+ KLRG1+ undepleted mice. Mice 
treated with αCD90 have complete masking of CD90 staining on their ILC2s. Plots are 
representative of many independent experiments. b. Percentage of live cells that are ILC2s in 
the lung during primary infection with and without IL-2c treatment and αCD90 treatment as 
per Figure 6.9. 
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8.2 Flow cytometer configurations 
Cytometer Laser Filter set Fluorophore (bold denotes used 
in this thesis) 
BD LSRII- UV 355nm UV 740/35A BUV737 
SORP  BUV740 
  UV 450/50B AlexaFluor350 
   DAPI 
   Hoescht Blue 
   Dyecycle Violet 
   LIVE/DEAD Fixable Blue 
  UV 395/28C BUV395 
 Violet 450nm V 780/60A Brilliant Violet 786 
   QDot800 
  V 720/40B Brilliant Violet 711 
   QDot705 
  V 660/20C Brilliant Violet 650 
   QDot 655 
   eFluor 650 nc 
  V 605/40D Brilliant Violet 605 
   QDot585 
   QDot605 
 QDot625 
   eFluor605 
  V 560/40E Pacific Orange 
   AlexaFluor 430 
   QDot565 
   Brilliant Violet 570 
   Krome Orange 
   Lucifer Yellow 
   QDot545 
  V 525/50F Brilliant Violet 510 
   AmCyan 
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   AlexaFluor 430 
   Cascade Yellow 
   Horizon V500 
   LIVE/DEAD Fixable Aqua 
   VivoGreen 
   Pacific Green 
   Zombie Aqua 
  V 450/50G DAPI 
   HorizonV450 
   Cell Tracer Violet 
   Violet Proliferation Dye 450 
   LIVE/DEAD Fixable Violet 
   SYTOK Blue 
   AlexaFluor 405 
   Cascade Blue 
   Brilliant Violet 421 
   Cell Trace Casein Violet AM 
   DyLight 405 
   eFluor 450 
   PO-PRO-1 
   Vibrant DyeCycle Violet 
   CFP 
   Pacific Blue 
   VioBlue 
   FXCycle-Violet 
 Blue 488nm B 705/70A PerCP 
   PerCP-Cy5.5 
   PerCP-eFluor 710 
   EMA 
  B 515/20B FITC 
   YO-PRO-1 
   GFP 
   DHR 
 216
   AlexaFluor 488 
   AlexaFluor 500 
   Cell Trace Green AM 
   CFSE 
   Dylight 488 
   GS (CyToxLux) 
   JC-1 
   LIVE/DEAD Fixable Green 
   Cytox Green 
  B 488/10C SSC 
 Green 532nm G 780/60A PE-Cy7 
   FM4-64 
   PE-Vio770 
  G 610/20B PI 
   Texas-Red 
   LIVE/DEAD Fixable Red 
   PE-CF594 
   PE-TexasRed 
   AlexaFluor 568 
   AlexaFluor 594 
   PE-AlexaFluor 610 
   Mitotracker Red 
  G 575/26C PE 
   AlexaFluor 546 
   AlexaFluor 555 
   CTO 
   Cy3 
   DS-Red 
   Dylight 549 
   MitoSox Red 
   Phrodo 
   Vybrant Dyecycle Orange 
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 Red 640nm R 780/60A LIVE/DEAD Fixable Near IR 
   APC-Cy7 
   APC-H7 
   APC-177 
   AlexaFluor 750 
   APC-AlexaFluor 750 
   APC-eFluor 780 
  R 710/50B DyLight 680 
   AlexaFluor 633 
   AlexaFluor 700 
   Cell Proliferation Dye eFluor670 
   DyLight 633 
   eFluor 660 
   LIVE/DEAD Fixable Far Red 
   SyFox Red 
   TFL4 (Cytolux) 
   TO-PRO-3 
  R 670/14 APC 
   AlexaFluor 633 
   AlexaFluor 647 
   Cell Proliferation Dye eFluor 670 
   DyeLight 633 
   eFluor 660 
   LIVE/DEAD Fixable far red 
   Sytox Red 
   TFL4 (Cytoxilux) 
   TO-PRO- 3 
   Cell Vue Claret 
   eFluor 670 
BD LSR  Violet 450nm V 780/60A Brilliant Violet 786 
Fortessa   QDot800 
  V 710/20B Brilliant Violet 711 
   QDot705 
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  V 660/20C Brilliant Violet 650 
   QDot 655 
   eFluor 650 nc 
  V 610/20D Brilliant Violet 605 
   QDot585 
   QDot605 
 QDot625 
   eFluor605 
  V 560/40E Pacific Orange 
   AlexaFluor 430 
   QDot565 
   Brilliant Violet 570 
   Krome Orange 
   Lucifer Yellow 
   QDot545 
  V 525/50F Brilliant Violet 510 
   AmCyan 
   AlexaFluor 430 
   Cascade Yellow 
   Horizon V500 
   LIVE/DEAD Fixable Aqua 
   VivoGreen 
   Pacific Green 
   Zombie Aqua 
  V 450/50G DAPI 
   HorizonV450 
   Cell Tracer Violet 
   Violet Proliferation Dye 450 
   LIVE/DEAD Fixable Violet 
   SYTOK Blue 
   AlexaFluor 405 
   Cascade Blue 
   Brilliant Violet 421 
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   Cell Trace Casein Violet AM 
   DyLight 405 
   eFluor 450 
   PO-PRO-1 
   Vibrant DyeCycle Violet 
   CFP 
   Pacific Blue 
   VioBlue 
   FXCycle-Violet 
 Blue/Violet 
445nm 
BV 405/12 AmCyan 
 Blue 488nm B 685/35A PerCP 
   PerCP-Cy5.5 
   PerCP-eFluor 710 
   EMA 
  B 515/20B FITC 
   YO-PRO-1 
   GFP 
   DHR 
   AlexaFluor 488 
   AlexaFluor 500 
   Cell Trace Greem AM 
   CFSE 
   Dylight 488 
   GS (CyToxLux) 
   JC-1 
   LIVE/DEAD Fixable Green 
   Cytox Green 
  B 488/10C SSC 
 Green 532nm G 780/60A PE-Cy7 
   FM4-64 
   PE-Vio770 
  G 695/40 PE-AlexaFluor 680 
 220
   PE-AlexaFluor 700 
   PE-Cy5.5 
  G 670/30 PE-Cy5 
   7AAD 
   PE-AlexaFluor 647 
  G 610/20D PI 
   Texas-Red 
   LIVE/DEAD Fixable Red 
   PE-CF594 
   PE-TexasRed 
   AlexaFluor 568 
   AlexaFluor 594 
   PE-AlexaFluor 610 
   Mitotracker Red 
  G 575/25E PE 
   AlexaFluor 546 
   AlexaFluor 555 
   CTO 
   Cy3 
   DS-Red 
   Dylight 549 
   MitoSox Red 
   Phrodo 
   Vybrant Dyecycle Orange 
 Red 640nm R 780/60A LIVE/DEAD Fixable Near IR 
   APC-Cy7 
   APC-H7 
   APC-177 
   AlexaFluor 750 
   APC-AlexaFluor 750 
   APC-eFluor 780 
  R 710/50B DyLight 680 
   AlexaFluor 633 
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   AlexaFluor 700 
   Cell Proliferation Dye eFluor670 
   DyLight 633 
   eFluor 660 
   LIVE/DEAD Fixable Far Red 
   SyFox Red 
   TFL4 (Cytolux) 
   TO-PRO-3 
  R 670/14 APC 
   AlexaFluor 633 
   AlexaFluor 647 
   Cell Proliferation Dye eFluor 670 
   DyeLight 633 
   eFluor 660 
   LIVE/DEAD Fixable far red 
   Sytox Red 
   TFL4 (Cytoxilux) 
   TO-PRO- 3 
   Cell Vue Claret 
   eFluor 670 
Table 8-1 - Laser and filter configurations of the BD LSR II SORP and BD LSR 
Fortessa flow cytometers.  
Listed are the common fluorophores that could be detected with each laser and filter set, in bold 
are the fluorophores used in this thesis. 
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